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Abstract 
 
 Positron emission tomography (PET) enables noninvasive tumour imaging, as 
changes in metabolic activity secondary to therapy can be measured before changes in 
tumour size are evident on standard anatomic imaging. Two imaging approaches 
representing proliferation dependent and independent technologies are evolving as 
potential methods for assessing growth signalling and, thus, treatment response: 
[18F]3’-deoxy-3’-fluorothymidine (FLT) and [11C]choline. The validity of the former in 
patients with pancreatic cancer is unproven and likewise, the role of the latter in 
response to androgen deprivation/radiotherapy in prostate cancer (PCa) remains 
unexplored. Using a variety of approaches, the aim of this thesis was to provide an 
understanding of the role of these tracers in lesion detection and response assessment 
in patients by PET/computed tomography (PET/CT). 
 Given the high physiological hepatic localisation of FLT, a recently reported 
kinetic spatial filtering (KSF) algorithm was evaluated as a way to de-noise abdominal 
FLT-PET data from patients with advanced pancreatic cancer. Application of KSF led to 
improved lesion detection. FLT uptake (SUV60,max) significantly increased in mid-
treatment (gemcitabine based) progressors (p=0.04). In this limited number of patients, 
reduction in FLT uptake did not predict overall survival. 
 The role of [11C]choline PET/CT in lesion detection and response in prostate 
cancer (PCa) was also investigated using semi-quantitative and quantitative methods. 
As a prelude to the quantitative imaging studies, it was established that irreversible 
tracer uptake characterised tumour (breast cancer) [11C]choline kinetics. Similar 
irreversible uptake characterised PCa. An important finding was that tumour 
[11C]choline uptake (in 29 PCa patients) correlated with choline kinase (CHK) 
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expression but not proliferation, as assessed by Ki67 labelling index. 
Immunohistochemistry of the above patients’ prostate cores with CHKα antibody 
demonstrated a spectrum of CHKα expression, ranging from expression in prostatic-
intraepithelial-neoplasia to low to high expression in malignant cores. These findings 
were further corroborated in a larger cohort of 75 malignant cores derived from non-
imaging studies. Having established [11C]choline as a proliferation independent marker 
of growth, its role in assessing treatment response was investigated. [11C]choline PET 
was sensitive to metabolic changes within prostate tumours following androgen 
deprivation and radical radiotherapy. 
 While promising data were obtained with [11C]choline PET, the radiotracer is 
subject to metabolic degradation complicating data analysis. To this end, a novel 
metabolically stable analogue of choline ([18F]fluoromethyl-[1,2-2H4]-choline 
([18F]D4FCH)) was transitioned into volunteers and patients to study its 
pharmacokinetics and preliminary diagnostic potential. This tracer embodies deuterium 
isotope substitution as a means to discourage systemic metabolism. The radiotracer 
had favourable dosimetry (effective-dose: 0.025mSv/MBq) and safety. Preliminary 
results in non-small cell lung cancer showed that the tracer is taken up in tumours. 
Further studies are warranted to characterise this new tracer in different tumour types. 
 As a prelude to imaging cancer cell death in tumours, a caspase-3 specific 
radiotracer, [18F](S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4- 
difluorophenoxymethyl)-pyrrolidine-1-sulfonyl) isatin ([18F]ICMT-11) was also 
transitioned into volunteers. The radiotracer had favourable dosimetry (effective-dose: 
0.025mSv/MBq) and safety. 
 In summary, FLT-PET/CT combined with KSF and [11C]choline PET/CT were 
shown to be promising methods for imaging early treatment response in patients. 
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Further work will be required to evaluate the clinical relevance of these data in terms of 
overall patient outcome. Furthermore, a new choline-based radiotracer and a caspase-
3 specific radiotracer  have been transitioned into humans. 
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Chapter 1: Introduction 
 
Cancer cells exhibit diverse phenotypic abnormalities, such as loss of 
differentiation, increased motility/ invasiveness, decreased drug sensitivity and 
dysregulation of cell cycle control. The growth of tumours, characteristic of cancerous 
process is related to the balance between growth (sustained proliferation) and cell 
death properties. A cell’s ability to replicate in an orderly and controlled fashion is an 
essential component of life. The molecular machinery controlling the cell division is 
performed with great fidelity and is highly organised. Aberrations of normal cell cycle 
control lead to molecular alterations that are characteristic of cancer cells.  
Cell Cycle 
 
In any proliferating mammalian cell, the process of replication can be broken 
down into 4 distinct phases (Figure 1).  
 Cells have evolved checkpoints to regulate the complex and irreversible 
process of cell division. These are biochemically defined points in the cell cycle which 
can be activated to prevent transition across certain phases (Alberts 2008). Loss of 
these checkpoints is implicated in malignant transformation.  
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Figure 1: Schematic representation of phases of cell cycle.  
Growth factors drive a quiescent cell from G0 into cell cycle. Once the cell cycle passes beyond 
the restriction point (R), mitogens are not required for progression. DNA replication occurs in S 
phase and the chromosomes are condensed in mitotic (M) phase. Cell cycle check points are 
denoted by *. G0 phase: a quiescent state, G1 phase: first phase of the cell cycle where the cell 
undergoes biochemical changes in preparation for entry into S phase, S phase: synthesis 
phase where new DNA is synthesisesynthesised. A complete copy of the cells genetic material 
is generated, G2 phase: second preparatory phase called Gap 2 (G2), M phase: Mitotic phase, 
in which replicated DNA is condensed into compact chromosomes that are precisely segregated 
and distributed into daughter cells. Following M phase, a proliferative cell directly enters G1 
phase in preparation for further replication.  
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Regulation of cell cycle 
 
Regulation of the cell cycle involves control of the key regulatory proteins by 
post-translational modifications in a cell cycle dependent manner orchestrated by 
cyclins and cyclin-dependent kinases (cdk), which are central to all phases of the cell 
cycle and shown in Figure 2 (Sherr and Roberts 2004; Malumbres and Barbacid 2005).  
There is an elegant system of several regulators which control the transition 
between the different phases of the cell cycle (Schafer 1998; Alberts 2008). The 
activated cyclin/cdk complex phosphorylates a variety of substrates to facilitate both the 
G1 to S phase and G2 to M phase transitions. The M phase entry and exit is regulated 
by mitosis promoting factor (MPF) which is characterised by a complex of cyclin B and 
cdk1.  
 
Figure 2: Schematic representation of changes in cyclins and cdk through cell cycle.  
Growth factors stimulate synthesis of cyclin D in G1 phase. Cyclin E is synthesised later in G1 
phase. Cyclin A is synthesised late in G1, throughout S and into early G2 phase. Cyclin B is 
synthesised in late G2 and M phase. The loss of cyclin B/ cdk1 at end of M phase is required for 
re-entry into next G1 phase.  
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Cell cycle checkpoints 
 
The events of cell cycle are highly ordered and sequential such that the initiation 
of any event in the cell cycle is dependent on completion of earlier events. DNA 
damage by intrinsic or extrinsic processes inhibits cell cycle progression by invoking the 
check points: before entry into S phase, with in S phase or before entry into mitosis 
(Bertoli, Skotheim et al. 2013; Foley and Kapoor 2013). This limits the propagation of 
genetic mutations to daughter cells by allowing for DNA repair (Figure 3). 
 
Figure 3: Schema of cell cycle check points.  
Ionising radiation causes DNA damage in the form of strand breaks and activates several signal 
transduction pathways. For cells in G1, DNA damage leads to increase in the p53 protein 
through ATM. This induces apoptosis or an increase in p21 and causes cell cycle arrest. For 
cells in S phase, DNA damage arrests further DNA synthesis in an ATM and nbs-1 dependent 
manner (Lim, Kim et al. 2000). For cells in G2 and M phase, DNA damage activates check point 
kinases (CHK 1 & 2) which phosphorylate cdc25. This prevents activation of cyclin B/ cdk1 
(Mitosis promoting factor: MPF) which is critical for entry into mitosis. Another checkpoint 
involves the spindle apparatus, which prevents metaphase to anaphase transition (Foley and 
Kapoor 2013). 
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Hallmarks of Cancer 
 
Mammalian cells possess molecular machinery that regulates their proliferation, 
differentiation, and death. Malignant transformation is a multistep process involving 
genetic alterations, disruption of regulatory circuits and dynamic changes in the 
genome. It has been suggested that malignant growth is governed by six essential 
alterations in cell physiology: self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis 
(Hanahan and Weinberg 2000).  
Recent advances in understanding tumour biology led to the notion that 
progressive evolution of normal cells to a neoplastic state involves not only acquiring a 
succession of these hallmark capabilities, but also requires the contributions of the 
recruited normal cells (which form tumour-associated stroma, constituting the ‘‘tumour 
microenvironment’’) to tumourigenesis (Hanahan and Weinberg 2011). 
It has been suggested that sustained proliferative signalling could also be 
attributed to:  
 Somatic mutations activating downstream signalling such as Raf to mitogen-
activated protein (MAP)-kinase pathway in melanoma (Davies and Samuels 
2010), and mutations in phosphoinositide 3-kinase (PI3-kinase) isoforms in an 
array of tumour types, hyper-activate the PI3-kinase signalling pathway (Yuan 
and Cantley 2008; Jiang and Liu 2009). 
 Telomere maintenance and delayed activation of telomerase (Hansel, Meeker 
et al. 2006; Kawai, Hiroi et al. 2007).  
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The six hallmarks are all linked to cell proliferation of cancerous cells, thus making cell 
proliferation an important capability leading to immortalisation and generation of 
macroscopic tumours.  
The above framework of hallmarks assumes a homogeneous population of 
cancer cells and considers the hallmarks as distinct entities, with a one-to-one relation 
between oncogenic events (the inducers), the signalling pathways (transmission), and 
the hallmarks (the effects). However, one oncogenic event, or one signalling cascade, 
could induce several hallmarks accounting for the dynamic and spatial heterogeneity of 
tumours (Floor, Dumont et al. 2012). This heterogeneity provides a framework to 
interpret pathological, diagnostic, and therapeutic observations of tumours and 
supports the need for noninvasive serial studies on the whole tumour mass and the use 
of simultaneous, multi target therapies for treating cancer. 
Need for imaging 
 
Cell Proliferation 
 
As discussed in the previous section, the basic tenet of all the deranged cell 
regulatory processes is an increase in cell proliferation. The rates of tumour cell division 
have been demonstrated to be of prognostic value with the slow growing tumours 
having a markedly different prognosis than the aggressive ones. Hence the 
quantification of cell proliferation would facilitate decisions to be accurately made in 
choosing the right therapeutic options to treat cancer.  
Cells in the M phase show morphological features called “mitotic figures” which 
can be counted and the mitotic index has been the most commonly used quantitative 
measure to assess proliferative activity (O'Leary and Steffes 1996). However, the 
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number of mitotic figures may not correlate well with proliferation and are subject to 
sampling artifacts (Lehr, Rochat et al. 2013). The other methods explored to improve 
measurement of proliferation include estimation of growth fraction of tumour cells. 
Growth fraction quantification using immunohistochemistry techniques (estimate 
nuclear antigens such as Ki67, proliferating cell nuclear antigen (PCNA) and geminin) 
have demonstrated good applicability (Lopes, Hannisdal et al. 1998; Colozza, 
Azambuja et al. 2005; Yerushalmi, Woods et al. 2010). Other  measures include flow 
cytometry (Barnard 2012), and two dimensional  or three dimensional  assessment of 
the S-phase fraction (Montironi, Diamanti et al. 1992; Tekola, Baak et al. 1996).  
The “gold standard” for assessing proliferation is using bromodeoxyuridine 
(BrdU) and tritiated thymidine assays (Cavanagh, Walker et al. 2011). However this has 
limited clinical utility due to the need for fresh material, invasiveness and involvement of 
radioactivity. Therefore, at tissue level, mitotic counting and the Ki67 labelling index 
(Ki67) provide the most feasible and accurate means of quantifying proliferation. 
Apoptosis  
 
Apoptosis is an essential process for eliminating unwanted cells during 
embryonic development, growth, differentiation and maintenance of tissue 
homeostasis. Deregulation of apoptosis signalling pathways is, therefore, associated 
with various pathologies (Reed 2002), and the capacity to evade apoptosis has been 
defined as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Most of the 
current anti-cancer therapeutics and radiotherapy act by a variety of mechanisms but, 
by shifting the proliferation: apoptosis ratio, may share the common outcome of 
apoptosis (Kaufmann and Earnshaw 2000; Storey 2008).  
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The classical assessment of apoptosis was based on morphological criteria 
(Wyllie, Kerr et al. 1972) and biochemical criteria (Kroemer, Galluzzi et al. 2009). Other 
methods, which utilise tumour biopsies, have been developed. These include the 
TUNEL assay where the double strand breaks generated secondary to DNA 
fragmentation, are marked by labelled bromodeoxyuridine, and catalysed by terminal 
deoxynucleotidyl transferase (Loo 2011; Wlodkowic, Telford et al. 2011). The other 
method includes morphological assessment by H&E staining alongside 
immunohistochemistry (IHC) to assess caspase substrates such as cytokeratin 18 
(CK18) or Poly ADP-ribose polymerase (PARP) (Tong, Chen et al. 2010). However, 
these methods applied to biopsies fail to provide detailed spatial relationship data on a 
pharmacodynamic response, as only a small part of the tumour can be evaluated, 
leading to lack of appreciation of intra-tumoural heterogeneity. Moreover, quantification 
of IHC is somewhat subjective and only observes a snapshot of cell death at a given 
point in time.  
Hence, there is a need for development of imaging techniques that could enable 
monitoring of these biological processes. Imaging biomarkers differ from conventional 
tumour biopsy derived biomarkers as they allow noninvasive serial studies on the whole 
tumour mass. 
Current standards for response evaluation  
 
The clinical evaluation of cancer therapeutics involves assessment of the 
change in tumour burden (anatomical measurements). Tumour shrinkage (objective 
response) and time to disease progression are both important, as these have been 
linked to an improvement in overall survival or other time to event measures in 
randomised phase III studies (Buyse, Thirion et al. 2000). These also determine the 
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efficacy of the drug under consideration. In order to have standardised and widely 
accepted criteria for measurement of response to allow comparisons to be made 
across studies, the Response Evaluation Criteria in Solid Tumours (RECIST) criteria 
were formulated (Therasse, Arbuck et al. 2000). These criteria have been widely 
adopted for trials where the primary endpoints are objective response or disease 
progression. Since the introduction of RECIST in 2000, the increasing utilisation of 
imaging technologies such as MRI, FDG PET and targeted cytostatic therapies, have 
prompted an update in the guidelines (RECIST v1.1) (Eisenhauer, Therasse et al. 
2009).  
According to RECIST v1.1 guidelines, tumour responses to cancer treatment 
are graded as follows: 
1) Complete Response (CR): disappearance of all target lesions. Any 
pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm. 
2) Partial Response (PR): at least a 30% decrease in the sum of diameters of 
target lesions, taking as reference the baseline summed diameters. 
3) Progressive Disease (PD): at least a 20% increase in the sum of diameters 
of target lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study). In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. Appearance of new lesions not present previously 
is also considered progression. 
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4) Stable Disease (SD): neither enough shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum of 
diameters.  
However, since measuring response by RECIST relies on the change in tumour 
size with therapy, this method has certain limitations. Firstly, uni-dimensional 
measurements may be apparent only after 3-4 cycles of chemotherapy. In non-
responders, this means subjecting them to cumulative toxicity of 3-4 cycles of treatment 
with little benefit. Moreover, the change in the tumour diameter may not be uniform. 
Secondly, changes in measurements of smaller lesions are not reliable (Revel, Bissery 
et al. 2004). Thirdly, tumours may be responding to cytostatic treatment which may not 
necessarily cause a decrease in tumour size or volume even though they may be 
affecting tumour proliferation. Due to these limitations in quantifying objective response 
to treatment, the advent of functional imaging has changed the way in which response 
to cancer therapy can be measured.  
Positron Emission Tomography 
 
 Positron emission tomography (PET) is an imaging method which uses short 
lived radioisotopes to visualise their distribution, to study molecular interactions and 
quantify regional biochemistry or metabolism in living tissues. A typical PET study 
comprises of (i) radiotracer production (ii) synthesis of radiopharmaceuticals from the 
tracers (iii) patient administration of radiopharmaceutical (iv) measuring the radioactivity 
distribution in the region of interest and (v) interpretation of activity distribution as a 
physiologic  function parameter. 
 A positron is a positively charged electron. The positrons used in PET arise 
from disintegration of unstable atomic nuclei having an excess positive charge. The 
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radio nuclides are produced in a cyclotron. Table 1 gives the reactions used to produce 
the principal radio nuclides used in PET.  
 
Table 1: Principal radio nuclides used in PET and the nuclear reaction notations and 
physical characteristics of the isotopes 
Positron 
emitting 
product 
Stable 
element 
Nuclear 
reaction 
Half life 
of 
product 
(min) 
Stable 
nucleus 
after 
positron 
emission 
Average 
Positron 
energy 
(keV) 
Positron 
range 
In soft 
tissue 
(mm) 
11
C Nitrogen (
14
N) 
14
N(p, α)
11
C 20.4 
11
B 386 1.23 
18
F Oxygen (
18
O) 
18
O(p, n)
18
F 109.8 
18
O 250 0.61 
15
O Nitrogen (
14
N) 
15
N(p, n)
15
O 2.03 
15
N 735 2.97 
13
N Carbon (
12
C) 
13
C(p, n)
13
N 10 
13
C 491 1.73 
The nuclear reaction notation 
14
N(p, α)
11
C implies that a proton (p) is bombarded into a target 
14
N nucleus, ejecting an alpha particle (α), resulting in a 
11
C nucleus. n= neutron. 
  
 The success of these positron emitters as in vivo radiotracers is due to the fact 
that (i) they are radioisotopes of physiological elements like carbon, oxygen and 
fluorine and (ii) they have short half lives (time taken for activity to decay to half the 
original activity, t1/2) requiring the need for an on-site cyclotron. The radiotracer 
produced is normally incorporated into a specific compound, target agent or drug which 
is to be imaged and is injected intravenously into the body. The radiotracer is taken up 
preferentially by certain tissues in the body depending on the region or metabolic 
pathway to be imaged.  
 The isotopes (11C, 18F) emit positrons which travel a short distance in tissues 
before colliding with an electron in the tissues causing annihilation energy in the form of 
two 511 keV photons at 180 degrees to each other (Figure 4).  
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Figure 4: Coincidence detection along the Line of Response (LOR). 
  
The emitted positron interacts with an electron in the tissue leading to annihilation photons at 
180
0
.  These photons are detected by the ring detectors containing bismuth germinate oxide 
(BGO) crystals which convert photons into an electric signal.  
 
As these photons are emitted in opposite directions, a “true” count or a “coincidence 
event” is one which consists of paired photons from a single atom somewhere along 
the line that joins the two detectors (LOR). In addition to the true coincidence, there 
could be “random” events which occur when photons from two or more atoms strike two 
oppositely arranged detectors at the same time or "multiple" coincidences when more 
than 2 photons arrive in coincidence. 
Image reconstruction 
 
 The coincident events detected are stored over preselected time frames in 
sinogram data matrices which are a stack of slices of the acquired projection views 
from 00 to 3600. There is a greater interest to store data in a list mode, where each 
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event is stored separately to disk. This allows correction for patient motion and 
improves temporal resolution. The slices from the projection views are processed into 
transaxial slices by the process of reconstruction. This is done by (a) Filtered Back 
Projection (FBP) (Webb 1990; Abella, Vaquero et al. 2009) or (b) Iterative 
reconstruction (Hudson and Larkin 1994; Hutton 2011).  
Resolution of the scanner 
 
 The resolution of a scanner  is the smallest distance (in millimetres) that side by 
side objects can be differentiated as separate in an image with infinite counts. This 
depends on (a) the distance travelled by the positron before annihilation (between 0.5 – 
2 mm) (b) variation in angle between the annihilated photons and (c) the size of the 
detectors (typically 1-3 mm). These factors taken together limit the resolution to about 
4-7 mm. Recent advances in novel detectors with 3D positioning capability (Figure 5) 
such as  cadmium-zinc-telluride (CZT) and position-sensitive avalanche photodiodes 
(PSAPDs) have a great potential for achieving spatial resolution better than 1 mm 
(Peng and Levin 2010). 
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Figure 5: Coincidence combinations for 2D and 3D modes. 
Axial cross section of a multiple ring scanner showing, the septae absorbing the photons 
scattered between the planes (dotted line), in the 2D mode. The 3D mode records the events 
between the planes increasing the number of events recorded for the same amount of 
radioactivity in the patient. This will enable reduction in scanning time. 
 
Recent Advances in PET 
 
Advances in PET detector technology 
 
Lutetium oxyorthosilicate (LSO) and its derivates paved the way for fast 
coincidence timing thereby reducing random events and improving image quality. There 
is also an increasing impetus for replacing the photo multiplier tubes (PMTs) by novel 
semiconductor-based light detectors, such as avalanche photodiodes (APDs). The 
advantages are their compactness and their insensitivity to magnetic fields and 
therefore ideal as PET light detectors in combined PET-MRI scanners (Judenhofer, 
Wehrl et al. 2008). These novel, high-sensitivity, and high-resolution PET detectors 
along with an improved computer power, and advanced electronics could potentially aid 
in the reduction of scanning time and the injected radioactivity dose.  
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Time-of-Flight PET 
 
Conventional PET uses a coincidence timing window of 3–15 nanoseconds, to 
determine if two events occur close enough in time to be a valid coincidence event. 
Therefore, it is unable to determine which voxel along the line is the source of the 
annihilation photons, giving the same probability of emission to all the voxels along the 
LOR. TOF technology provides a precise estimate of the arrival time of a photon in the 
scintillator to within a few hundred picoseconds and uses this estimate to better locate 
the annihilation position of the emitted positron with much higher precision than is 
achieved in conventional PET. This has the potential to improve image quality in PET 
scans, especially those of obese patients, due to a gain in the signal-to-noise ratio 
(SNR) (Conti 2009), and improved contrast resolution ultimately resulting in more 
efficient imaging and possibly shortened imaging times that are better tolerated by 
patients (Karp, Surti et al. 2008). This other clinical benefit is increased confidence of 
lesion detectability and accuracy of quantification (Basu, Kwee et al. 2011). 
 
PET/MRI 
 
 The merging of PET and MRI allows the combination of functional information 
provided by PET with the high soft-tissue contrast offered by MRI. Scanners that 
combine PET and MRI imaging have recently been assembled for use in humans, and 
may have diagnostic performance superior to that of PET/CT for particular clinical and 
research applications. The major strengths of MRI compared to CT, include: superior 
soft-tissue contrast, multiplanar image acquisition, functional imaging capability through 
specialised techniques such as diffusion-weighted (DW) imaging, MR spectroscopy, 
and lack of ionising radiation from MRI (Torigian, Zaidi et al. 2013). The other 
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advantages of MRI include guiding PET image reconstruction, partial volume 
correction, and motion compensation. These features enable more accurate disease 
quantification and improve anatomic localisation of sites of radiotracer uptake in various 
clinical disorders. However, the clinical applications of PET/MRI are currently not 
clearly defined as the PET/MRI technology is not clinically mature yet. The challenges 
include lack of PMT's compatible with magnetic field, MRI data not readily usable for 
PET attenuation correction, and interference of surface coils with gamma rays from 
PET (von Schulthess, Kuhn et al. 2013). 
Quantification of PET data 
Semi-quantitative Analysis  
 
PET images can be acquired in a static or dynamic mode. Static mode refers to 
the image acquired in a specific time period usually after sufficient clearance of the 
radiotracer from circulation. This is the commonest method in clinical PET imaging 
used for diagnosis and relies on the difference in tracer uptake between the region of 
interest and surrounding tissues. Visual assessment of such images is often employed 
for staging and diagnosis in oncology but is non-quantitative.  For static imaging, a 
semi-quantitative index of uptake like the Standardised Uptake Value (SUV) normalised 
by body weight, which is unit less, is useful for response assessment (Young, Baum et 
al. 1999; Tomasi and Aboagye 2013).  
xBW
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tSUV
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t
)(         Equation 1 
where, A is the activity (kBq/mL) at time t,  -the decay constant for [18F] (6.311 x 10-3) 
and for [11C] is (3.379 x 10-2), Ainj is the injected dose of tracer (kBq) and BW is body 
weight in grams. 
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Quantitative Analysis 
 
Although, in clinical practice [18F]FDG data are usually assessed visually and/ or 
using SUV, there is a need for quantitative analysis in oncology to characterise the 
pharmacokinetic properties, especially for the newer radiotracers (such as [18F]3’-
deoxy-3’fluorothymidine, [11C]choline) being introduced. Quantitative assessment is 
superior to visual assessment as it is more objective and less user dependent. It can be 
fully automated and it allows an easier comparison between centres. The changes in 
quantitative indices with treatment may help in the interim evaluation of therapeutic 
efficacy and to predict early response assessment (Tomasi and Aboagye 2013). 
Quantitative analysis requires dynamic scanning and invasive arterial blood 
sampling to measure the radiotracer concentration time activity curve in plasma (TAC).  
The parent plasma input function (IF: parent fraction of radiotracer) and total plasma IF 
(total radiotracer in plasma (parent plus metabolite)) are used together with a modelling 
approach appropriate for the radiotracer in order to estimate physiological parameters 
(the ‘‘rate constants’’), such as delivery, clearance, irreversible uptake rate, and rate of 
binding.  
The most common approach is to assign the possible distribution of the 
radiotracer to a number of discrete compartments, within which it could be free or 
trapped. This is called compartmental modelling and is the most accurate method to 
analyse PET data. There are other more data-led approaches such as Graphical and 
Spectral analyses, which have been explored as an alternative to compartmental 
modelling (Tomasi, Turkheimer et al. 2012).  
As arterial sampling requires considerable technical expertise, is invasive for the 
patient and inappropriate for routine clinical practice, alternative strategies are being 
considered which could be applied routinely in the clinical setting. If the heart is in the 
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scanner field of view the radiotracer concentration time activity curve in blood can be 
estimated directly from the PET image (image derived IF) (Cheebsumon, Velasquez et 
al. 2011). The validity of this approach however, depends on several factors, one of 
which is the confounding signal in the left ventricle due to the myocardial uptake. 
Alternative methods, such as population derived IF (Contractor, Kenny et al. 2012) and 
reference-region approach (Zheng, Wen et al. 2012), are also being extensively 
studied.  
In oncology there are other specific issues which require further consideration. 
The influence of partial volume correction (PVC), motion correction, and the penetration 
of radiometabolites into tissue and contribution to the signal measured with PET need 
to be taken into account. Deconvolution algorithms (Soret, Bacharach et al. 2007) and 
respiratory gating (Rahmim 2007) have been evaluated for PVC and motion correction, 
respectively. To account for the contribution of radiometabolites, especially for tracers 
that are rapidly metabolised, compartmental modeling and spectral analysis based on a 
double-input-function approach in which the parent radiotracer and the radiometabolite 
plasma TACs are both required as input functions has been proposed (Tomasi, 
Kimberley et al. 2012; Tomasi and Aboagye 2013). 
The standard modelling approaches are described in brief, below. 
Compartmental analysis 
  
This enables the application of the model to arterial/ venous blood and tissue 
data to calculate equilibrium blood- tissue exchange rate constants and binding kinetics 
of radiotracer into tissues like tumours (Gunn, Gunn et al. 2001; Gunn, Gunn et al. 
2002). This helps in quantitatively measuring the behaviour of radiotracer in tumours, 
reflecting tumour biology as well as possible changes in uptake with treatment. In 
compartmental modelling, knowledge of the compartments into which the radiotracer is 
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expected to be present spatially is defined a priori. These compartments include blood 
or tissue compartments including tumour (Figure 6). Kinetic parameters of interest 
which can be derived include: 
K1 - rate constant of clearance from plasma to tissue (mL/g/min) 
k2 - rate constant of clearance from tissue to plasma (min-1)  
k3 - rate constant of phosphorylation of radiotracer in tumours (min-1) 
k4 – rate constant of dephosphorylation of radiotracer in tumours (min-1) 
Compartmental modelling is based on the following assumptions: 
1. The radiotracer mixes instantly within the compartments. 
2. Concentration of the radiotracer is very small so as not to interfere with the system 
under study.  
 
Figure 6: Schematic representation of the Compartmental model.  
The radiotracer enters the tissue and can be in the free or the trapped (Csp) state. The rate 
constants (K1, k2) represent clearance between plasma and tissue. The top panel represents a 
3k model where in there is irreversible trapping of the tracer (k3). The bottom panel represents a 
4k model where there is dephosphorylation (k4).  
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Compartmental analysis is performed by modelling dynamic PET tissue uptake 
data with the blood arterial IF. If dephosphorylation is assumed to be negligible (i.e.; k4 
is negligible) during the PET scanning period, then a 3-constant (K1, k2 and k3) 
approach (3k) may be used. If dephosphorylation is expected with a radiotracer, then a 
4-constant (4k) approach (all 4 kinetic rate constants) may give better fits with this 
modelling technique. The fit of the model is decided by the goodness of fit estimated by 
one of a number of methods including the akaike information criteria (AICw) and the 
residual sum of squares (RSS). 
Modified Patlak’s method 
 
The original Patlak technique (Patlak, Blasberg et al. 1983) allows estimation of 
blood-to-tissue transfer constants from multiple time uptake data. This method is valid if 
there are no reversible metabolites. If the parent tracer is metabolised, then a 
correction is needed (Mankoff, Shields et al. 1996) to exclude the contribution of 
metabolites (which is betaine in the case of choline and FLT-glucuronide in the case of 
FLT) in the tissue-blood interface (modified Patlak method). This modification of 
Patlak’s original method has been developed for irreversible tracers to allow estimation 
of Ki (rate constant for net irreversible uptake of radiotracer into tumour) in the 
presence of reversible metabolites (Kenny, Vigushin et al. 2005). The modified Patlak 
method for [11C]choline uptake in tumours assumes that tumours don’t convert choline 
to betaine, but rather that almost all the betaine is from circulation (from liver and 
kidneys). Therefore, it is hypothesised that the Ki for [11C]choline thus derived reflects 
true net phosphorylation of [11C]choline in tumours. The Modified Patlak formula is: 
V
C
C
K
C
A
Tot
x
x
Tot

 
                      (Equation 2) 
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where V is defined as (Mankoff, Shields et al. 1996; Kenny, Vigushin et al. 2005);  
b
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VV             (Equation 3) 
A= total tissue radioactivity (kBq/mL) 
Kx= Ki   for [
11C]choline (ml plasma/s/ml tissue) 
CTot= total blood radioactivity
 (kBq/ml), 
Cx= radioactivity of parent compound determined
 by HPLC (kBq/ml) 
Cm = radioactivity of metabolite (kBq/mL) 
= time interval from time (s) of injection 
Vox= steady state space of exchangeable
 region occupied by parent 
Vom= steady state space of exchangeable
 region occupied by the metabolite 
Vb=    blood volume. 
Using this modified form of Graphical analysis, the rate constant of net uptake of 
radiotracer Ki can be calculated by fitting the metabolite corrected parent plasma IF to 
tissue activity data. If a discernible linear phase fit is observed, it signifies irreversible 
uptake; the higher the slope, the higher the Ki in tumours for the concerned radiotracer. 
The goodness of fit is expressed as the value of standard deviation (SD) of the fit.  
Spectral analysis 
 
Use of compartmental analysis is useful if the fate of the radiotracer in tissue 
and blood is known correctly. This requires prior knowledge of the biological properties 
of the radiotracer. Compartmental models however could be biased, especially in 
heterogeneous tissues such as tumours (Meikle, Matthews et al. 1998). This may also 
be the case when a priori knowledge is unavailable such as with experimental 
radiotracers. Therefore a generalised modelling approach called Spectral Analysis was 
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proposed (Cunningham and Jones 1993). With spectral analysis, linear kinetics are 
modelled without any prior assumptions of the compartmentalisation of the tracer. This 
method produces a simple spectrum of the kinetic components which relate the tissue's 
response to the blood activity curve. From this summary of the kinetic components, the 
tissue's unit impulse response (IRF) can be derived. The convolution of the arterial 
input function with the derived unit impulse response function gives the curve of best fit 
to the observed tissue data (Cunningham and Jones 1993). The IRF also helps in 
deriving fractional retention of radiotracer (FRT) at 60 min relative to 1 minute. 
Therefore, this method takes into account the time dependent contribution of 
radioactivity from plasma. The tissue activity at time “t” using spectral analysis can be 
expressed as:  
)()()( tCtIRFtA x        (Equation 4)  
Kinetic parameters, IRF and FRT, are derived from this as described below, where;  
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IRF
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FRT                          (Equation 6) 
n=number of identifiable kinetic components. 
β=constant such that λ< βi < 1 (λ=decay constant) 
α=intensity of the kinetic component at βi 
 
 
 
 
 44 
PET in Oncology 
 
Evaluation of response to anti-cancer therapy, currently, relies on routine 
imaging methods like x-rays, ultrasound scanning and computed tomography (CT). 
These methods give information about changes in anatomy and dimension of the 
tumour, which may take weeks or months to occur. The use of PET has resulted in 
accurate imaging of subtle changes in tumour biology and the detection of early 
response to anti-cancer therapy (Dose Schwarz, Bader et al. 2005). Increasing use of 
PET would help in noninvasive evaluation of early response to efficacious treatment 
agents and stop research into those with no response. 
The use of PET has generated interest in tumour imaging as biologic activity of 
the tumour and early response to therapy could be measured. This may be evident 
before any clinical or radiological response is evident by change in tumour size. PET 
imaging uses compounds labelled with a radioisotope, which is taken up by a particular 
metabolic pathway of the human cells. Since tumours have increased activity of certain 
pathways, it results in their taking up greater amounts of radioactive tracer as 
compared to adjacent normal functioning tissue. Similarly any change in activity of a 
pathway due to therapy or treatment would result in change in uptake of the tracer on 
PET (Juweid and Cheson 2006). Thus, PET is a useful tool in oncology to image 
certain metabolic pathways and response to therapy. 
 
[18F]Fluoro-deoxyglucose ([18F]FDG) 
 
Energy production in normal viable cells is predominantly the result of oxidative 
phosphorylation, as opposed to glycolysis. However, tumours use glycolysis as a 
means of energy production irrespective of oxygen levels (Warburg O 1924), resulting 
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in much faster energy production and utilisation (Warburg effect). The high rate of 
glycolysis in tumours is associated with increased glucose uptake into cells secondary 
to up regulation of membrane bound glucose-uptake-transporter proteins (GLUT1 and 
GLUT3). The glucose transporters primarily transport glucose into cells by an active-
transport mechanism and are up regulated in a wide variety of cancers (Ohba, Fujii et 
al. ; Chung, Lee et al. 1999; Laudanski, Koda et al. 2004; Nguyen, Lee et al. 2007; 
Ciampi, Vivaldi et al. 2008; Fonteyne, Casneuf et al. 2009). In addition, cancer cells 
also demonstrate  up regulation of hexokinase (HK) enzymes HK1 and HK2 causing 
increased conversion of glucose to glucose-6-phosphate and ultimately to lactate 
(Arora, Parry et al. 1992). This up regulation of GLUT and HK accounts for the high 
levels of [18F]FDG uptake in tumours (Mamede, Higashi et al. 2005). 
Initially developed as an anti-glycolytic agent, but later discontinued due to its 
adverse side-effect profile, deoxyglucose was used to measure local brain utilisation of 
glucose using [14C]deoxyglucose (Sokoloff, Reivich et al. 1977). It was shown that 
fluoro-deoxyglucose (FDG) follows the same metabolic pathway of glucose, being 
transported into cells by GLUT1 and GLUT3 and phosphorylated to FDG-6-phosphate. 
However, unlike glucose-6-phosphate, [18F]FDG-6-phosphate is not a substrate for 
further glycolytic metabolism due to substrate specificity of glucose phosphate 
isomerase, and is thus retained in the cells (Kelloff, Hoffman et al. 2005). This forms 
the basis for imaging glucose metabolism of tumours with FDG. FDG is a stable 
molecule and does not interfere with metabolic processes, making it an ideal PET 
radiotracer. Radiolabelling FDG with [18F] (medium half life of 109.7 min) enables 
transport to other centres for clinical use. 
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Application of [18F]FDG-PET in oncology 
 
[18F]FDG-PET is widely used in assessing various tumour types and has shown 
usefulness in staging, diagnosis and response assessment. In a large pooled review of 
over 18,000 patient studies, it has been shown that [18F]FDG-PET has a sensitivity of 
84% and a specificity of 88% for tumour detection (Gambhir, Czernin et al. 2001). The 
intrinsic variability or the reproducibility of [18F]FDG uptake (without treatment) ranges 
from 10 to 20% in different tumour phenotypes (Minn, Zasadny et al. 1995; Weber, 
Ziegler et al. 1999). Some of the various tumour types that have been imaged with 
[18F]FDG PET are described in Table 2. 
Table 2: Role of [
18
F]FDG PET in different tumour sites  
Tumour site Role of [18F]FDG 
Central Nervous system  
(Chen 2007; Herholz, Coope et al. 2007)  For guiding biopsy and grading 
 Determination of recurrence and 
anaplastic transformation 
Head and Neck  
(Menda and Graham 2005; Facey, Bradbury et 
al. 2007; Isles, McConkey et al. 2008) 
 Local staging (Sn:82-87%, Sp:94-
100%) 
 Detection of distant metastases 
 Assessment of treatment response 
 Detection of recurrence (Sn:94%, 
Sp:80%) 
Breast  
(Isasi, Moadel et al. 2005; Fletcher, 
Djulbegovic et al. 2008; Shie, Cardarelli et al. 
2008; De Giorgi, Mego et al. 2010) 
 For detection of recurrence and 
metastases 
 Limited value in lobular cancers, small 
tumours and low grade tumours 
 Useful for differentiating scar from 
recurrence in breast cancer 
Lung  
(Fischer, Mortensen et al. 2001; Hellwig, 
Ukena et al. 2001; van Tinteren, Hoekstra et 
al. 2002; Mac Manus and Hicks 2003; 
Vansteenkiste and Stroobants 2004; Fischer 
and Mortensen 2006; Vansteenkiste and 
Dooms 2007; Fletcher, Kymes et al. 2008) 
 Distinguishing benign from malignant 
lung nodules (Sn: 97%, Sp: 78%). 
 Accurate detection of both nodal and 
distant metastatic disease  
 Useful in staging, diagnosis and 
assessing recurrence - accuracy of 
95% compared to CT. 
 Reduce futile thoracotomies compared 
to conventional work up  
 Predictive of  patient survival 
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GI tract  
Oesophageal 
(van Westreenen, Westerterp et al. 2004) 
 Staging-detection of distant 
metastases 
Pancreatic cancer 
(Pakzad, Groves et al. 2006) 
 For initial diagnosis 
GIST 
(Esteves, Schuster et al. 2006) 
 Role in restaging- of prognostic value 
Colorectal cancer 
(Huebner, Park et al. 2000; Esteves, Schuster 
et al. 2006; Wiering, Krabbe et al. 2007) 
 Primary utility is for detecting 
metastasis after definitive therapy. 
 Detecting hepatic metastasis (Sn: 97, 
Sp: 76%). 
 Preoperative tool for potentially 
resectable liver metastases 
Genito-urinary  
(Jadvar and Conti 2004; Bouchelouche and 
Oehr 2008) 
 Staging of Seminoma 
 Detection of recurrence and residual 
mass evaluation 
Lymphoma  
(Isasi, Lu et al. 2005; Zijlstra, Lindauer-van der 
Werf et al. 2006) 
 Initial staging (pooled Sn: 91%) 
 Early response evaluation 
 
Sarcoma  
(Bourguet 2003; Bastiaannet, Groen et al. 
2004) 
 Guiding biopsy and detection of local 
recurrences 
 Differentiating low grade and high 
grade tumours 
Melanoma  
(Friedman and Wahl 2004)  Initial staging 
 
Based on pooling together reproducibility data, a consensus for quantifying PET 
response by The European Organisation for Research and Treatment of Cancer 
(EORTC) PET study group was reached (Young, Baum et al. 1999) . The tumour 
responses were graded as follows: 
1) Complete metabolic response (CMR): Complete resolution of FDG uptake. 
2) Partial metabolic response (PMR): A decrease (across all lesions) of 
minimum of 15% in tumour SUV after one cycle or >25% after more than 1 
cycle of chemotherapy.  
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3) Stable metabolic disease (SMD): An increase of < 25% or a decrease of < 
15% in SUV, and no visible increase in extent of FDG tumour uptake (20% 
in longest dimension). 
4) Progressive metabolic disease (PMD): An increase in FDG tumour SUV of > 
25% within tumour region defined on baseline scan; visible increase in 
extent of FDG tumour uptake (20% in longest dimension) or appearance of 
new FDG uptake in metastatic lesions. 
 
More recently PET Response Criteria in Solid Tumours (PERCIST) guidelines 
have been formulated (Wahl, Jacene et al. 2009). These are based on the premise that 
cancer response as assessed by PET is a continuous and time dependent variable. 
The tumour responses were graded as follows: 
1) CMR: Visual disappearance of all metabolically active tumours.  
2) PMR: More than a 30% and a 0.8-unit decline in SULpeak between the most 
intense lesion before treatment and the most intense lesion after treatment, 
although not necessarily the same lesion. 
3) SMD: Not CMR, PMR, or PMD. 
4) PMD: More than a 30% and 0.8-unit increase in SULpeak or new lesions, if 
confirmed. A greater than 75% increase in total lesion glycolysis is also 
proposed as another metric of progression. 
 
The differences between EORTC and PERCIST criteria are discussed in Table 3. 
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Table 3: Comparison between EORTC and PERCIST criteria 
EORTC criteria PERCIST criteria 
SUV normalisation 
 To body surface area (calculated with 
Dubois formula). 
SUV normalisation 
 To lean body mass (SUL: with no 
particular algorithm stated). 
Target lesion 
 The most [
18
F]FDG avid lesion on 
baseline scans, and followed on each 
subsequent scan.  
Target lesion 
 The single most metabolically active 
lesion with highest SULmean, identified, 
with a 1.2 cm diameter spherical 
region of interest (ROI) drawn in the 
hottest part of that lesion. SULmean of 
this ROI is SULpeak. 
 Baseline SULpeak had to exceed 
1.5*liver SULmean+2*SD of liver 
SULmean or 2*aorta SULmean+2*SD of 
aorta SULmean for the tumour to qualify 
as a target lesion. 
 On subsequent scans, SULpeak could 
be located in a different lesion from the 
one measured at baseline, as long as 
the lesion had been present since 
baseline. 
Number of lesions 
 Not specified 
Number of lesions 
 Five tumours (up to 2 per organ) with 
the most intense [
18
F]FDG uptake. 
Imaging variable 
 Not specified whether to use SUVmax 
or SUVmean for response calculation. 
Imaging variable 
 Recommended to use SULmean (as it 
has better test–retest variability (8%–
10%) and is statistically less 
susceptible to variance. 
Cutoff value  
 25% for PMR and PMD is based on a 
literature review 
Cutoff value 
 30% for PMR and PMD is based on 
the correlation found between a 
decrease in SUV of > 30%–35% and 
good outcome.  
Background level of [
18
F]FDG uptake 
 No definitions are stated of a 
background level of [
18
F]FDG uptake 
that a viable tumour should exceed in 
order to qualify as a target lesion. 
Background level of [
18
F]FDG uptake 
 Because of less test–retest variance, a 
liver background area is 
recommended, and clear definitions of 
target lesion [
18
F]FDG uptake in 
proportion to background uptake are 
given. 
 The size of the ROI, number of target 
lesions to be considered are outlined 
more as guidelines with options rather 
than clear definitions, therefore more 
susceptible to inter-observer 
differences than PERCIST. 
 Clear definitions of target lesions and 
therefore less subjective 
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However, [18F]FDG has the following limitations: (1) False positive uptake in 
some benign processes, such as infectious and inflammatory lesions (van Waarde and 
Elsinga 2008); (2) low sensitivity in well-differentiated low-grade tumours that have 
relatively low glucose metabolism such as carcinoid tumours, bronchoalveolar cell 
carcinoma, and renal cell carcinoma (Higashi, Ueda et al. 1998; Schoder and Larson 
2004; Fleming, Gilbert et al. 2010); (3) low sensitivity in hypo cellular cancers such as 
desmoplastic or mucinous tumours (Higashi, Saga et al. 2003); (4) increased [18F]FDG 
accumulation in some normal body areas such as lymphoid tissue and brown fat 
(Wechalekar, Sharma et al. 2005); and (5) Lack of clinical utility due to increased 
urinary excretion and lower expression of GLUT in prostate cancer (Schoder and 
Larson 2004). Thus, newer radiotracers to image tumours accurately are being 
developed to address these shortcomings, as well as explore other metabolic pathways 
of tumours which can be imaged using PET. 
 [18F]3’-deoxy-3’fluorothymidine ([18F]FLT) 
 
Proliferation Imaging 
 
 Self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) 
signals and limitless replicative potential, all lead to increased cellular proliferation; a 
hallmark of cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). Of 
the 4 nucleosides, thymidine is exclusively used in DNA synthesis, making it an 
attractive substrate to image cell proliferation. Various methods of measuring the rate of 
tumour growth have been proposed as early as 1960. The first methods to measure 
proliferation involved incorporation of radiolabelled [3H-methyl]thymidine or [14C-
methyl]thymidine  by either injecting these radiochemicals directly into tumours before 
 51 
biopsy or applying to fresh tumour samples and then assayed by thin-section 
autoradiography. Quantification was done by counting the fraction of tumour cells 
containing the radioactivity (the thymidine labelling index).  
Thymidine transport and metabolism 
 
 Thymidine, after entering the cells by multiple different transporters passively or 
actively (Perumal, Pillai et al. 2006; Plotnik, Emerick et al. 2010), is phosphorylated by 
thymidine kinase 1 (TK1) into a more charged molecule and cannot freely exit the cells. 
Tumour uptake of [3H]thymidine was first demonstrated in mice and dogs by Shields et 
al (Shields, Larson et al. 1984). Its use in nuclear imaging, when labelled with [11C], has 
been limited by the short half-life of the tracer and its rapid catabolism in the body 
(Shields, Mankoff et al. 1996). This limitation has led to development of a newer 
thymidine analogue, 3’-deoxy-3’fluorothymidine (Grierson and Shields 2000).  
[18F]3’-deoxy-3’fluorothymidine (FLT) 
 
 The replacement of the hydroxyl group at the 3’ position of deoxyribose 
converts thymidine to FLT. FLT has been developed as a tracer for imaging 
proliferation. FLT is transported into the cell by Na+-dependent active nucleoside 
transporters and to a lesser extent by passive diffusion (Reske and Deisenhofer 2006; 
Plotnik, Emerick et al. 2010). FLT is a selective substrate for TK1 and a very poor 
substrate for TK2 (Munch-Petersen, Cloos et al. 1991). TK1 phosphorylates FLT to 
FLT-monophosphate (FMP) which, being a highly charged molecule, is trapped 
intracellularly. Slow dephosphorylation of FMP probably occurs via a putative 5-
nucleotidase enzyme (Grierson, Schwartz et al. 2004; Wells, West et al. 2004). Unlike 
thymidine, FLT is not incorporated into DNA and remains trapped in the cytoplasm. FLT 
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incorporation into the DNA fraction is negligible (0.2%) (Toyohara, Waki et al. 2002). 
TK1 activity is virtually absent in quiescent cells but is up regulated in the S-phase of 
the cell cycle in proliferating cells.  Therefore, up regulated TK1 activity is 
representative of the S-phase fraction  (Toyohara, Waki et al. 2002) and FLT uptake as 
a measurement of TK1 activity, acts as an indirect marker of cell proliferation. Animal 
studies (Barthel, Cleij et al. 2003; Leyton, Latigo et al. 2005) have validated [18F]FLT as 
a marker of proliferation and formed the basis of clinical studies using [18F]FLT as PET 
ligand (Table 4). A meta-analysis of the studies on [18F]FLT uptake and tumours 
expressing Ki-67 showed a persistent correlation between them (Chalkidou, Landau et 
al. 2012). 
Application of [18F]FLT in imaging tumours 
 
 Imaging of tumour proliferation with [18F]FLT can be applied to predict the 
response to treatment based on imaging values obtained during the course of 
treatment. The rationale being, treatment-induced changes in tumour physiology will 
predict tumour cell viability earlier than anatomic imaging. To date, early clinical trials 
using [18F]FLT PET, supported by pre-clinical data, have shown encouraging results in 
validating [18F]FLT to be a biomarker of tumour proliferation and for predicting response 
to cancer therapy (Bading and Shields 2008; Tehrani and Shields 2013) (Table 4). In 
general [18F]FLT uptake has frequently been reported to be lower than [18F]FDG uptake 
in these tumours. No toxicities have been reported in the literature in relation to the use 
of [18F]FLT for PET imaging (Spence, Muzi et al. 2008). 
 However, abdominal imaging with [18F]FLT is challenging due to glucuronidation 
of the radiotracer resulting in the physiological uptake in the liver (Shields 2003); in the 
kidneys and bladder, where it is excreted; and in the marrow, where proliferation 
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occurs. A scanning protocol and an associated mathematical kinetic spatial filtering 
(KSF) algorithm that permits imaging of abdominal tumours, including liver metastases 
have been developed (Gray, Contractor et al. 2010). No data were found in the 
literature with respect to [18F]FLT-PET as a marker of early tumour response in 
pancreatic cancer, and this marker therefore needs to be qualified in order to define its 
potential role in clinical practice and in assessing the efficacy of new, targeted 
therapies. Hence [18F]FLT was chosen as a PET radiotracer in this thesis to further 
explore the feasibility of the kinetic filter to enable visualisation of the pancreatic 
primary and liver metastases and to evaluate detection of early tumour response 
(Chapter 2). 
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Table 4: Selected studies evaluating the role of [
18
F]FLT 
Preclinical  
(Barthel, Cleij et al. 2003) 52.2% and 72.9% reduction of [
18
F]FLT at 24 and 48 hours respectively after 
administration of 5-Fluorouracil to mice bearing radiation induced fibrosarcomas. 
(Barthel, Perumal et al. 2005) In vivo [
18
F]FLT kinetics in mouse lymphoma tumours are dependant on thymidine kinase 
(TK1) protein expression. 
(Sugiyama, Sakahara et al. 2004; Waldherr, 
Mellinghoff et al. 2005) 
Tumour bearing mice imaged with [
18
F]FLT and [
18
F]FDG showed that [
18
F]FLT levels in 
tumours declined by 30% at 6 hours whereas [
18
F]FDG uptake decreased at 3 days 
following treatment. [
18
F]FLT uptake in these studies also reflected decrease in tumour 
proliferation. 
(Leyton, Latigo et al. 2005) Mean tumour [± Standard deviation (± SD)] [
18
F]FLT uptake decreased by 24% (± 8%) 
and 49% (± 8%) at 1 and 2 days, respectively after administration of cisplatin in mice 
bearing radiation induced fibrosarcomas. 
(Leyton, Alao et al. 2006) [
18
F]FLT PET evaluated for monitoring the biological activity of the histone deacetylase 
inhibitor, LAQ824 showed that drug induced changes in tumour [
18
F]FLT uptake were due 
to reductions in TK1 transcription and translation. 
(Perumal, Pillai et al. 2006) Thymidylate synthase inhibition measured by [
18
F]FLT PET, as early as 1 to 2 hours after 
treatment with 5-FU involves redistribution of nucleoside transporters to the plasma 
membrane. 
(Perumal, Stronach et al. 2012) Therapeutic inhibition of AKT activation in acquired platinum-resistant ovarian cancer can 
be imaged noninvasively by [
18
F]FDG and [
18
F]FLT PET. 
  These studies underpinned clinical studies using [
18
F]FLT as a radiotracer in PET. 
Central Nervous System  
(Miyake, Shinomiya et al. 2012) A comparative study of [
18
F]FDG, [
18
F]FLT, and [
11
C]methionine PET showed that both 
[
18
F]FLT and [
11
C]methionine are able to differentiate patients with grade II–IV gliomas. 
The mean [
18
F]FLT SUVs were 0.36 and 2.38, respectively, and [
11
C]methionine SUVs 
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were 3.04 and 5.12, respectively. [
18
F]FLT retention correlated with Ki-67 index. 
(Schwarzenberg, Czernin et al. 2012)  In 30 patients with gliomas [
18
F]FLT, particularly at 6 wk post bevacizumab combination 
therapy, was the best predictor of overall survival (responders; 12.5 m vs. nonresponders; 
3.8 m (P <0.001)) and more accurate than MR imaging alone.  
(Harris, Cloughesy et al. 2012) [
18
F]FLT uptake was associated with longer progression-free survival in recurrent 
malignant gliomas after bevacizumab treatment. 
Head & Neck Cancer  
(Linecker, Kermer et al. 2008)  In 19 untreated patients of primary head and neck cancers, who had both [
18
F]FLT and 
[
18
F]FDG PET, the mean SUVmax of [
18
F]FLT was lower than that of [
18
F]FDG SUV  (5.81 
± 2.28 vs. 8.91 ± 3.58). There was no correlation between the number of Ki-67–positive 
cells and [
18
F]FLT uptake. 
(Troost, Bussink et al. 2010) In 10 patients undergoing radiation treatment for oropharyngeal tumours, [
18
F]FLT uptake 
decreased rapidly (as early as 1 wk) after the start of therapy and before CT volumetric 
changes. There was even further reduction before the fourth week of treatment. 
(Hoshikawa, Kishino et al. 2012)  In 23 patients with metastatic lymph nodes who had [
18
F]FLT PET and [
18
F]FDG PET, the 
[
18
F]FLT SUV was lower than that of [
18
F]FDG SUV  (4.8 ± 2.9 vs. 6.9 ± 4.9, respectively 
(P <0.001)).  
(Kishino, Hoshikawa et al. 2012) [
18
F]FLT PET during radiation treatment and early follow-up may help with prediction of 
outcome. 28 patients with head and neck squamous cell carcinomas undergoing chemo 
radiation, had [
18
F]FLT and [
18
F]FDG PET before therapy, 4 wk after the start of therapy, 
and then 5 wk after completing radiation therapy. Both FLT & FDG had high negative 
predictive value (97% & 100%, respectively).  
Breast Cancer  
(Smyczek-Gargya, Fersis et al. 2004)  In a study of newly diagnosed breast cancer patients, [
18
F]FLT was able to detect 13 of 14 
primary lesions and 7 of 8 patients with positive axillary nodes. 
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(Kenny, Coombes et al. 2007)  Changes in [
18
F]FLT uptake were detectable as early as 1 wk after initiation of 
chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide. The average 
decrease in SUV in responding lesions was 41.3%, in contrast to an increase of 3.1% in 
nonresponders. 
This study also tested the reproducibility of [
18
F]FLT; i.e. the intrinsic variability between 
two scans before treatment. An [
18
F]FLT-PET metabolic response is defined as a 
decrease in average semi-quantitative [
18
F]FLT uptake SUV of > 18% from baseline. 
(Contractor, Kenny et al. 2011) Early changes in [
18
F]FLT PET uptake after initiation of neoadjuvant docetaxel 
chemotherapy in 20 breast cancer patients, predicted midtherapy lesion response with 
85% sensitivity and 80% specificity. 
Lung Cancer  Most studied malignancy using [
18
F]FLT PET.  
 Uptake of [
18
F]FLT in lung cancers is significantly lower than that of [
18
F]FDG, with 
lower sensitivity, higher specificity, and higher positive predictive value 
(Buck, Halter et al. 2003)  Twenty-six patients with lung cancer were imaged with [
18
F]FDG and [
18
F]FLT. [
18
F]FLT 
uptake was only a third of that of [
18
F]FDG with a lower sensitivity of detection (85% for 
FLT compared with 100% for FDG). However, this study demonstrated that [
18
F]FLT 
uptake correlated better with proliferation in lung tumours as measured by Ki-67. 
(Yamamoto, Nishiyama et al. 2007; 
Yamamoto, Nishiyama et al. 2008)  
Eighteen patients with newly diagnosed NSCLC were imaged with [
18
F]FLT PET and 
[
18
F]FDG PET. The sensitivity was detected to be 72% and 89%, respectively. Four of the 
5 false negative [
18
F]FLT PET findings occurred in bronchoalveolar carcinoma. This could 
be attributed to the slower growth and differences in the kinetics and dynamics of [
18
F]FLT 
in these tumours. 
Sohn (Sohn, Yang et al. 2008) This study showed the ability of [
18
F]FLT in predicting response to an EGFR inhibitor 
gefitinib in lung cancer patients, as early as 7 days after initiation of therapy. 
(Brockenbrough, Souquet et al. 2011)  Twenty-five suspected lung cancer patients underwent [
18
F]FLT PET before surgical 
resection. The SUVmax was compared to Ki-67 and TK1 expression determined by 
immunohistochemical staining and TK1 enzymatic activity. The SUVmax correlated with the 
overall (r = 0.57, P = 0.006) and maximal (r = 0.69, P < 0.001) immunohistochemical 
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expressions of Ki-67 and TK1 but not with TK1 enzymatic activity (r = 0.34, P = 0.146). 
(Zander, Scheffler et al. 2011) In this study, 34 patients were imaged with [
18
F]FDG and [
18
F]FLT uptake after 1 and 6 wk 
of erlotinib treatment. The changes in uptake were compared with response measured by 
CT after 6 wk of treatment. Early [
18
F]FLT response predicted longer PFS but not overall 
survival and could not predict non-progression after 6 wk of therapy. 
(Yang, Zhang et al. 2012)  SUVmax significantly correlated with the Ki-67 in 68 patients with NSCLC 
(Kahraman, Holstein et al. 2012)  Thirty patients with stage IV NSCLC were imaged with [
18
F]FLT and [
18
F]FDG PET, 
before, 1 wk, and 6 wk after the start of erlotinib treatment. Patients with lower early and 
late residual [
18
F]FDG and [
18
F]FLT uptake had a significantly prolonged progression-free 
survival (PFS). A cut-off value of 30% decrease in [
18
F]FLT uptake was used to define 
metabolic response. 
Gastro-intestinal Cancers  
(van Westreenen, Cobben et al. 2005)  In this study on 10 patients with biopsy-proven oesophageal and gastro-oesophageal 
cancer, the SUVmean of [
18
F]FDG was higher than that of [
18
F]FLT and neither correlated 
with Ki-67 expression. 
(Herrmann, Ott et al. 2007)  Forty-five gastric cancer patients had both [
18
F]FLT and [
18
F]FDG PET. All tumours were 
visible with [
18
F]FLT PET but 14 tumours were not detectable with [
18
F]FDG because of 
high normal gastric uptake. The SUVmean of [
18
F]FDG was higher than that of [
18
F]FLT. 
Interestingly, signet ring cell tumours had similar uptake of both tracers. 
(Herrmann, Eckel et al. 2008)  In 31 patients with pancreatic lesions, receiver-operating-characteristic analysis using a 
[
18
F]FLT SUVmean cut off of 1.8 had a sensitivity of 81% and specificity of 100% to 
differentiate cancer from benign pancreatic lesions. On visual interpretation, 15 of 21 
malignant tumours had higher uptake (sensitivity-71.4%). All 10 benign pancreatic lesions 
were negative on [
18
F]FLT PET. 
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(Quon, Chang et al. 2008)  Visual discrimination between benign and malignant pancreatic tumours has proven 
difficult in this study with 5 patients. 
(Kameyama, Yamamoto et al. 2009)  In 21 patients with advanced gastric cancer, the sensitivities of [
18
F]FLT PET and 
[
18
F]FDG PET were 95.2% and 95.0%, respectively. The SUVmean of [
18
F]FDG was higher 
than that of [
18
F]FLT and neither correlated with Ki-67 expression.  
(Eckel, Herrmann et al. 2009)  [
18
F]FLT PET imaging in untreated patients with hepatocellular carcinoma (16 patients) 
showed sensitivity for tumour detection of 69%, correlating with Ki-67 score. 
(Yamamoto, Kameyama et al. 2009) In evaluation of colon cancer patients, all primary tumours were detected. [
18
F]FLT 
uptake was found to be lower than [
18
F]FDG uptake, with a SUVmean of 5.4 and 12.4, 
respectively (P=0.003). There was no correlation between [
18
F]FLT uptake and Ki-67. 
(Yue, Chen et al. 2010)  In imaging proliferation and response to radiation and chemotherapy in oesophageal 
squamous tumours, it was shown that [
18
F]FLT uptake rapidly decreased after the start 
of radiotherapy, as early as after 2 Gy of radiation.  
(Ott, Herrmann et al. 2011) In 45 patients with gastric cancer, early response (2 wk after initiation) to neo-adjuvant 
chemotherapy was evaluated with [
18
F]FLT PET and [
18
F]FDG PET. [
18
F]FLT was found to 
have significant prognostic impact and a good correlation with histological proliferation (Ki-
67). However, neither [
18
F]FLT nor [
18
F]FDG uptake predicted clinical or pathologic 
response. 
(Kameyama, Yamamoto et al. 2011) Demonstrated a significant correlation between [
18
F]FLT SUV and thymidine kinase 1 
(TK1) messenger RNA expression, in 21 patients with GI cancer. However, no significant 
correlation was found between SUV and messenger RNA expression of equilibrating 
nucleoside transporter 1 (ENT1). 
(Herrmann, Erkan et al. 2012)  Pancreatic cancer has significantly lower uptake of [
18
F]FLT than of [
18
F]FDG, leading to 
lower sensitivity (70% vs. 91%, respectively) and higher specificity (75% vs. 50%) in 
differentiating malignant from benign tumours, in a study with 41 patients (33 with 
pancreatic malignancy and 8 with benign disease). The average SUVmax in all malignant 
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tumours was 3.0 (range, 1.1–6.5) for [
18
F]FLT and 7.9 (range, 3.3–17.8) for [
18
F]FDG. 
(Dehdashti, Grigsby et al. 2013)  In rectal cancer patients receiving neo-adjuvant chemo-radiotherapy, [
18
F]FLT uptake 
and the percentage decrease during therapy predicted the disease-free survival, but did 
not predict the pathologic response to treatment. 
Hematologic Malignancies  
(Herrmann, Wieder et al. 2007)  In patients with high-grade NHL, treatment with CHOP/R-CHOP (rituximab, 
cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone) resulted in a 77% 
decrease in [
18
F]FLT retention as early as a week after therapy initiation.  
(Vanderhoek, Juckett et al. 2011)  A pilot study on 7 patients imaged with [
18
F]FLT PET immediately after completion of 
induction chemotherapy was able to accurately predict remission (5 patients) or relapse (2 
patients) at 1 month. 
(Herrmann, Buck et al. 2011)  In a study of 66 patients with mantel cell lymphoma, the relative uptake of [
18
F]FLT before 
the start of therapy was predictive of the ultimate response to treatment, with those 
achieving complete response having a lower mean SUV of 7.1, compared with 9.5 in the 
other patients The authors also noted a rapid decline in [
18
F]FLT retention after 1 wk of 
therapy. 
(Wang, Zhu et al. 2012) In this study of 38 non-Hodgkin lymphoma (NHL) patients, staging with [
18
F]FLT PET/CT 
had a higher sensitivity and specificity than CT alone. 
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 [11C]methylcholine 
Choline transport and metabolism 
 
Choline is one of the components of phosphatidylcholine (PC), an essential 
part of phospholipids in the cell membrane (Zeisel 1981) and is required for 
structural stability and cell proliferation. It is also essential for the synthesis of 
neurotransmitters like acetylcholine (by reaction of choline with acetyl-CoA), and 
production of potent lipid mediators such as platelet-activating factor. Choline kinase 
(CHK) is the first enzyme in the Kennedy pathway (Gibellini and Smith 2010), and is 
responsible for the de novo synthesis of PC. CHK phosphorylates choline to 
phosphocholine (PCho), the rate limiting step in the Kennedy pathway. PCho is 
further phosphorylated to cytidine diphosphate-choline (CDP-choline) by the 
enzyme cytidyltransferase and then to other intermediates before being 
incorporated into cell membrane phospholipids as PC. 
 Besides choline metabolism, altered choline transport has also been 
proposed to play an important role in multiple clinical manifestations in various 
cancers, including prostate, breast, lung and ovarian cancer (Iorio, Ricci et al. ; 
Ackerstaff, Pflug et al. 2001; Villa, Caporizzo et al. 2005; Wang, Li et al. 2007). As 
cells have a limited capacity to synthesise choline, the major source of choline is 
principally from the extra cellular choline pool through uptake by the choline 
transport system (Zeisel 2000; Michel, Yuan et al. 2006). Three protein mediated, 
saturable uptake systems for transport have been documented (van Rossum and 
Boyd 1998):  
1. Facilitated diffusion – driven by a choline concentration gradient. 
2. High affinity active transport – this is Na+ and energy dependent and plays a 
role in acetylcholine synthesis in neuronal tissues. 
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3. Low affinity active transport – this process is more widely distributed and 
plays a role in choline uptake for the purpose of phospholipid synthesis. 
Depending on the affinity for choline, the proteins playing a role in transport have 
been categorised into 3 groups (Michel, Yuan et al. 2006): 
1. Organic cation transporters (OCTs and OCTNs) – both with low affinity for 
choline, have been widely detected in human tissues and they may be 
involved in transport of choline for phospholipid synthesis.  
2. Choline transporter-like proteins (CTLs) – intermediate affinity for choline. 
They are responsible for Na+ independent choline transport and production 
of membrane phospahtidyl choline in some non-neuronal tissues. 
3. High affinity choline transporters (CHTs) – involved in acetylcholine 
synthesis. These have been detected in human brain and spinal cord.  
In addition to phosphorylation, free choline also participates in 2 other 
enzyme catalyzed pathways in mammalian tissues: oxidation and acetylation, of 
which the predominant pathway is oxidation. Choline is oxidised to betaine 
aldehyde, which is then converted into betaine by the enzyme system of choline 
oxidase (choline dehydrogenase and betaine aldehyde dehydrogenase) (Ueland 
2011). Liver and kidney are the major sites for choline oxidation. Betaine synthesis 
from choline is controlled by the choline transport into the mitochondria 
(O'Donoghue, Sweeney et al. 2009).  
Hence, the expression pattern and characteristics of choline transporters 
choline phosphorylation and choline oxidation are of central importance to 
understand the process of choline metabolism that underlies cell signalling & growth 
and membrane integrity in various diseases. 
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Choline and Malignancy 
 
Malignant tumours show high proliferation and increased cell membrane 
components that will lead to an increased uptake of choline. The progression of 
normal cells to malignant phenotype is associated with altered membrane choline 
phospholipid metabolism (Aboagye and Bhujwalla 1999). Generation of PCho from 
CHK activity has been described as an essential event in growth factor induced 
mitogenesis in fibroblasts (Jimenez, del Peso et al. 1995) and has been found to 
cooperate with several mitogens (Chung, Crilly et al. 1997). CHK has been 
extensively linked to cell proliferation and human carcinogenesis (Ramirez de 
Molina, Penalva et al. 2002; Ramirez de Molina, Rodriguez-Gonzalez et al. 2002; 
Yoshimoto, Waki et al. 2004). CHK consists of 2 sub-types α and β (Gallego-
Ortega, Ramirez de Molina et al. 2009). 
CHKα is thought to regulate cell proliferation and transformation by 
regulating the G1 to S phase transition of the cell cycle and apoptotic signalling 
(Ramirez de Molina, Gallego-Ortega et al. 2008). A strong correlation between CHK 
activity and cancer onset has been proposed based on the fact that CHK 
dysregulation is a frequent event occurring in a variety of human tumours such as 
breast, lung, colorectal and prostate tumours (Ramirez de Molina, Rodriguez-
Gonzalez et al. 2002; Ramirez de Molina, Banez-Coronel et al. 2004). CHKα has 
also been described as a new relevant prognostic factor in lung cancer (Glunde and 
Bhujwalla 2007; Ramirez de Molina, Sarmentero-Estrada et al. 2007). 
All this evidence points to the central role of CHKα in the progression of 
certain tumour types, hence detecting increased CHKα expression in cancer 
patients could enable identification of a cohort in whom CHK inhibitors may prove 
beneficial.  
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Application of [11C]choline in imaging tumours 
 
Malignant transformation is postulated to be associated with changes in 
pathways of choline transport, utilisation and increased CHKα expression that will 
lead to an increased uptake of choline (Ackerstaff, Pflug et al. 2001; Glunde, 
Bhujwalla et al. 2011). Radiolabelling of choline with [11C] enables this molecule to 
be used as a PET tracer. During phosphorylation, the carbon label [11C] is trapped 
intracellularly (Hara, Kosaka et al. 1998), thus enabling imaging of this metabolic 
pathway. Hara and colleagues have also shown that [11C]choline had good uptake 
in brain tumours with almost negligible activity in the blood after 5 minutes. This 
work inspired others to use [11C]choline as a PET radiotracer to image other 
tumours including renal (Schoder and Larson 2004), oesophageal (Kobori, Kirihara 
et al. 1999; Jager, Que et al. 2001; Tamura, Yoshikawa et al. 2002; Tian, Zhang et 
al. 2004; Ramirez de Molina, Sarmentero-Estrada et al. 2007) and NSCLC (Ramirez 
de Molina, Sarmentero-Estrada et al. 2007).  
[11C]choline is particularly useful in prostate cancer as there is negligible 
urinary bladder excretion, a problem with [18F]FDG due to rapid excretion of FDG in 
urine, causing an accumulation of activity in the bladder, making visualisation of the 
prostate difficult. The utility of [11C]choline in visualising and staging prostate cancer 
has been published (Hara, Kosaka et al. 1998; Reske, Blumstein et al. 2006). The 
published studies show varied and conflicting results in the sensitivity of detection of 
the primary prostate tumours and the nodal metastases (Farsad, Schiavina et al. 
2005; Kwee, Coel et al. 2005; Yamaguchi, Lee et al. 2005; Reske, Blumstein et al. 
2006).  
Preliminary studies of [11C]choline PET in pelvic nodal staging in prostate 
cancer patients have shown early promise (Kotzerke, Prang et al. 2000; de Jong, 
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Pruim et al. 2003; Schiavina, Scattoni et al. 2008). However, no study to date has 
established a direct relationship between CHKα expression and [11C]choline uptake 
in prostate tumours. Hence, [11C]choline PET/CT was evaluated as a non invasive 
method for detecting pelvic lymph node status in patients with high risk localised 
prostate cancer. The relationship between [11C]choline uptake (SUV), choline kinase 
expression (immunohistochemistry scores) and Ki67 in prostate tumours and 
involved nodes were compared. 
Furthermore, there has been no prior study documenting the use of 
[11C]choline PET/CT to predict early response to a combination of androgen 
deprivation and radiotherapy.  Hence, [11C]choline has been chosen to establish 
[11C]choline PET/CT as a biomarker for assessing early response of neo-adjuvant 
androgen deprivation and radiotherapy in patients receiving radical treatment for 
prostate cancer. These studies are described in detail in subsequent chapters. 
Choline Kinase Immunohistochemistry 
 
Malignant transformation causes the prostate epithelial cells to lose their 
differentiation. In addition, there is an increased turnover of cells, with proliferation 
of tumour cells and apoptosis. This increased cell turnover results in an increase of 
choline-containing molecules within the prostate gland (Daly, Lyon et al. 1987; 
Ackerstaff, Pflug et al. 2001). In vitro data and Magnetic Resonance Spectroscopy 
(MRS) of the prostate have demonstrated that it is possible to distinguish between 
healthy prostate tissue, with high concentration of citrate and low concentration of 
free choline containing molecules, and malignant prostate tissue with decreased 
concentration of citrate and increased concentration of free choline-containing 
molecules (Garcia-Segura, Sanchez-Chapado et al. 1999; Ackerstaff, Pflug et al. 
2001). 
  
65 
 
Immunohistochemistry (IHC) is an investigative tool which provides 
supplemental information to the routine morphological assessment of tissues. Its 
use in studying cellular markers that define specific phenotypes has provided 
important diagnostic, prognostic, and predictive information about the disease status 
and tumour biology. IHC against CHKα has been used with encouraging results in 
human breast and lung cancer tissue samples (Gallego-Ortega, Ramirez De Molina 
et al. 2006). However, there is a paucity of data with regards to the patterns of 
expression of CHKα in human prostate cancer tissue samples.  
The correlation between the expression of CHKα and [11C]choline uptake 
parameters will help evaluate if [11C]choline PET can be used as a surrogate for 
CHKα expression. Hence a new CHKα antibody staining protocol has been 
optimised to assess patterns of CHKα expression in human prostate tissue 
samples. The rationale and findings are discussed in detail in chapter 3. 
Modelling of [11C]choline PET data 
 
After [11C]choline injection, the specific PET signal is due to its 
phosphorylated product, [11C]phosphocholine. This PET signal is confounded by the 
contribution from the parent tracer [11C]choline (transport), and the oxidative by-
product [11C]betaine (Figure 7). The [11C]choline is oxidised to [11C]betaine by 
choline oxidase mainly in the kidney and the liver. The metabolites are detected in 
the plasma soon after the injection of the radiotracer (Roivainen, Forsback et al. 
2000). This makes the discrimination of the relative contributions of the parent 
radiotracer and the metabolites difficult.  It has been shown preclinically in tumours 
in mice, that there could be oxidation of choline to betaine even in the tumour 
tissues contributing to the radiotracer uptake (Leyton, Smith et al. 2009). However, 
there is inadequate data on the proportion of betaine oxidised in the liver , kidney 
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and that oxidised in tumours. Moreover, the metabolism is faster in rodents than in 
humans (Roivainen, Forsback et al. 2000). The two possible mechanisms 
contributing to betaine levels in the blood could therefore be:  (1) rapid elimination 
through oxidation in liver and kidney; (2) efflux from the tumour cells. Therefore, 
assessment of [11C]choline phosphorylation and choline oxidation by kinetic 
modelling of PET data may help in our understanding of the role of choline 
metabolism in tumours and improve the specificity of the choline signal. The full 
arterial blood data available from the [11C]choline PET breast data have been 
explored and the information has been used to predict the performance of a limited 
sampling venous data set in prostate cancer patients. The results have been 
described in detail in chapter 3.  
 
Figure 7: Putative fate of [
11
C]choline after injection into blood stream.  
Choline is transported into tissues by choline transporters or passive diffusion. It is then 
phosphorylated into phosphocholine by CHK via the Kennedy pathway. Choline is oxidised 
to betaine in the liver and kidney. 
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New Tracers: [18F]fluoromethyl-[1,2-2H4]choline ([
18F]D4FCH) 
[18F]Fluorocholine 
 
[
18
F]Fluorocholine ([18F]FCH) was developed to overcome the short physical 
half-life of carbon-11 (20.4 min). The longer half-life (109.8 min) of [
18
F] was 
deemed potentially advantageous in permitting late imaging of tumours when 
sufficient clearance of parent tracer in systemic circulation had occurred. Since the 
use of [18F]FCH was first reported by DeGrado and co-workers (DeGrado, Coleman 
et al. 2001), [18F]FCH has been extensively used in patients and has been proven 
safe for human administration (Table 5). None of the studies have reported any 
adverse effects with the use of this radiopharmaceutical. Furthermore the 
radiopharmaceutical has been approved for diagnostic use in Europe. The main 
approved indications are for the detection of bone metastases of prostate cancer, 
the localisation of lesions of well-differentiated hepatocellular carcinoma, and the 
characterisation and/or staging of hepatocellular carcinoma, when [
18
F]FDG PET is 
inconclusive and/or when surgery is scheduled 
(http://www.rcr.ac.uk/docs/radiology/pdf/BFCR%2812%293_PETCT.pdf).  
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Table 5: Summary of selected [
18
F]FCH PET studies in humans. 
Author 
Sample 
size 
Conclusions 
Prostate  
(Schmid, John et al. 
2005) 
9 
Nine patients evaluated with FCH PET for staging prostate cancer. FCH could not differentiate between 
Benign Prostate Hypertrophy (BPH) and Carcinoma Prostate (PCa). 
(Kwee, Coel et al. 
2005) 
17 
Increased uptake of FCH was demonstrated in biopsy positive regions than in biopsy negative areas in 17 
patients. 
(Kwee, Wei et al. 
2006) 
15 Delayed imaging up to 1 hour is needed to differentiate between BPH and PCa. 
(Hacker, Jeschke et 
al. 2006) 
10 In node negative patients, FCH PET detected nodes in 1 patient and 2 cases were false positive. 
(McCarthy, Siew et al. 
2010) 
26 
In hormone refractory prostate cancer (HRPC), FCH findings were concordant with bone scan and CT in 
detecting metastases. 
(Husarik, Miralbell et 
al. 2008) 
111 
Delayed imaging increased pick up rate of bone metastases, but time of scan had no influence on Local 
Recurrence (LR)/nodal metastases. 
(Langsteger, Heinisch 
et al. 2006) 
49 6/49 high risk patients were upstaged with FCH PET. 
(Cimitan, Bortolus et 
al. 2006) 
52 Cannot detect LR/Metastases if the PSA<4ng/ml 
(Pelosi, Arena et al. 
2008) 
56 FCH PET sensitivity increases with increasing PSA. 
(Beauregard, Williams 
et al. 2010) 
16 
Compared FDG and FCH PET. Both were more sensitive than MRI/CT in providing clinical information (88% 
vs. 56%) 
(Beheshti, Imamovic 
et al. 2010) 
130 
In pre op staging of Intermediate Risk (IR)/High Risk (HR) patients, FCH PET changed treatment in 15% of all 
patients and in 20% of HR patients. It also excluded bone metastases. 
(Poulsen, 
Bouchelouche et al. 
2010) 
25 FCH PET is a tool for nodal staging, but larger studies are needed. 
Central Nervous System  
(Lam, Ng et al. 2010) 2 High Grade Glioma (HGG) showed increased choline uptake 
(Hara 2002)  Showed an increased tumour to normal tissue uptake ratio with FCH and hence better image quality. 
(DeGrado, Coleman et 1 FCH is feasible for brain tumour imaging 
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al. 2001) 
(Kwee, Coel et al. 
2004) 
2 
Increased uptake in areas of HGG correlates with increased areas of choline metabolites on Magnetic 
resonance spectroscopy (MRS). 
(Kwee, Ko et al. 2007) 30 
Used FCH PET in differential diagnosis of solitary brain lesions. FCH can differentiate between Gliomas, 
metastases, benign lesions. FCH can differentiate between Radiotherapy changes and tumour recurrence. 
(Roselli, Pisciotta et 
al. 2010) 
1 FCH PET aids in the selection of therapeutic options. 
Hepatocellular carcinoma 
(HCC) 
 
(Talbot, Gutman et al. 
2006) 
12 FCH can localise Hepatocellular carcinoma (HCC) in the liver. 
(Talbot, Fartoux et al. 
2010) 
81 FCH is more sensitive than FDG at detecting HCC.  It is useful for the detection and surveillance of HCC. 
(van den Esschert, 
Bieze et al. 2010) 
21 FCH can differentiate between focal nodular hyperplasia (FNH) and adenoma. 
Lung  
(Balogova, Huchet et 
al. 2010) 
15 FCH & FDG PET have similar detection rates in lung nodules suggestive of bronchoalveolar carcinoma. 
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Deuterium Substituted Fluorocholine ([18F]D4-FCH) 
Impetus for compound development 
 
[
11
C]choline (and its fluoro-analogue ([18F]FCH)) is oxidised to [
11
C]betaine by 
choline oxidase mainly in kidney and liver tissues, with metabolites detectable in 
plasma soon after injection of the radiotracer (Roivainen, Forsback et al. 2000). This 
makes discrimination of the relative contributions of parent radiotracer and catabolites 
difficult when a late imaging protocol is used.  
A more metabolically stable FCH analogue, [18F]fluoromethyl-[1,2-2H4]choline 
([18F]D4-FCH), based on the deuterium isotope effect (Gadda 2003) has been 
developed. The simple substitution of Deuterium (2D) for Hydrogen (1H) improves the 
stability of the compound and reduces degradation of the parent tracer. This could 
increase the net availability of the parent tracer for phosphorylation and trapping within 
cells leading to an improved signal-to-background contrast, thus improving the 
sensitivity of the PET imaging of tumours. [18F]D4-FCH has been validated for imaging 
tumours pre-clinically and was found to be a very promising, metabolically stable 
radiotracer for imaging choline metabolism in tumours (Leyton, Smith et al. 2009). 
Therefore this tracer has been translated into humans in the form of a micro-dosing, 
first-in-human study in healthy volunteers. The safety, biodistribution and radiation 
dosimetry of [18F]D4-FCH were evaluated.  
New Tracers: [18F]ICMT-11 
 
Apoptosis is an essential process for eliminating unwanted cells during 
embryonic development, growth, differentiation, and maintenance of tissue 
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homeostasis. Apoptosis is regulated by both intrinsic (via mitochondria) and extrinsic 
(activation of death receptors) signalling networks that control a family of enzymes 
known as caspases (cysteine aspartate specific proteases) (Nicholson and Thornberry 
1997; Degterev, Boyce et al. 2003). Based on various biochemical events that 
characterise apoptosis, a number of positron emitting radiotracers have been 
developed to noninvasively detect this process, both in preclinical studies and in 
humans (Nguyen, Challapalli et al. 2012).  
 [18F](S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4- 
difluorophenoxymethyl)-pyrrolidine-1-sulfonyl) isatin ([18F]ICMT-11) was designed as 
a small molecule radiotracer with potential advantages such as facile radiolabelling, 
improved biodistribution and clearance profiles. It has been characterised as a novel 
reagent designed to noninvasively image caspase-3 activation and, hence, drug-
induced apoptosis. The promising mechanistic and biological profile of [18F]ICMT-11 
supports its transition into clinical development (Nguyen, Challapalli et al. 2012). 
Therefore this tracer has also been translated into humans in the form of a micro-
dosing, first-in-human study in healthy volunteers. The safety, biodistribution and 
radiation dosimetry of [18F]ICMT-11 were evaluated. 
Thesis Overview 
 
This thesis expounds the imaging of growth and death of cancer cells in 
tumours. It aimed to investigate tumour growth signalling using [18F]FLT to assess 
proliferation and the choline analogue ([11C]choline) to measure phospholipid 
metabolism, and to develop them as imaging biomarkers for response assessment in 
lesions where they are likely to be used.  
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This chapter describes the cell cycle, its regulation and hallmarks of cancer: in 
particular sustained proliferation and evading apoptosis. The mechanisms of action of 
common anti-cancer treatment strategies causing alteration in the balance between cell 
proliferation and cell death have been alluded to highlighting the need for imaging. The 
traditional methods of quantification of cell proliferation and cell death and their 
limitations, along with the limitations of standard anatomic measurements have been 
discussed. The roles of PET, recent advances in PET technology and the newer PET 
radiotracers have also been described in this chapter.  
The thesis initially explored the modulation of FLT kinetics employing the kinetic 
spatial filter (KSF) in pancreatic tumours as well as quantifying the changes in kinetics 
with gemcitabine based chemotherapy. The molecular and physiological basis of 
[11C]choline as a PET radiotracer in prostate tumours was studied next, to establish the 
correlation of [11C]choline uptake in prostate tumours with quantitative estimation of 
CHKα expression on immunohistochemistry.  The further application of [11C]choline as 
an imaging biomarker in detecting changes in choline metabolism following androgen 
deprivation and radical radiotherapy to the prostate was studied.  
To overcome the metabolic instability of [11C]choline, a novel choline analogue 
that has improved systemic stability ([18F]D4-FCH) was evaluated in humans. In order 
to translate [18F]D4-FCH into clinical imaging, its uptake and kinetics were studied in 
patients with newly diagnosed non-small cell lung cancer (NSCLC). As a prelude to 
imaging cancer cell death in tumours, a caspase-3 specific radiotracer has also been 
transitioned into humans. Table 6 gives a brief overview of the studies in this thesis. 
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Table 6: Overview of the studies in this thesis 
 
Study Chapter 
No 
Author 
 Imaging cell proliferation with 
[
18
F]Fluorothymidine in advanced pancreatic 
cancer: Effect of gemcitabine based therapy 
2 A. Challapalli 
 Non invasive detection of pelvic lymph nodal 
metastases from prostate cancer using 
[
11
C]choline PET/CT and relationship with 
choline kinase expression 
3 A Challapalli (image data 
of patients from Dr 
Contractor’s thesis 
analysed and reported; 
Western Blotting & PCR 
was by S. Trousil; Choline 
breast data of Dr 
Contractor completely re-
analysed). 
 Exploring the potential of [
11
C]choline PET/CT 
as a novel imaging biomarker for predicting 
early treatment response in prostate cancer. 
4 A. Challapalli 
 Deuterium substituted [
18
F]fluoromethyl-[1,2-
2
H4]choline PET/CT: Biodistribution, radiation 
dosimetry and imaging in Non-Small Cell Lung 
Carcinoma. 
o [
18
F]D4-FCH: Biodistribution and 
radiation dosimetry in healthy 
volunteers. 
o [
18
F]D4-FCH PET/CT in Non-Small Cell 
Lung Carcinoma: Proof of concept 
study. 
5 A. Challapalli 
Additional work   
 [
18
F]ICMT-11, a Caspase-3 specific PET tracer 
for Apoptosis: Biodistribution and Radiation 
dosimetry. 
6 A. Challapalli 
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Hypotheses Tested 
 
The hypotheses tested include: 
1. Use of Kinetic Spatial Filtering (KSF) would improve localisation of tumours in 
the pancreas and liver metastases (Chapter 2). 
2. Use of functional imaging with PET would predict early response to treatment 
and the potential for alternative management strategies (Chapter 2, 4). 
3. Untreated malignant lesions will have enhanced radiolabelled choline 
accumulation due to their high expression and activity of CHKα (Chapter 3, 5). 
4. Altered choline transport and choline oxidation could confound the specificity of 
[11C]choline uptake in tumours (Chapter 3). 
5. The novel PET tracers ([18F]D4-FCH and [18F]ICMT-11) would have a 
favourable dosimetry profile and safe for use in humans (Chapter 5, 6). 
 
Aims of Thesis 
 
• To validate and explore FLT kinetics using FLT PET/CT combined with kinetic 
spatial filtering (FLT PET/CTKSF) in pancreatic tumours and in response to 
therapy (Chapter 2).  
• To evaluate the accuracy and biological basis for [11C]choline PET/CT in the 
nodal staging of high risk localised prostate cancer, to understand the molecular 
and physiological basis of [11C]choline tracer kinetics in prostate tumours, and to 
establish the correlation of [11C]choline uptake in prostate tumours with 
quantitative estimation of CHKα expression on immunohistochemistry (Chapter 
3).  
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• To explore the potential of [11C]choline PET/CT as an early response biomarker 
to neo-adjuvant androgen-deprivation (NAD) and radical radiotherapy combined 
with concurrent androgen-deprivation (RT-CAD) in patients with prostate cancer 
(Chapter 4).  
• To transition a novel metabolically stable analogue of choline ([18F]fluoromethyl-
[1,2-2H4]-choline ([
18F]D4FCH)) into humans and to study its pharmacokinetics 
in patients with NSCLC (Chapter 5). 
• To evaluate the biodistribution, internal dosimetry and the safety profile of 
[18F]ICMT-11 in healthy volunteers (Chapter 6). 
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CHAPTER 2: Imaging cell proliferation with 
[
18
F]fluorothymidine in advanced pancreatic cancer: 
Effect of gemcitabine based therapy 
Rationale 
 
Pancreatic cancer is the fourth leading cause of cancer mortality world-wide 
(Siegel, Naishadham et al. 2012). It is a genetically heterogeneous disease with 
alterations in several core signalling pathways and processes including K-ras, JNK, 
Wnt/Notch, hedgehog and integrin signalling, as well as control of G1/S transition 
control and apoptosis (Jones, Zhang et al. 2008). A combination of aggressive tumour 
biology and a propensity to present with inoperable disease, makes advanced 
pancreatic cancer incurable with median survival of less than 1 year, despite systemic 
therapy (Cartwright, Richards et al. 2008).  Symptom control and quality of life are 
extremely important in these patients. Randomised trials have demonstrated a potential 
benefit both in terms of survival and symptom control in patients who receive 
gemcitabine based chemotherapy (Sultana, Smith et al. 2007). However the use of 
combination chemotherapy is not without significant toxicity and many patients will 
experience significant morbidity due to febrile neutropenia, anemia, thrombocytopenia,  
nausea, and vomiting (Ciliberto, Botta et al. 2013). Therefore there is a need for early 
assessment of tumour response in order to minimise patient exposure to potentially 
toxic treatment regimens, especially in those patients who are unlikely to respond.   
Objective response to chemotherapy is routinely assessed by change in tumour 
size on CT imaging based on RECIST 1.1 criteria (Eisenhauer, Therasse et al. 2009).  
However, reliable estimation of therapeutic effect is challenging as changes in tumour 
dimensions may take months to become apparent limiting evaluation of therapeutic 
effect early during treatment, and these techniques may not provide information 
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regarding the viability of the residual tumour mass. The emergence of PET technology 
has generated interest in imaging the biologic activity of the tumour and early response 
to therapy. Qualification of PET as an early response biomarker would also enable its 
subsequent use as noninvasive marker of novel drug efficacy or a pharmacodynamic 
marker in the management of pancreatic cancer. Notably, there are no accepted 
predictive or response biomarkers for pancreatic cancer although several, including 
hENT1, miR-21, and circulating tumour cells are being evaluated (Costello, Greenhalf 
et al. 2012). 
[18F]Fluorodeoxyglucose (FDG), a glucose analogue, is the most widely used 
oncological PET tracer for staging and response assessment (Juweid and Cheson 
2006; Zhu, Lee et al. 2011).  In a tabulated summary of the FDG PET literature, the 
weighted sensitivity and specificity of FDG PET for detection of the primary pancreatic 
tumours was 94% and 90 %, respectively (Gambhir, Czernin et al. 2001). Several small 
studies have assessed the utility of FDG PET to predict survival in pancreatic cancer 
patients (Maisey, Webb et al. 2000; Choi, Heilbrun et al. 2010) and the early effects of 
radiotherapy (Higashi, Sakahara et al. 1999) and/ or chemotherapy (Rose, Delbeke et 
al. 1999; Bang, Chung et al. 2006; Kuwatani, Kawakami et al. 2009; Choi, Heilbrun et 
al. 2010). A study of 10 pancreatic cancer patients showed that FDG PET aided in 
assessing the effectiveness, 2 weeks after completion of treatment with concurrent 
arterial chemo infusion and  5 weeks of external radiation (Yoshioka, Sato et al. 2004). 
Small studies in patients with locally advanced pancreatic adenocarcinoma have 
evaluated FDG PET post neoadjuvant chemoradiotherapy (CRT) to predict which 
patients would achieve complete surgical resection and have found % change in 
tumour SUVmax to be of some utility but not consistently reliable (Rose, Delbeke et al. 
1999; Choi, Heilbrun et al. 2010).  
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The sensitivity and specificity of predicting response to CRT (4 weeks after 
completion of treatment) was 30% and 60%, respectively in 15 patients using clinical 
benefit as the standard (Bang, Chung et al. 2006). However, the use of FDG-PET is 
limited by false positive uptake in the presence of active, chronic or autoimmune 
pancreatitis, which can mimic pancreatic cancer (Buck, Schirrmeister et al. 2001) and 
low sensitivity in relatively hypo cellular cancers such as desmoplastic or mucinous 
tumours (Higashi, Saga et al. 2003). Furthermore, there was no association between 
FDG uptake and proliferative activity in pancreatic cancer, even though the proliferative 
activity was tenfold higher in malignant pancreatic tumours than in benign tumours 
(Buck, Schirrmeister et al. 2001). 
Pancreatic adenocarcinomas show a relatively high average Ki-67 labelling 
index, of 37% (Klein, Hruban et al. 2002), and several drug combinations in use for this 
disease target DNA replication (Costello, Greenhalf et al. 2012). Hence there may be a 
potential for alternative tracers such as [18F]3’-deoxy-3’-fluorothymidine (FLT), a 
surrogate marker of DNA synthesis, which are less susceptible to inflammatory 
changes (van Waarde, Cobben et al. 2004), as imaging biomarkers for prognosticating 
pancreatic cancer and response evaluation (Barwick, Bencherif et al. 2009).  An initial 
FLT PET/CT pilot study by Quon and co-workers in 5 patients showed that a standard 
2-dimensional static imaging protocol, 40 min post FLT injection was unsuitable for 
detection of pancreatic tumours (Quon, Chang et al. 2008). They concluded that FLT 
PET/CT was not suitable for primary detection of pancreatic adenocarcinoma and may 
serve as a poor baseline scan for subsequent follow-up imaging when monitoring 
therapy (Quon, Chang et al. 2008). More recently, FLT PET was shown to detect 
malignant tumours of the pancreas in a study of 31 patients (Herrmann, Eckel et al. 
2008). FLT PET was evaluated for the detection and characterisation of pancreatic 
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tumours in 41 patients and was found to be more specific than FDG (75% vs. 50%, 
respectively). A SUVmax cut off of 2 was proposed for the discrimination of benign and 
malignant lesions in their series (Herrmann, Erkan et al. 2012).  
There are no data in the literature with respect to FLT PET/CT as a marker of 
early tumour response in pancreatic cancer. Furthermore assessment of liver 
metastases may be hampered by high background activity due to glucuronidation of 
FLT and hence, physiological accumulation in the liver (Shields, Grierson et al. 2002), 
making abdominal imaging challenging. Recently, the Aboagye group devised a new 
temporal intensity information-based voxel-clustering approach – kinetic spatial filter 
(KSF) - for removing the normal liver FLT uptake and to enable visualisation of specific 
uptake (i.e. uptake due to phosphorylation) in liver metastases (Gray, Contractor et al. 
2010; Contractor, Challapalli et al. 2012). Briefly, the KSF compares, on a voxel by 
voxel basis, the time activity curves (TACs) of the image with the TAC of predefined 
tissue classes.  The set of predefined tissue classes were determined by generating the 
average TACs for each of the major tissue types, including the cardiac blood pool, 
lungs, liver, tumour, normal breast and vertebra. Since the time profile of an individual 
voxel is too noisy to allow the accurate determination of the tissue type it represents, 
the mean time profile obtained from a voxel and its six nearest neighbours was 
considered. An additional background curve was also defined, to fit voxels located 
within the field of view, but outside the body of the patient. These TACs were 
normalised to the injected dose, and then the mean and standard deviation activity 
were calculated for every tissue type. Each voxel in turn was compared against the 
seven predefined classes. Only the voxels classified by the filter as being “tumour-like” 
will be saved in the post-filter image, thereby removing areas of physiological uptake 
that do not relate to FLT retention.   
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 Therefore, this prospective nonrandomised exploratory clinical trial was 
conducted  
 To generate data for assessing the efficiency of the FLT PET/CTKSF in 
pancreatic cancer.  
 To assess whether FLT PET/CT and FLT PET/CTKSF could be used to predict 
the clinical responsiveness of gemcitabine based chemotherapy in patients with 
pancreatic cancer.  
 
This study was used to test the hypotheses that the use of KSF would improve 
localisation of tumours in the pancreas and liver metastases and that the use of 
functional imaging with PET would predict early response to treatment and the potential 
for alternative management strategies.  
Materials & Methods 
Patients 
 
Patients with histologically confirmed locally advanced or metastatic carcinoma 
of the pancreas, suitable for gemcitabine based chemotherapy, ECOG performance 
status ≤2 and with at least one (primary or metastatic) lesion ≥20 mm as assessed by 
CT imaging were included. Patients who progressed after previous radical surgery or 
from previous treatment, and were due to start gemcitabine based chemotherapy were 
also eligible. Patients who received chemotherapy or radiotherapy 8 weeks prior to the 
baseline FLT PET/CT were excluded.  
Thus the main inclusion and exclusion criteria for this study were: 
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Inclusion criteria: 
1) Diagnosis of histologically/ cytologically proven carcinoma of the pancreas. 
2) Locally Advanced or metastatic disease. 
3) Patient planned for treatment with gemcitabine based chemotherapy. 
4) At least one measurable lesion  > 2 cm, suitable for imaging 
5) ECOG PS < 2  
6) Aged 18 years and above  
7) Written informed consent. 
Exclusion criteria: 
1) Patients who received chemotherapy/ radiotherapy  within 8 weeks of study 
enrolment 
2) Psychological, familial, sociological or geographical condition potentially 
hampering compliance with the study protocol  
3) Pregnant or lactating women 
4) Presence of any underlying medical conditions which in the investigators 
opinion would make the patients unsuitable for treatment 
5) Baseline hematologic and liver/renal function not acceptable for 
chemotherapy 
6) Patient not expected to be able to tolerate the scanning sessions 
Fifteen patients were recruited from Imperial College Healthcare NHS Trust (ICHNT) 
and 5 patients from Newcastle-Upon-Tyne Hospitals NHS Foundation Trust (NHNFT). 
All patients received gemcitabine as a single agent or in combination with other agents. 
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Ethical approval for the study was granted by the West London REC 1 Committee. All 
patients gave fully informed consent to participate in the study, which was done 
according to the Declaration of Helsinki guidelines. The administration of radioactivity 
for the PET scans was approved by the Administration of Radioactive Substances 
Advisory Committee, United Kingdom. 
Imaging protocol 
 
FLT was manufactured according to standard protocol (Cleij 2001). All patients 
were scanned on a Siemens Biograph PET/CT scanner (15 on a 64-slice with True V at 
ICHNT, 5 on a 40-slice with True V at NHNFT: axial field-of-view (FOV), 21.6 cm; 
transaxial, 60.5 cm)). Baseline FLT PET/CT was performed within a week prior to start 
of chemotherapy. Post-treatment PET/CT was performed three weeks after the start of 
first cycle of chemotherapy. There was a minimum of 72 hrs gap between the last dose 
of gemcitabine and the FLT PET/CT (median of 5 days). All the baseline and post-
treatment scans were performed on the same scanner. In all cases the primary tumour 
and any liver metastases, were imaged in a single bed position (covering the liver and 
the pancreas). Patient positioning was followed by a diagnostic quality CT scan (300 
mA, 120kVp, 1.35 pitch, 0.8 sec/rotation) that was used for both attenuation correction 
and co-registration with PET images, to allow good anatomical visualisation and 
localisation of FLT activity. FLT was injected as a bolus intravenously and a dynamic 
emission scan in the 3D mode, lasting 66 minutes was undertaken (Contractor, Kenny 
et al. 2011).  
All patients had a staging contrast-enhanced CT (CECT) 3 weeks before 
(baseline) and 3 months after the start of treatment.  
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Image analysis 
 
Raw PET data were corrected for scatter, attenuation and reconstructed with an 
iterative algorithm consisting of 8 iterations and 21 subsets. The data were binned into 
time frames as follows: 1 * 30 (background), 6* 10, 4* 20, 4* 30, 5* 120, 4* 180 and 4* 
600 seconds. The KSF was applied to the dynamic PET data. Decay corrected images 
(unfiltered and filtered) were then viewed using Analyze® software (Analyze Version 11; 
Biomedical Imaging Resource, USA). Volumes of interest (VOI) were defined on the 
summed images manually around the tumours, employing the patient’s diagnostic 
contrast-enhanced CT (CECT) scan and the filtered images. The VOI encompassed 
the whole tumour for the SUV and voxel analysis. The FLT radioactivity concentration 
within the VOIs was then normalised for injected radioactivity and body weight to obtain 
the average and maximum SUV at 60 minutes (SUV60,ave, and SUV60,max) on the 
baseline and post-treatment FLT PET/CT (unfiltered) studies. The percentage change 
in SUV was then calculated for each patient. 
Selection of target lesions 
 
 Target lesions in the pancreas and the liver were defined as lesions with the 
longest diameters (LD) as defined by RECIST 1.1 (Eisenhauer, Therasse et al. 2009) 
on CT. The lesions on the FLT PET/CT corresponding to those on the CT, showing an 
increased uptake and visualised on both the unfiltered and the filtered images were 
considered as target lesions. In patients with multiple lesions, the parameters of the 
most metabolically active lesion on the FLT PET/CT was considered for further 
analysis, as per the PERCIST guidelines (Wahl, Jacene et al. 2009). Data analyses 
with the sum of the parameters (SUV) of all the lesions, in patients with multiple lesions 
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are described in Appendix 2. The LD of the target lesions was measured using 
electronic callipers on the PACS work station. Lesions smaller than 20 mm were 
documented but not chosen as targets to enable the visualisation of the lesions on the 
FLT PET/CTKSF: the tissue classes defined in the KSF considered the individual voxel 
and 6 of its neighbouring voxels (Gray, Contractor et al. 2010). The same target lesions 
were used for analyses on both the PET/CT and CECT, before and after treatment.  
Voxel analysis 
 
Voxel quantification analysis was performed on filtered data by determining the 
number of voxels in each tumour volume and then binning the number of occurrences 
of each voxel intensity value. The maximum voxel intensity was limited to 30 (single 
unit intervals) as none of the tumours had a voxel intensity value greater than 25. Each 
voxel-intensity was then normalised by injected dose and body weight and decay 
corrected to obtain the SUV for the voxel. Two variables representing both low and high 
intensity voxels (LoVox: SUV ≥ 1) or only high intensity voxels (HiVox: SUV ≥ 2 for 
pancreatic tumours and SUV ≥ 3 for liver metastases (Contractor, Challapalli et al. 
2012)) were computed. The arbitrary SUV cut-off values are typically characteristic of 
low and high FLT uptake in different malignant lesions (Francis, Freeman et al. 2003; 
Buck, Hetzel et al. 2005; Kenny, Vigushin et al. 2005; Quon, Chang et al. 2008).  
Response assessment  
 
According to the RECIST 1.1 criteria (Eisenhauer, Therasse et al. 2009), the 
sum of the LD’s of the target lesions was computed on the CECT scans before and 
after treatment. Patients with either partial response or stable disease were classed as 
non-progressors (NP) and those with progressive disease were classed as progressors 
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(P). The changes in the FLT imaging variables (SUV60,ave, SUV60,max, and HiVox)  were 
then categorised into R and NR, retrospectively using the receiver operating 
characteristic (ROC) curve analysis and prospectively using 20% reduction in SUV as a 
threshold for response (Kenny, Coombes et al. 2007; de Langen, Klabbers et al. 2009).  
The progression-free survival (PFS) was calculated as the time from start of 
treatment to unequivocal progression as documented clinically or on CT, and the 
overall survival (OS) was calculated as the time from the diagnosis to death. 
 
Statistical considerations 
 
 Preliminary data have shown that patients with changes in FLT uptake of >20% 
in individual patients can be classified as radiotracer responsive (Kenny, Coombes et 
al. 2007). Variability in the measured change within individuals in FLT has been 
estimated at ~0.15 (Kenny, Coombes et al. 2007; de Langen, Klabbers et al. 2009).  
Expected response to therapy is 20% of patients receiving chemotherapy.  This will 
dilute the expected “group” effect to 0.124 and inflate the variability to 0.17.  Power 
calculation (paired t-test) suggests that a number n=20 of patients will give to the 
design a minimum power of .80 to detect a group difference in FLT at a 0.05 error rate.  
The addition of n=4 patients to compensate for dropout and/or 4 patients to 
compensate for technical problems with imaging brings the total number of patients to 
n=28. 
 Quantitative measurements of the FLT imaging variables are reported using 
descriptive statistical measures. ROC curves were used to identify the optimal cut-off 
value of the imaging variables to differentiate R and NR. Statistical comparisons 
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between pre and post-treatment, unfiltered and filtered, variables were done using 
Wilcoxon signed rank test. Analysis of PFS and OS was performed by using Kaplan-
Meier estimates and the log-rank test. A two-sided p value <0.05 was considered 
statistically significant. All analyses were done using Graph Pad (Prism software®-
version-4). The ROC analysis was performed using MedCalc statistical software 
(version 11.6.1, Mariakerke, Belgium).  
Results 
Patients 
 
The study recruited 25 patients out of whom 20 patients had completed both the 
baseline and post-treatment FLT PET/CT. Fifteen patients were recruited from Imperial 
College Healthcare NHS Trust (ICHNT) and 5 patients from Newcastle-Upon-Tyne 
Hospitals NHS Foundation Trust (NHNFT). All patients received gemcitabine as a 
single agent or in combination with other agents. Ten patients had locally advanced 
disease and 10 had metastatic disease (Table 7). All patients tolerated the FLT 
PET/CT scans without any complications. The mean (±SD) age of patients was 69 (±8) 
years and all patients had gemcitabine based chemotherapy. The mean (±SD) injected 
activity of FLT was 211 (±10.4) MBq with a radiochemical purity of >95%. 
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Table 7: Patient characteristics  
Pt No 
Age 
(yrs) 
Sex Stage 
Target 
Lesion 
LD 
(mm) 
Non-
Target 
Lesion 
LD 
(mm) 
Chemotherapy 
PFS 
(m) 
OS 
(m) 
1 62 M LA Primary 58   
Gemcitabine, 
Caecitabine 
2.97 4.33 
2 67 F M LM 71 Primary 34 
Gemcitabine, 
Cisplatin 
6.10 9.43 
3 78 M M LM2 40 Primary 58 
Gemcitabine, 
Cisplatin 
2.63 7.80 
      LM1 57    
4 73 M M LM2 22 LM1 18* 
Gemcitabine, 
Cisplatin 
8.57 12.80 
5 73 M LA Primary 36   
Gemcitabine, 
Caecitabine 
7.60 32.43 
6 60 F M Primary 30 LM 17* 
Gemcitabine, 
Cisplatin 
5.60 11.10 
7 77 F M Primary 40 LM 9* Gemcitabine 11.77 17.53 
8 61 M LA Primary 58   Gemcitabine 3.97 8.73 
9 70 M M LM2 42 Primary 49 Gemcitabine 0.47 1.43 
      LM1 20    
10 68 F LA Primary 34   Gemcitabine 11.83 12.90 
11 64 M LA Primary 51   
Gemcitabine, 
Dasatinib/Placebo 
8.63 11.50 
12 77 M M 
Remnant
† 
24   
Gemcitabine, 
Vandatinib/Placebo 
7.37 7.37 
13 69 M LA Primary 26   
Gemcitabine, 
Vandatinib/Placebo 
8.03 8.03 
14 78 F M LM 20 Primary 58 Gemcitabine 1.20 1.87 
15 69 M LA Primary 24   
Gemcitabine, 
Cisplatin 
1.77 4.27 
16 65 F M LM 20 Primary 56 Gemcitabine 1.80 3.73 
17 62 F LA Primary 29   Gemcitabine 2.63 13.07 
18 61 M LA Primary 38   Gemcitabine 4.83 8.43 
19 86 F M‡ Primary 32   Gemcitabine 9.47 9.47 
20 56 M LA Primary 48   Gemcitabine 10 10 
Mean 69        5 10 
PFS-progression free survival, OS-Overall survival, m-months, LM-liver metastases, LA-locally 
advanced, M-metastatic 
* Liver metastases not seen on Kinetic Spatial Filter, †Recurrence in pancreatic remnant, ‡ Liver 
metastasis (10mm) seen on CT not visualised on unfiltered FLT PET/CT. 
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Imaging characteristics of FLT uptake at baseline 
 
On visual analysis of the unfiltered images the pancreatic tumours were visible 
above the background in 15 out of 20 (75%) patients.  The mean unfiltered SUV60,max 
(±SD) for the primary tumours and normal pancreas were 4.23 (±1.52), and 2.14 
(±1.26), respectively. The 11 liver metastases, seen in 8 patients, were typically 
photopenic relative to normal liver background on the unfiltered images (Figure 8). The 
mean unfiltered SUV60,max (±SD) for the liver metastases and the surrounding normal 
liver background was 8.41 (±2.21) and 7.99 (±1.83), respectively. Physiological activity 
was seen in the liver, kidneys and the vertebrae.  
 KSF qualitatively improved image visualisation of the tumours (Figure 8). All the 
pancreatic tumours were visualised on the filtered FLT PET/CT images. However, only 
8 liver metastases (out of 11) were visible on the filtered images. The 3 liver 
metastases not visualised by the KSF, were less than 20 mm and had higher tissue 
activity than the average for the liver metastases (Table 7, Figure 9). Small liver 
lesions typically had a homogeneous appearance, whereas liver lesions >3 cm were 
characterised by perilesional tracer uptake with no measurable FLT trapping in the 
necrotic centre of the liver metastases. As seen previously (Contractor, Challapalli et al. 
2012), and unrelated to proliferation, liver capsule resembling a thin margin, retained 
signal following application of KSF. Since KSF is associated with removal of delivery 
components within the data (Gray, Contractor et al. 2010), there was a mean (±SD) 
signal reduction in untreated primary tumours of 18.3% (±24.6) and 27.5% (±1.6) in 
liver metastases relative to the unfiltered images and the background signal in the liver 
and pancreas were reduced to ~0. Thus, KSF provides a measure of FLT retention 
within the tumour tissue. The time course of injected activity, decay corrected and 
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normalised to injected activity (tissue activity (mL-1)) for the tumours and normal tissue 
compared well with the tissue activity curves of the tissue classes defined by Gray and 
co-workers (Figure 9).  
A voxel-by-voxel representation of data was also computed to appreciate the 
heterogeneity of the tumours (Figure 10a-d). KSF-derived voxel-based data were 
available for all the pancreatic tumours and the 8 liver metastases (Table 8). The 
variable representing both low and high intensity voxels (LoVox) was unremarkable 
with respect to changes between R and NR and therefore was not further explored. 
Hence, only high intensity voxels (HiVox) derived from KSF were explored (Figure 11a-
d). 
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Figure 8: [
18
F]FLT uptake in tumours and normal tissues and changes with treatment.  
The primary tumour (red arrow) is not visible above background and the liver metastasis (white 
arrow), is photopenic on the unfiltered PET-CT (a). The filtered image shows better tumour 
visualisation in the tail of the pancreas (red arrow) and the liver metastasis a rim of uptake with 
no uptake in the necrotic centre (c). There is physiological uptake in liver, kidney and vertebra. 
After treatment there is a marked reduction of activity in the primary tumour (red arrow), most 
obvious in the filtered images (a, b), The liver metastases also show a reduction in the [
18
F]FLT 
uptake with treatment (red arrow; c, d). The diagnostic CT (done after 4 cycles of 
chemotherapy) shows a slight reduction in the lesion size. Overall this patient (Pt No. 2 in Table 
7) had a partial response to treatment. 
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Figure 9: Decay corrected time activity curves, normalised by injected activity (tissue activity) 
for selected tissue types including (a) tumour, (b) liver metastases, (c) pancreas, (d) liver, (e) 
aorta, (f) kidney, (g) vertebra and (h) liver metastases not visualised on KSF. Data are average 
tissue activity values and error bars represent one SD. 
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Figure 10: Voxel representations depicting tumour heterogeneity  
in pancreatic tumours (a-b) and liver metastases (c-d) in a tumour of size<30 mm 
(homogeneous tumour on filtered images), and in a tumour of size>55 mm (heterogeneous 
tumour on filtered images). The dotted line on the X-axis corresponds to SUV of 2 (a-b) and to 
SUV of 3 (c-d). Note different scales of Y-axis. 
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Table 8: Baseline characteristics of lesions: Unfiltered SUV and percentage occurrences 
of KSF derived voxels with high intensities. 
Pt No Lesion(s) 
Overall 
RECIST 
response* 
SUV60,ave SUV60,max HiVox 
1 Primary PD 2.19 5.01 85.7 
2 Primary PR 1.61 3.08 33.7 
 LM  2.13 5.58 23.2 
3 Primary PD 2.17 5.51 71.7 
3a LM1  3.43 10.08 78 
3b LM2  5.22 10.96 99.5 
4a LM1 PR 5.48 9.40 † 
4b LM2  4.38 7.05 100 
5 Primary SD 2.56 8.50 83.5 
6 Primary SD 2.79 4.68 83.9 
 LM  6.55 7.39 † 
7 Primary SD 1.86 3.37 40.4 
 LM  4.20 4.47 † 
8 Primary SD 2.23 4.78 43.9 
9 Primary PD 2.93 5.62 71.3 
9a LM1  7.34 10.02 100 
9b LM2  4.80 10.28 69 
10 Primary SD 0.92 2.17 6.7 
11 Primary SD 2.13 4.85 48.2 
12 Remnant SD 1.53 2.98 13.9 
13 Primary SD 0.94 2.84 16.7 
14 Primary PD 2.22 5.25 48 
 LM  4.48 7.43 79.1 
15 Primary PD 1.85 3.42 37.5 
16 Primary SD 1.96 3.74 36.6 
 LM  5.65 5.90 100 
17 Primary PD 1.43 2.85 51.2 
18 Primary PD 1.65 2.88 50.6 
19 Primary SD 2.49 5.54 0.65 
20 Primary SD 1.79 3.26 30.8 
* RECIST response based on mid treatment CT scan.  
†Tumours not visible on filtered images. Data were excluded from further analysis.  
PR-partial response, SD-stable disease, PD-progressive disease, SUV60,ave- SUV average,   
SUV60,max -SUV maximum, HiVox - high intensity voxels (corresponding to SUV≥2 for primary 
pancreatic tumours and SUV≥3 for the liver metastases).  
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Figure 11: Changes in voxel intensities with therapy  
in the pancreatic tumour (a, b) and in the liver metastases (c, d) with treatment in a non-
progressor and progressor, respectively. The dotted line on the X-axis corresponds to SUV of 2 
(a, b) and to SUV of 3 (c, d). Note different scales of Y-axis. 
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Effect of Treatment on FLT PET variables 
 
 Since this is, to the best of our knowledge, the first study of early response 
assessment with FLT PET/CT in pancreatic cancers, the characteristics of the different 
imaging variables that could be used to describe proliferation in this tumour type were 
evaluated. All proportional comparisons were performed only in the lesions visible after 
kinetic filtering (i.e. all target lesions (>2cm) and a subset of non-target lesions). A 
reduction in proliferation detected by FLT PET/CT was seen in several tumours at three 
weeks post-treatment (Figure 8). The waterfall plots of the most metabolically active 
tumours and the ROC curves are shown in Figure (12 a-d). For SUV60,ave and SUV60,max 
nearly half of the tumours showed some degree of reduction in proliferation. Most of 
tumours also showed some degree of reduction in proliferation when the measure was 
HiVox (Figure 13). Interestingly, majority of the RECIST lesion P showed an increase 
in SUV60,max; 6 out of the 7 progressors had a 12-132% increase in the SUV60,max. The 
one progressed patient, who had a decrease in the SUV60,max, was classed as a P by 
virtue of developing new liver metastases. The RECIST lesion response showed a 
good correlation with the FLT lesion response (Spearman’s r=0.43, p=0.04). The mean 
percentage reduction after treatment was 2%, -3%, and 19% for SUV60,ave, SUV60,max, 
and HiVox, respectively. Using a prospective cut-off of 20% reduction in SUV60,max 
(Kenny, Coombes et al. 2007; de Langen, Klabbers et al. 2009) as response, the 
sensitivity and specificity of FLT PET/CT in predicting a progressor was 38.5% and 
85.7%. However, using a retrospective cut-off of 12% reduction in  SUV60,max based on 
the ROC curves, the sensitivity improved to 46.2% retaining the same specificity 
(85.7%; AUC-0.88, p=0.0001). These results suggest that SUV60,max is the variable of 
choice at discrimination between non-progressors and progressors.  
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Figure 12: Waterfall plots and Receiver Operating Characteristic curves of the most 
metabolically active lesions. 
Waterfall plots for the measures of (a) SUV60,ave, (b) SUV60,max. The RECIST lesion non-
responders are shaded in grey. Majority of the RECIST lesion progressors showed an increase 
in FLT uptake when the measure was SUV60,ave, SUV60,max; 6 out of the 7 progressors had the 
biggest increase in SUV60, max. The * refers to the patient who was a progressor by virtue of 
developing new liver metastases. Receiver Operating Characteristic curves for changes in (c) 
SUV60,ave, (d) SUV60,max. 
 
 Group analyses of the imaging data were also performed. The difference 
between baseline and post-treatment FLT uptake showed a statistically significant 
increase of SUV60,max in the progressors (Figure 14 a-c). 
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Figure 13: Waterfall plot of changes in HiVox for the most metabolically active lesions. 
The * refers to the patient who was a progressor by virtue of developing new liver metastases. 
 
Figure 14: Group analysis of the imaging data  
showing the difference between baseline and post-treatment FLT uptake in the most 
metabolically active lesions in non-progressors and progressors: box and whiskers plots for the 
measures of (a) SUV60,ave, (b) SUV60,max, and (c) HiVox.  
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Prediction of Survival 
 
 Of the 20 patients only 6 patients were alive after mean follow up of 10 months 
(range: 1.4 to 32.4 months). Based on the cut-off of 12% reduction in SUV60,max derived 
from the ROC curves, the median PFS of FLT non-progressors and progressors was 
7.6 and 3.9 months (p=0.5, CI=0.24-2.01; Log rank test), respectively and the median 
OS was 11.5 and 8.7 months (p=0.15, CI=0.15-1.33; Log rank test), respectively  in the 
non-progressors and progressors. When the CT RECIST criteria were used for 
response assessment, the median PFS of non-progressors and progressors were 8.6 
and 2.6 months (p<0.0001, CI=0.006-0.16; Log rank test), respectively and the median 
OS was 11.5 and 7.8 months (p=0.03, CI=0.06-0.88; Log rank test), respectively in the 
non-progressors and progressors (Figure 15). 
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Figure 15: Kaplan-Meier Survival curves  
for progression free survival (PFS; a, b) and overall survival (OS; c, d). The response 
classification was based on RECIST response (CT) and a cut-off of 12% reduction in SUV60, max 
for FLT.  
 
Discussion 
 
FLT PET/CT is increasingly being explored as an early biomarker of response 
to therapy (Weber 2010; Tehrani and Shields 2013). In this exploratory study it was 
demonstrated that FLT PET may be useful in the setting of advanced pancreatic 
cancer. In particular a qualitative visual distinction between tumours, normal pancreas 
and normal liver was seen in FLT PET/CTKSF images. SUV60,max  (unfiltered) was able to 
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differentiate between non-progressors and progressors. There was a significant 
increase in the SUV60,max in progressors (Figure 10), suggesting that rise in SUV60,max is 
a poor prognostic indicator, i.e. patients who have an early increase in SUV60,max are 
less likely to respond to the treatment. However, overall changes in FLT uptake were 
not predictive of PFS or OS.  
The KSF has previously been validated (Gray, Contractor et al. 2010) and its 
utility in imaging proliferation in liver metastases been evaluated (Contractor, Challapalli 
et al. 2012). As seen in these 2 studies, the KSF was able to completely remove the 
signal from the normal liver and pancreas (fast and reversible kinetics), thus exposing 
the underlying tumours (slow and irreversible kinetics). Similarly, the larger liver 
metastases showed a central core of almost no FLT uptake surrounded by a rim of 
varying uptake at the periphery, as seen previously (Gray, Contractor et al. 2010; 
Contractor, Challapalli et al. 2012). This suggests that the rim of proliferation phenotype 
of the liver metastases is independent of the site of origin of the primary tumours. 
These findings were also consistent with that from Semelka et al, who using gadolinium 
enhanced magnetic resonance imaging, showed that there was perilesional contrast 
enhancement. They concluded that this could be due to hepatic parenchymal changes 
secondary to vascular proliferation (Semelka, Hussain et al. 2000). This reflects the fact 
that rapidly growing tumours may undergo central hypoxia and necrosis at the core with 
proliferating cells at the rim due to better blood supply (Harris 2002).  
All the primary pancreatic tumours were visible on the FLT PETKSF, but only 8 
out of the 11 liver metastases were visualised, thus detecting 73% of the liver 
metastases. This detection rate is similar to that seen in our earlier study (Contractor, 
Challapalli et al. 2012). Interestingly, the 3 liver lesions that were completely “filtered 
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out” by the KSF were less than 20 mm. Their kinetic profiles were found to be 
remarkably different from those employed in the KSF validation (Figure 19) (Gray, 
Contractor et al. 2010). The inability of the KSF to retain signal in lesions <20 mm could 
also be due to the consideration of the mean time profile obtained from a voxel and its 
six nearest neighbours to allow the accurate determination of the tissue type it 
represented (Gray, Contractor et al. 2010).  
Other than tumour detection, the very heterogeneous nature of these tumours 
supports the use of quantitative voxel analysis (Figure 10). However, most of the non-
responders (5 out of 7) showed a reduction in proliferation when the measure was 
HiVox. Furthermore, HiVox could not differentiate non-progressors and progressors. 
This could be due to the lower uptake of FLT in the primary pancreatic tumours (mean 
SUV60,max of 4.23), similar to that previously reported; mean SUV60,max of 3.0 (Herrmann, 
Erkan et al. 2012), and that the early voxel changes do not necessarily translate into 
durable suppression of proliferation. Longer post-treatment imaging interval may 
improve the predictive value of durable responses. 
FLT PET/CT and FLT PET/CTKSF variables detected the sensitivity of 
chemotherapy, demonstrated as a decrease in imaging variables at 3 weeks post-
treatment. FLT PET/CT correctly predicted mid-therapy clinical progression with 
sensitivity and specificity of 46.2% and 85.7% when the measure was SUV60,ave or 
SUV60,max. Sensitivity and specificity could be calculated prospectively with 20% used 
as the cut-off for response, for changes in SUV (Kenny, Coombes et al. 2007; Shields, 
Lawhorn-Crews et al. 2008; de Langen, Klabbers et al. 2009). The sensitivity & 
specificity of 46.2% & 85.7% are superior to those seen by FDG PET; 30% and 60%, 
respectively from a study by Bang and co-workers (Bang, Chung et al. 2006). However, 
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clinical response was used as a comparator and >50% reduction in FDG uptake was 
considered as partial response. Unlike SUV, reproducibility of HiVox has not been 
assessed. Therefore, the individual sensitivity and specificity of HiVox were not 
assessed prospectively. For HiVox, specificity was reasonable at 85.7% when the cut-
off was arbitrarily set at 50%. Retrospective ROC curves, however, favoured SUV60,max 
as the imaging variable of choice (AUC-0.88, p=0.0001).  
 In patients with pancreatic cancer, levels of human equilibrative nucleoside 
transporter 1 (hENT1) have been linked with survival (Farrell, Elsaleh et al. 2009). 
hENT's mediate the transport of both Gemcitabine and FLT, therefore performing FLT 
PET/CT after gemcitabine therapy may indicate response to therapy and it could be 
hypothesised that baseline FLT uptake would predict gemcitabine uptake  (Paproski, 
Young et al. 2010). Gemcitabine is known to cause an increase in FLT uptake at 24 hrs 
after treatment, decreasing to baseline by 72 hrs (Dittmann, Dohmen et al. 2002). To 
obviate the early increase of FLT uptake it was ensured that the post-treatment FLT 
PET/CT was performed with a minimum of 72 hrs after a dose of gemcitabine. 
Therefore, the changes in FLT uptake seen represent a true effect of suppression of 
proliferation rather than change in uptake due to the pharmacodynamic effect of 
gemcitabine.  
 Early changes in FLT uptake have been shown to predict long term outcome in 
breast, lung and brain tumours, but not in rectal cancer, lymphoma and germ cell 
tumours (Weber 2010). Likewise, there was no significant difference observed in the 
median PFS or OS between FLT non-progressors and progressors, in this study. This 
suggests that inhibition of proliferation may be necessary but not sufficient for a 
favourable response with certain types of treatment.  
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 A small sample size and the lack of Ki-67 indices are limitations of our study. 
However, pancreatic adenocarcinomas have been shown to have an average Ki-67 
labelling index of 37% (Klein, Hruban et al. 2002). This supports the use of FLT 
PET/CT in our cohort of patients. Another limitation of this study is the consideration of 
just the most metabolically active lesion for the evaluation of treatment response.  
 In summary, this study has shown that FLT PET/CT could potentially be a 
promising imaging biomarker to assess response to gemcitabine based therapy in 
advanced pancreatic cancer. SUV60,max appeared to be the variable of choice to 
differentiate between non-progressors and progressors and is a strong negative 
predictor. This enables subsequent use of FLT PET/CT as a vehicle to evaluate 
efficacy of newer therapeutic agents and targeted therapy in the management of 
pancreatic cancer. However, changes in FLT uptake were not predictive of PFS or 
overall survival. Further studies, in a larger cohort of patients are needed to establish 
the value of FLT PET/CT in predicting long term outcome. 
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CHAPTER 3: Non invasive detection of pelvic lymph 
nodal metastases from prostate cancer using 
[
11
C]choline PET/CT and relationship with choline 
kinase expression 
 
3.1.1: Rationale 
 
 The evaluation of lymph nodes (LNs) has important therapeutic and prognostic 
significance in patients diagnosed with prostate cancer (PCa). Whilst a curative 
approach can be adopted for those with organ confined node-negative disease with 
modalities such as surgery, external beam radiotherapy or brachytherapy, those with 
node-positive disease ultimately relapse with metastatic disease (relapse rate 30-50% 
at 5 years, 90% at 10 years) (Danella, deKernion et al. 1993; Leibel, Fuks et al. 1994). 
As such, the presence of LN involvement reduces the 5 year disease free survival from 
85% to approximately 50% with a shift in the focus of treatment to long-term androgen 
deprivation with the addition of pelvic radiotherapy to reduce loco-regional recurrence 
(Robnett, Whittington et al. 2002; Kumar, Shelley et al. 2006). Pelvic LN dissection is 
currently the gold standard for evaluating the presence of nodal involvement (Stone 
and Stock 1999; Allaf, Partin et al. 2006). This procedure can either be open or 
laparoscopic and is usually limited to the external iliac and obturator nodes, though a 
more extended procedure to include the internal iliac nodes is usually advocated for 
those with a higher risk of nodal disease (Wyler, Sulser et al. 2006). Either way, both 
these methods are invasive, associated with morbidity (Parkin, Keeley et al. 2002) and 
importantly may not be able to sample all potential LN areas.   
 It is thus important to have a sensitive and reliable noninvasive means of 
detecting nodal involvement. The criteria for nodal characterisation using cross-
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sectional imaging such as CT or Magnetic Resonance Imaging (MRI) relies primarily on 
morphological assessment based on size and shape, with a nodal short axis diameter 
of 1cm generally accepted as an upper limit of normal.  A threshold of 1cm in the short 
axis diameter for oval nodes and 0.8cm for round nodes has been recommended as 
criteria for diagnosis of prostate cancer nodal metastases (Jager, Barentsz et al. 1996). 
A recent meta-analysis on the diagnostic accuracy of cross-sectional imaging in the 
staging of pelvic LNs in prostate cancer reported a high pooled specificity for MRI of 
0.82  with a low and heterogeneous pooled sensitivity of 0.39  (Hovels, Heesakkers et 
al. 2008).  The lack of sensitivity belies the fact that nodal involvement is not always 
correlated with enlargement and enlarged nodes may also be due to a benign 
aetiology. Neither MRI nor lymphangiography has demonstrated higher sensitivity than 
CT scanning in the detection of nodal metastases (Rorvik, Halvorsen et al. 1998; 
Hovels, Heesakkers et al. 2008). The use of an MR contrast agent containing ultra-
small particles of iron oxide (ferumoxtran10-Sinerem, USPIO) has been shown to yield 
sensitivity and specificity above 90% in the detection of prostate cancer LN metastases 
(Harisinghani, Barentsz et al. 2003). However, this is not widely available and its 
intravenous infusion is not without side effects (Bernd, De Kerviler et al. 2009). Further 
studies using diffusion weighted MRI have demonstrated that the method, while 
undoubtedly having improved intra-prostatic tumour detection and localisation, it is less 
satisfactory for assessing pelvic nodal disease (Roy, Bierry et al. 2010). 
 PET offers functional information regarding tissue activity, thereby having the 
potential to provide superior staging information as well as the ability to monitor the 
response to treatment.  The clinical experience with [18F]FDG PET in prostate cancer is 
limited due to variable uptake of [18F]FDG in prostate cancer and the rapid excretion of 
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FDG in urine, causing an accumulation of activity in the bladder (Effert, Bares et al. 
1996; Hoh, Seltzer et al. 1998; Hain 2005). 
 [11C]choline is a radiopharmaceutical for PET imaging and its utility in visualising 
and staging prostate cancer has been published (Hara, Kosaka et al. 1998; Reske, 
Blumstein et al. 2006). The tumour PET signal from [11C]choline, comprises of free 
[11C]choline and [11C]phosphocholine, as well as the oxidation product, [11C]betaine 
(Leyton, Smith et al. 2009). The PET signal (tumour [11C]choline uptake) therefore, 
largely reflects transport and phosphorylation of [11C]choline, and to a lesser extent 
(given that liver and kidneys produce most of the circulating [11C]betaine), [11C]choline 
oxidation. Unlike [18F]FDG it has low renal elimination, and therefore visualisation of the 
prostate  and surrounding nodes may be enhanced by the low accumulation of tracer 
within the bladder (Hain 2005). Preliminary studies of [11C]choline-PET in pelvic nodal 
staging in prostate cancer patients have shown early promise (Kotzerke, Prang et al. 
2000; de Jong, Pruim et al. 2003; Schiavina, Scattoni et al. 2008). However, no study to 
date has established a direct relationship between CHKα expression and [11C]choline 
uptake in prostate tumours. Also the accurate documentation of the pelvic nodal status 
would facilitate image guidance and allow safe radiotherapy dose escalation, 
minimising the dose to small bowel in the radiotherapy field. 
To summarise, the main aims of the study were: 
 To compare the use of [11C]choline PET/CT with MRI in determining pelvic 
nodal status in patients with high risk localised prostate cancer undergoing surgical 
staging with pelvic lymphadenectomy (reference standard).  
 To document the early kinetics of [11C]choline from dynamic imaging up to 60 
minutes post radiotracer injection.  
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 To evaluate the association between [11C]choline uptake (SUV) and 
immunohistochemistry scores for CHKα expression, Ki67 in prostate tumours and 
involved nodes. 
 This study was used to test the hypothesis that untreated malignant lesions will 
have enhanced radiolabelled choline accumulation due to their high CHKα expression.  
 
3.1.2: Materials and Methods 
 
3.1.2.1: Patients 
 
 Patients with histologically confirmed prostate cancer staged as either high risk 
localised (either PSA >20ng/mL or Gleason score 8-10 or TNM stage ≥ T2) / locally 
advanced (nodal disease on staging MRI of the pelvis), were eligible for the study. 
Patients with visceral or bone metastases were ineligible. Thus the main inclusion and 
exclusion criteria for this study were: 
Inclusion criteria: 
1) Histologically confirmed adenocarcinoma of the prostate. 
2) High risk prostate cancer- either PSA >20ng/mL, or Gleason score 8-10 or 
AJCC Stage T2c or higher, who on cross sectional MRI imaging of the 
pelvis, demonstrated nodal disease. 
3) More than 30% risk of nodal disease based on the Roach formula. 
4) WHO performance status 0 or 2.  
5) Normal blood counts; Haemoglobin >10g/dl, WBC >4000/mm3, platelets 
>100,000/mm
3
.  
6) Normal liver and renal function.  
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7) Written informed consent and fit for surgery.  
Exclusion criteria:  
1) Patients with visceral or bone metastases. 
2) Prior radical prostatectomy or previous open lower abdominal or pelvic 
surgery which may contra-indicate laparoscopic pelvic nodal dissection. 
3) On any concurrent investigational agent.  
4) Life expectancy less than 5 years. 
5) Previous malignancy within the last five years other than basal cell 
carcinoma.  
 
Ethical approval for the study was granted by the Hospital Research Ethics Committee. 
All patients gave written informed consent to participate in the study, which was carried 
out according to the Declaration of Helsinki guidelines. The administration of 
radioactivity for the PET scans was approved by the Administration of Radioactive 
Substances Advisory Committee, United Kingdom. 
3.1.2.2: Imaging protocol 
 
 [11C]choline  was synthesised at Hammersmith Imanet® according to the method  
described by Pascali et al (Pascali 2000). To minimise post-biopsy effects, all imaging 
studies were performed at least 6 weeks after the transrectal biopsy. Subjects were 
asked to fast for 6 hours prior to the procedure (as bowel choline uptake interferes with 
interpretation of [11C]choline images). All patients were scanned on a PET/CT (GE-
Discovery RX®) scanner after being positioned such that the field of view (FOV) 
included the whole pelvis and the lower abdomen. This was followed by a diagnostic 
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quality CT scan (settings were; 300 mA, 120kVp, 0.8 sec/rotation i.e. 65 mAs, 8 x 
2.5mm slices and pitch 1.35) which was used for attenuation correction and co-
registration with the PET images. [11C]choline was administered by a bolus intravenous 
injection over 10 to 30 seconds. PET  scanning (3-dimensional acquisition) was 
commenced over 2 bed positions (3 minutes per bed position) starting from the distal 
margin of the pelvic floor, covering the pelvis and lower abdomen (axial FOV per bed 
position, 15.7 cm; transaxial, 70 cm) for 65 minutes. Raw PET data were corrected for 
scatter and attenuation, and reconstructed with an iterative OSEM (ordered subset 
expectation maximum) algorithm comprising 8 iterations and 21 subsets. Decay 
corrected images were then viewed using Analyze® software (Analyze Version 7; 
Biomedical Imaging Resource, Rochester, MN, USA). From summed images, regions 
of interest (ROIs) were drawn manually around visible tumours in the prostate, and any 
visible pelvic nodes.  The [11C]choline radioactivity concentration within the ROIs was 
then determined and normalised for injected radioactivity and body weight to obtain 
SUV. The average and maximum SUV at 60 minutes (SUV60,ave, and SUV60,max) were 
determined. Due to the rapid systemic metabolism of [11C]choline (Kenny, Contractor et 
al. 2010), SUV has also been determined at an earlier time point (SUV15,ave, and SUV15, 
max).  
3.1.2.3: MRI acquisition 
 
 All patients underwent standard non-contrast staging MRI of the pelvis from 
aortic bifurcation to pubic symphysis comprising of T1-weighted axial images; axial, 
sagittal and coronal T2-weighted images and small FOV axial T2-weighted images 
through the prostate. The imaging was performed on a 1.5 Tesla Philips scanner in 5 
patients and a 1.5 Tesla Siemens-Magnetom scanner in 21 patients. 
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3.1.2.4: Extended Laparoscopic extra-peritoneal Pelvic 
Lymphadenectomy (eLPL) 
 
 This was performed in a standard pre-defined protocol by the Urologists within 
an average of 22 days (2-49 days) of the [11C]choline PET/CT. Nodal status was 
discussed with the surgeon before lymphadenectomy using information from both MRI 
and the [11C]choline PET/CT images.  The eLPL included nodes along the external and 
internal iliac vessels to the ureter proximally, obturator nerve medially and the 
genitofemoral nerve laterally.  All nodes removed were carefully labelled for size and 
anatomical location. Nodes were fixed, paraffin embedded, stained with haematoxylin 
and eosin and reported as negative or positive for metastasis by a histopathologist with 
a specialist interest in urologic malignancy. The samples were also subjected to 
additional immunohistochemistry with Ki67 and CHKα (vide infra). 
3.1.2.5: Image interpretation 
 
 The images of the [11C]choline PET/CT were interpreted prospectively in order 
to outline the ROIs, perform SUV analysis and discuss outcome with surgeons pre-
operatively. Furthermore, all the imaging data (MRI, [11C]choline PET and [11C]choline 
PET/CT were pooled and evaluated by a dual accredited nuclear medicine radiologist, 
blinded to the results of the histopathology, on separate occasions to avoid reporting 
bias. Any discrepancy between the two observers was resolved by a consensus 
reading. The criteria for nodal involvement on the PET only images were any focal 
uptake outside the normal physiological distribution of tracer in locations which 
corresponded to LN chains. For the PET/CT images, nodes with increased tracer 
uptake above background were considered positive for metastatic spread, even when 
they were <10mm in short-axis diameter. The site and size of nodes with increased 
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uptake were noted. In addition the level of diagnostic confidence for the PET and fused 
PET/CT scans was indicated on a five-point scale:  
i) Definitely normal 
ii) Probably normal (more likely to be physiological) 
iii) Indeterminate (equally likely to be pathological or physiological) 
iv) Probably abnormal (more likely to be pathological) 
v) Definitely abnormal.  
For subsequent analysis definitely normal, probably normal and indeterminate were 
considered benign and probably abnormal and definitely abnormal were considered 
malignant. 
For MRI analysis the short-axis and long-axis diameters of the identifiable LNs were 
measured using electronic callipers on the scanner console. The criteria used for the 
node diagnosis on MRI were size ratio criteria - nodes less than 8 mm short axis were 
considered benign, nodes more than 10 mm short axis were considered metastatic, 
and for nodes with a short axis between 8 and 10 mm, if the ratio of the short to long 
axis was more than 0.8 (i.e., a round node), the node was considered positive (Jager, 
Barentsz et al. 1996; Harisinghani, Barentsz et al. 2003). The following 5 point scale 
was used for ROC curve analysis of MRI:  
i) Nodes <4mm or not seen 
ii) Nodes = 4 – 5.9 mm 
iii) Nodes = 6 – 7.9 mm  
 112 
 
iv) Nodes ≥ 8mm but <10mm 
v) Nodes ≥ 10mm 
3.1.2.6: Blood sampling and [11C]choline metabolite analysis 
 
 The concentration of [11C]choline in venous blood was measured from discrete 
blood samples taken at 2.5, 5, 10, 30 and 60 minutes after [11C]choline injection. The 
relative contributions of [11C]choline parent fraction and its metabolite, [11C]betaine, 
were determined using reverse-phase high-performance liquid chromatography as 
previously described (Contractor, Kenny et al. 2009). 
3.1.2.7: Modelling of PET data 
 
Within the PET imaging time window (65 min), tumour [11C]choline uptake is a 
function of perfusion, and transport of the radiotracer from the extracellular space into 
cells, where it is either phosphorylated into phosphocholine or oxidised to betaine. 
Notably, incorporation of phosphocholine to membrane phosphatidylcholine is 
negligible within this time window (Yoshimoto, Waki et al. 2004; Bansal, Shuyan et al. 
2008; Kuang, Salem et al. 2010). Chromatographic analysis also indicates that further 
betaine metabolism or conversion of choline to acetylcholine is negligible (Leyton, 
Smith et al. 2009). Hence radiotracer uptake broadly represents transport and 
phosphorylation on the one hand, and transport and oxidation on the other. 
The full arterial blood data available from the [11C]choline PET breast data have 
been explored and the information has been used to predict the performance of a 
limited sampling venous data set in prostate cancer patients. 
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3.1.2.7.1: Kinetic modelling of [11C]choline PET breast data 
 
The aim was to evaluate the specificity of [11C]choline uptake and understand 
the role of choline metabolism in tumours through kinetic modelling of PET data. This 
evaluation was used to test the hypothesis that altered choline transport and choline 
oxidation could confound the specificity of [11C]choline uptake in tumours. 
The raw image data of 18 patients (8 primary and 10 metastatic cases) who had 
[11C]choline PET scans, from previous published data of Dr Contractor (Contractor, 
Kenny et al. 2011) were completely re-analysed for this thesis with his prior permission. 
The primary and metastatic lesions were manually outlined using the Analyze™ 
software (Analyze Version 7; Biomedical Imaging Resource, Rochester, MN, USA). The 
average [11C]choline SUV normalised to body weight at 60 minutes: SUV60,ave, in the 
VOIs was calculated from the tissue radioactivity concentrations. The kinetic rate 
constants were determined by 2-tissue irreversible (3k) and 2-tissue reversible (4k) 
compartment modelling and the best model fit assessed. The [11C]choline kinetic 
variable, Ki representing the net irreversible uptake of the radiotracer at steady state, 
was derived by Graphical analysis using in-house software. In addition, Spectral 
analysis of tumours was done to derive the IRF60 as well as FRT. The exponential 
range of base (log10β) used during analysis was from 0 to -3.24, with the minimum 
value -3.24 being the log10 of the decay constant λ for [
11C]choline. IRF1 (the 
relationship between parent plasma radioactivity and tissue radioactivity at 1 minute) 
was used instead of the intercept of the IRF curve due to high noise variance of IRF at 
zero time (IRF0) shown previously in a study (Cunningham and Jones 1993). 
Comparisons were done on a lesion by lesion basis for tumours. Descriptive statistics 
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were used to report SUV, Ki and FRT. Comparison of PET variables between primary 
and metastatic tumours was done using the Mann-Whitney test.  
Results 
Primary and metastatic tumours (total of 29 lesions from 18 patients) were well 
visualised with the steady state of tissue [11C]choline concentration achieved in 
approximately 20 minutes post injection of [11C]choline and showed a good retention up 
to 60 minutes post injection (Figure 16). The mean (± SD) SUV60,ave in primary, locally 
recurrent and metastatic lesions was 2.64 (± 0.9), 5.47 (± 1.41) and 3.43 (± 1.27) 
respectively.  
 
Figure 16: Decay corrected time activity curves of [
11
C]choline  
in (a) Primary (n=10), (b) Locally recurrent (n=5), (c) Metastatic lesions (n=14) and the (d) mean 
TACs. The SUV is higher for the locally recurrent tumours and lowest for the primary tumours. 
 
The 3k and 4k model were equivalent in terms of comparison of weighted 
akaike information criterion (AICw) and residual sum squares (RSS) for individual 
primary, nodal and bone metastases (p>0.05, Mann-Whitney test). However, in the 5 
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locally recurrent lesions the kinetics was better explained by the 4k model, suggesting 
that there could be dephosphorylation of the phosphocholine. The different rate 
constants derived by the 4k model in the primary, locally recurrent and metastatic 
lesions are shown in Figure 17. The average rate constants were K1 = 0.003553 
mL/g/min, k2 = 0.011862 min-1, k3 = 0.004799 min-1 and k4 = 0.0002078 min-1. The k2 
was high with a low k4. This high k2 could suggest that there is betaine efflux from the 
tumour cells (i.e. k2= very low, but k2’= high) hypothesizing that betaine is produced in 
the tumour tissues even in humans. 
 
Figure 17: The proportion of K1, k2, k3, k4 in the primary, locally recurrent and metastatic 
lesions calculated from the 4k model.  
There appears to be a negligible k4 but a higher k2.  
 
The model fits obtained by the modified Patlak method were acceptable with 
low SD of the goodness of fit (Figure 18). The median Kimod-pat in primary tumours (8.17 
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x 10-4 mL plasma/mL tissue/sec) was significantly lower (p=0.004) than the median 
Kimod-pat in the locally recurrent tumours (20.93 x 10
-4 mL plasma/mL tissue/sec), but not 
significantly lower (p=0.46) than the metastatic lesions (10.44 x 10-4 mL plasma/mL 
tissue/sec). The high median Kimod-pat in the locally recurrent lesions is indicative of an 
irreversible kinetic component, suggesting that the appearance of the recurrences is 
driven by CHK activity. 
 
Figure 18: Modified Patlak plots of tumour [
11
C]choline activity modelled with the 
metabolite corrected parent plasma IF.  
(a) Good fit using the modified Patlak model, (b) noisy fit seen in a metastatic axillary node from 
breast cancer.  
 
 Spectral plots showed fast and slow kinetics including kinetic components 
corresponding to irreversible uptake in tumours (at -3.24; λ) and reversible components 
(~0) blood volume (Figure 19). Tumour tissue fits were good with low RSS. The 
median FRT for primary, locally recurrent and metastatic tumours was 0.48, 0.63 and 
0.57 respectively. The FRT in primary tumours was not statistically different (p=0.06) 
from FRT of locally recurrent lesions or metastatic tumours (p=0.84) (Figure 20). 
However IRF60 was significantly higher in locally recurrent tumours compared to 
primary tumours (p=0.003). This suggests that there could be more metabolism of 
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choline to betaine in the metastatic lesions (low IRF60) and that the growth of 
metastases could be driven by pathways other than by choline kinase. 
 
Figure 19: Spectral analysis of [
11
C]choline in tumours showing IRF and spectra of 
modelled responses of a representative patient.  
Slower spectra signify irreversible kinetics (closest to λ) whereas fast kinetics signifies reversible 
kinetics signifying blood volume flow around tumour. 
 
 
 
 
 
Figure 20: FRT and IRF.  
Differences between a) FRT and b) IRF60 of primary, locally recurrent (LR) and metastatic 
lesions from Spectral analysis. 
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3.1.2.7.2: Kinetic modelling of [11C]choline PET prostate data 
 
A population-based total plasma input function CTOTALPOP(t) was derived from the 
[11C]choline breast cancer data set discussed in the previous section (Contractor, 
Kenny et al. 2011), by averaging the measured arterial plasma concentration time 
course after normalisation by injected dose and body weight. An approximated input 
function for each subject was then derived by fitting the ratios between measured 
venous plasma samples and corresponding values of CTOTALPOP(t) to a quadratic 
function g(t) as per equation 7.  
CTOTALINDVID(t)=  C
TOTAL
POP(t) x g(t)      Equation 7 
     
The parent fraction measured in the venous samples was then fitted to a sigmoid 
function (Gunn, Yap et al. 2000) as per equation 8. 
pf(t) =
  1
1
4
3
21



X
i
i
tX
tXX
       
Equation 8
 
The individual plasma concentrations of the parent [11C]choline (CPARENTINDVID) and the 
metabolite  [11C]betaine (CMETABINDVID) were, respectively, obtained as  
 CTOTALINDVID(t) x pf(t)   and C
TOTAL
INDVID(t) x [1- pf(t)]      Equation 9 
The modified Patlak plot (Mankoff, Shields et al. 1996), which takes account of 
plasma metabolites of  [11C]choline, as well as labeled metabolites within the 
exchangeable space in tumour, was used to derive Ki (Kimod-pat); a measure of the net 
irreversible retention at steady state within a VOI. The method implicitly assumes that 
the majority of labelled betaine in tumours derives from systemic circulation (Roivainen, 
Forsback et al. 2000; Witney, Alam et al. 2012). 
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3.1.2.8: Immunohistochemistry 
 
The CHKα staining was initially performed using the immunofluorescence (IF) 
method. However, there was difficulty in differentiating and interpreting the glandular 
architecture on these slides. Therefore a conventional IHC method was pursued and 
developed. The labelled streptavidin-biotin (LSAB) method was used (Figure 21). This 
involved the use of a biotinylated secondary antibody that links primary antibodies to a 
streptavidin-peroxidase conjugate (Chilosi, Lestani et al. 1994). As part of the protocol 
development, the CHKα primary antibody was optimised on human bronchus samples 
to determine the appropriate antigen retrieval method (heat induced retrieval in a citrate 
for 20 min) and the antibody dilution (1 in 75). The secondary antibody and peroxidase 
conjugation used were kit based.  
 
Figure 21: Labelled Streptavidin Biotin (LSAB) method.  
This uses a biotinylated secondary antibody that links primary antibodies to a streptavidin-
peroxidase conjugate. 
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3.1.2.8.1: Material analysed 
 
Twenty prostate tumour cores, 7 metastatic pelvic node sections from the 26 
patients, and 9 prostate tumour cores from 10 patients in the study discussed in 
chapter 4 were analysed (total 29 tumour cores and 7 nodal sections). All the tumour 
paraffin fixed sections were initially deparaffinised in xylene and then serially 
dehydrated using decreasing grades of ethanol (100 – 70%). 
3.1.2.8.2: CHKα Immunofluorescence  
 
The sections were subjected to heat-induced antigen retrieval pre-treatment 
with sodium citrate buffer, pH 6.0, in a water bath at 1000 Celsius for 20min. The 
sections were left to cool for approximately 10 min at room temperature and washed in 
running water. Endogenous peroxidase was neutralised with 3% hydrogen peroxide for 
10 minutes.  The sections were washed twice in TRIS buffered saline (TBS) for 5 min 
each.  Non-specific binding was blocked by incubating with a blocking buffer (1% 
bovine serum albumin (BSA) and 10% foetal calf serum (FCS)) for 1h. Incubation with 
primary antibody took place at 40C overnight in a humidified chamber with a mouse 
CHKα primary antibody (1:50 dilution; Abcam, Cambridge, UK, catalogue no ab38290). 
Human bronchus was used as positive control. The sections were then washed with 
TBS and incubated at room temperature with secondary antibody (1:400 dilution, Alexa 
Fluor® 594 goat anti-mouse antibody (Invitrogen, catalogue no A11005, Paisley, UK), 
for 1 hour and counter-stained with DAPI (ProLong® Gold Antifade, Paisley, UK) to 
stain the nuclei. Then cover slips were mounted using a mounting solution and sections 
visualised using red, blue and green filters. Areas of immunoreactivity were red and the 
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nuclei, blue. If there was nuclear staining with CHKα it stained pink. Negative control 
was obtained by omitting the primary antibody, replacing it with TBS+BSA.  
3.1.2.8.3: CHKα Immunohistochemistry 
 
After antigen retrieval and quenching endogenous peroxidase activity as 
described above, the sections were washed twice in TRIS buffered saline-Tween 
(TBST) for 5 min each.  Non-specific binding was blocked by incubating with a blocking 
buffer (5% BSA and 5% goat serum) for 1h. Incubation with primary antibody took place 
at 40C overnight in a humidified chamber with a polyclonal rabbit anti-human CHKα 
primary antibody (1 in 75 dilutions: catalogue No HPA024153, Sigma-Aldrich™, Dorset, 
UK). Human bronchus was used as positive control. The sections were then washed 
with TBST, and for subsequent reaction, a labelled streptavidin biotin (LSAB) kit 
(NovocastraTM, Newcastle Upon Tyne, UK) was used.  Biotinylated secondary antibody 
(anti-mouse and anti-rabbit) was added to the slides and incubated at room 
temperature for 60 minutes in a humidified chamber. The slides were again washed 
and incubated with streptavidin peroxidase for an additional 30 minutes.  The 
peroxidase activity was developed with the substrate, 3, 3’-diaminobenzidine (DAB) 
chromogen for 5 minutes.  Tissues were counterstained with haematoxylin for one 
minute and dehydrated with absolute ethanol and xylene. Then cover slips were 
mounted using a mounting solution and sections examined by light microscopy.  Areas 
of immunoreactivity were brown and nuclei, blue (haematoxylin). Negative control was 
obtained by omitting the primary antibody and replacing with TBST+BSA (Figure 22). 
Tumour slides were then independently scored. The intensities were scored as: 1+, 
mild intensity; 2+, moderate intensity; 3+, high intensity, including nuclear staining as 
compared to the positive control.  
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Figure 22: CHKα immunostaining in the human bronchial tissue.  
It was used as a positive control. Note brown staining in the positive control and lack of staining 
in the negative control. Magnifications of 200X. 
 
3.1.2.8.4: Ki67 labelling index 
 
After antigen retrieval, quenching endogenous peroxidase activity and blocking 
non specific binding as described above, sections were incubated with the primary 
antibody (1 in 200 dilutions: mouse Anti-Ki-67 antibody, Ki-67-MM1, Dako, Denmark) 
for 1 hour at room temperature. Human tonsil tissue was used as a positive control. 
The sections were then washed with TBST, and for subsequent reaction, a labelled 
streptavidin biotin (LSAB) kit (NovocastraTM, Newcastle Upon Tyne, UK) was used 
according to the manufacturer’s instructions. Finally, the slides were stained with weak 
haematoxylin before viewing. Areas of immunoreactivity with brown nuclear staining 
were positive for Ki67. The numbers of total tumour cells and positive Ki67 cells were 
then manually counted in four randomly selected tumour fields of view. The Ki67 
labelling index (expressed as a percentage) was calculated as the ratio of Ki67 positive 
tumour cells to total tumour cells.  
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3.1.2.8.5: Haematoxylin and Eosin (H&E) staining 
 
After deparaffinisation, the adjacent sections to those used for CHKα IHC were 
stained in haematoxylin for 10 minutes and washed in running water. They were then 
dipped in 1% acid alcohol, washed in running water and dipped in Scott’s tap water 
substitute for 30 sec. The sections were then stained with 1% Eosin for 5 minutes and 
washed in water. After dehydration with industrial methylated spirit and xylene, cover 
slips were mounted using a mounting solution and sections examined by light 
microscopy. The nuclei are stained blue and eosin counter-stains the cytoplasm and 
different types of connective tissue fibres with differing shades of pink. 
Photomicrographs were obtained using BX51 Olympus microscope (Olympus 
Optical, Tokyo, Japan) at 200x and 400x magnifications. 
3.1.2.9: Statistical considerations 
 
 The sample size for the study took into consideration two cohorts of patients 
with prostate cancer. The first cohort  involved cases of locally advanced prostate 
cancer with no visible nodes on MRI/CT but with greater than 30% chance of pelvic 
nodal disease based on Roach’s formula (Roach 1993) . The second cohort consisted 
of those patients with nodal disease (> 1cm) present on MRI  (assuming a 70% 
sensitivity of MRI in detecting nodal disease (Harisinghani, Barentsz et al. 2003)). The 
prevalence of overt nodal disease present on staging CT/MRI in clinical practice is 
much less than that of high risk localised prostate cancer. In the local hospital clinical 
practice it was evident that approximately three times more high risk disease cases 
were seen on average compared to those with overt node positive disease. Therefore, 
if for example 21 patients from the high risk group were recruited, there would be a 1 in 
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3 chance of finding positive lymph nodes on nodal dissection, i.e.; 7 patients. 
Correspondingly, if 7 patients with node positive disease on their staging MRI/CT were 
recruited, this would be sensitive in ~75% of cases, i.e.; 5 patients (assuming the 
maximum sensitivity of MRI to be ~75%). Thus 28 patients (21 pts + 7 pts) would give a 
reasonable chance of finding at least 12 node positive patients at the time of nodal 
dissection. 
 The mean, standard deviation (SD), medians, range, and frequencies were 
used as descriptive statistics. The sensitivity, specificity and number of correctly 
recognised cases with MRI, [11C]choline PET and [11C]choline PET/CT in nodal 
detection were calculated for per patient and per node analysis. The comparison of 
each imaging method was performed using the McNemar test implemented in its 
uncorrected exact form, based on the binomial distribution (Hawass 1997). Receiver 
operating characteristic (ROC) analysis and the area under the curve (AUC) was 
determined by recalculating sensitivity and specificity for MRI, PET and PET/CT along 
the five-point grading scale for a per patient and a per nodal analysis using MedCalc 
statistical software (version 11.6.1, Mariakerke, Belgium). SUV60,ave and SUV60,max were 
compared with CHKα and Ki67 scores using Spearman’s correlation test and a p value 
of ≤ 0.05 was considered significant.  
 
3.1.3: Results 
 
3.1.3.1: Patients 
 
 Twenty eight patients underwent [11C]choline PET/CT after fulfilling the inclusion 
criteria. Two patients could not undergo surgery after [11C]choline PET/CT as one 
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became unwell and the other changed his mind about undergoing surgery. Thus 26 
patients underwent [11C]choline PET/CT followed by eLPL/ sampling (one had LN 
sampling rather than dissection due to fibrotic and calcified lymph nodes). All patients 
subsequently had neo-adjuvant androgen deprivation followed by radical radiotherapy 
to the prostate and the pelvis. The median (mean; range) age of subjects was 67 years 
(67.7; 51 to 83 years), Gleason score of primary prostate biopsies was 7 (7.6; 6-9) and 
the pre-treatment PSA levels were 26.25 (44.25; 8.1 – 209).  
 The interval between the [11C]choline PET/CT and eLPL was an average of 22 
days (2-49 days). From the 26 patients, a total of 406 pelvic LNs sampled were 
available for pathology, with a median of 16 (range 3-36) nodes harvested per patient. 
27 (6.7%) involved pelvic nodes at eLPL were detected in 9 patients (Table 9). Of the 
involved nodes 17 out of the 27 LN were less than 10 mm in size. The average nodal 
size of the histologically positive nodes was 9.8 mm with an average tumour focus of 
5.7mm. The [11C]choline PET/CT was well tolerated with no immediate or delayed 
complications observed.  
3.1.3.2: [11C]Choline uptake within the malignant prostate and 
pelvic nodes 
 
 In addition to visualisation of nodal uptake, primary prostate tumours in all 26 
patients were well visualised with good tumour-to-background ratios (Figure 23 and 
24). The median (mean ± SD; range) SUV60,ave and SUV60,max were 4.85 (4.92 ± 1.75; 
2.19-9.28) and 9.97 (11.05 ± 3.72; 4.73-20.54) respectively (median SUV15,ave and 
SUV15,max were 4.82 and 8.80 respectively; Figure 25). Dynamic time versus 
radioactivity curves (TAC’s) for [11C]choline in primary prostate tumours and the nodal 
metastases demonstrated a good retention of activity after plateauing (achieving a 
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steady state) at ~15 min until 60 min with SUVave (Figure 26, 27).  However, with 
SUVmax there is a suggestion of increasing activity at 60 min which may be due to the 
contribution of [11C]betaine.  
There was a good linear fit of the modified Patlak plots suggesting net retention 
of [11C]choline. The median (range) Kimod-pat variables in the primary tumours, TP pelvic 
nodes and detected inguinal nodes were 0.095 mL/min/cm3 (0.03-0.23), 0.05 
mL/min/cm3 (0.021-0.18) and 0.021 mL/min/cm3 (0.006-0.08), respectively. A significant 
association was seen between the Kimod-pat and tumour [
11C]choline uptake when the 
imaging variable was SUV60,ave (Spearman’s r=0.9, p<0.0001) SUV60,max (r=0.8, 
p<0.0001). This association was seen even at earlier time points (SUV15,ave, SUV15,max).
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Table 9: Characteristics of patients with histologically positive nodes (9/26) and false positive nodes on PET/CT 
 
Pt No Age GS iPSA cT pN 
No of 
+ LN 
Site of + LN MRI 
Size 
(mm) 
 PET  PET/CT 
Size 
(mm) 
 
1 73 7 8.54 T3a N1 1 1-R Obt R Obt 11 TP 1-R Obt TP R Obt 11 TP 
10 82 8 13.5 T3 N1 5 3-R Obt, 1-R II, 1-R GF 2-R EI 21,8 TP 3-R EI TP 3-R EI 20,11,7 TP 
13 56 7 50 T1c N1 1 1-L Obt   FN  FN   FN 
15 65 9 209 T2b N1 7 4-L EI, 3-R II R II 19 TP 1-L EI, 3-R II TP 1-L EI, 3-R II 9,18,11,5 TP 
17 76 7 169 T4 N1 1 1-R Obt L Obt 9 FP R Obt TP R Obt 9 TP 
20 76 7 21 T2b N1 1 1-R Obt   FN R Obt TP R Obt 4 TP 
24 61 9 45 T3 N1 8 
1-R II, 2-R Obt, 3-L EI, 
2-L Obt 
  FN 1-R Obt TP 1-R Obt, 2-R II 6,6,4 TP 
25 76 9 24.5 T2b N1 2 2-R EI   FN  FN   FN 
27 51 7 44.8 T3b N1 1 1-L II L II 10 TP  FN L II 10 TP 
Mean 68.44 7.8 65.04      13.8     9.4  
Median 73 7 44.8      11     9  
False Positives            
1 73 7 8.54 T3a N1   L Obt 6 TN L Obt TN L Obt 6 FP 
        R EI 7 TN R EI FP R EI 7 FP 
11 70 7 8.1 T2 N0   R EI 7 TN R EI FP R EI 12 FP 
        L EI 10 FP L EI FP L EI 10 FP 
21 64 6 12 T3a N1   R EI 26 FP R EI FP R EI 26 FP 
26 69 7 8.2 T2a N1   L Obt 10 FP L Obt FP L Obt 10 FP 
GS-Gleason score; iPSA- initial prostate specific antigen; cT-clinical tumour stage; pN-pathological nodal stage; LN-lymph node; R-right; 
L-left; Obt-obturator; EI-external iliac; II-internal iliac; GF-genitofemoral; TP-true positive; FN-false negative; FP-false positive; + - 
positive. 
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Figure 23: T1 weighted MRI (i), Axial [
11
C]choline PET (ii), CT (iii), and fused PET/CT (iv) 
showing uptake in pelvic nodes.  
(a) Focal uptake seen in a 4mm right obturator node (arrowed) clearly separate to the ureter on 
the PET only (ii). In retrospect visible on MRI (i) but not called as well below size criteria, (b) 
Coronal T2 weighted MRI (i), [
11
C]choline PET Maximum Intensity Projection (MIP) (ii), CT (iii), 
and PET/CT fused (iv) shows focal uptake in cluster of right external iliac nodes (arrowed). Note 
uptake in prostate extending to seminal vesicle (green arrow on coronal MIP), (c) T1 weighted 
MRI (i) axial [
11
C]choline PET (ii), CT (iii), and PET/CT fused  (iv) shows focal uptake in 10 mm 
left obturator node (arrowed) which was false positive. 
  
 129 
 
 
Figure 24: T2 weighted MRI (i), Axial [
11
C]choline PET (ii) and fused PET/CT (iii) showing 
uptake in the prostate and Seminal vesicles. 
(a) Focal uptake in the prostate (arrowed), (b) right seminal vesicle involvement (arrowed), (c) 
capsular breech (T3a disease) on the left (arrowed). 
 
Figure 25: SUVave and SUVmax at early and late time points for primary prostate tumours 
and nodes. 
 130 
 
Primary Tumour TAC SUVave
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
6
7
8
9
10
a
Time (sec)
S
U
V
a
v
e
TP LN TAC SUV  ave
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
6
7
8
9
10
b
Time (sec)
S
U
V
 a
v
e
FP LN TAC SUVave
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
6
7
8
9
10
c
Time (sec)
S
U
V
 a
v
e
Ing LN TAC SUVave
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
6
7
8
9
10
d
Time (sec)
S
U
V
 a
v
e
Out of template LN TAC SUVave
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
6
7
8
9
10
e
Time (sec)
S
U
V
 a
v
e
Mean TAC's SUV ave
0 1000 2000 3000 4000
0
1
2
3
4
5
6
7
8
9
10  Primary Tumour TP LN FP LN
Inguinal LNOut of template LN
f
Time (sec)
S
U
V
a
v
e
 
Figure 26: [
11
C]Choline SUVave TAC curves.  
Profiles in (a) primary prostate tumours, (b) true positive nodes, (c) false positive nodes, (d) 
inguinal nodes, (e) out of template (common iliac & para aortic) nodes and, (f) the mean TACs 
demonstrating a good retention of activity after plateauing after ~15 min. 
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Figure 27: [
11
C]Choline SUVmax TAC curves.  
Profiles in (a) primary prostate tumours, (b) true positive nodes, (c) false positive nodes, (d) 
inguinal nodes, (e) out of template (common iliac & para-aortic) nodes and, (f) the mean TACs 
demonstrating a good retention of activity after plateauing after ~15 min. There is a hint of 
increasing activity at 60 min which may be due to contribution of [
11
C]betaine. 
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3.1.3.3: Diagnostic performance of MRI, [11C]choline PET and 
[11C]choline PET/CT in detection of nodal disease  
 
 On a per patient basis, the sensitivity and specificity were 50 % and 72.2%; 
66.7% and 76.4 % and 77.8% and 82.4% respectively for MRI, [11C]choline PET and 
[11C]choline PET/CT. On a per nodal basis the sensitivity and specificity were 18.5 % 
and 98.7%; 40.7% and 98.4 %; and 51.9% and 98.4% respectively for MRI, [11C]choline 
PET and [11C]choline PET/CT (Table 10). No statistical difference between any two 
modalities was detected in the patient analysis, mainly owing to the relatively low 
number of subjects. In the per nodal analysis the sensitivity was significantly improved 
with the use of [11C]choline PET/CT (p=0.007) and [11C]choline PET (p=0.07) compared 
to MRI imaging, without a decrease in the specificity (p= 1, 1 and 0.48 for [11C]choline 
PET versus MRI, [11C]choline PET/CT versus MRI and [11C]choline PET/CT versus 
[11C]choline PET comparisons, respectively).  
 ROC analysis (Figure 28) showed the overall diagnostic performance improved 
in the following order MRI < [11C]choline PET < [11C]choline PET/CT. Table 11 shows 
the detection rate of MRI, [11C]choline PET and [11C]choline PET/CT for nodal  
metastases according to the diameter of the infiltrated LNs. A higher LN detection rate, 
including the detection of sub centimetre nodes, was seen with [11C]choline PET/CT 
than MRI. The mean diameter of the positive LNs on histopathology was 9.8mm and 
that of the true positive LNs was 13.8 and 9.4 mm, respectively, on MRI and 
[11C]choline PET/CT (using CT component for size definition). 
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Table 10: Sensitivity & Specificity Analysis 
 
Imaging modality  
Histology 
Positive 
Histology 
Negative 
Sensitivity 
(%) (CI) 
Specificity 
(%) (CI) 
PPV (%) 
(CI) 
NPV (%) 
(CI) 
 + LR  
(CI) 
 -LR  
(CI) 
 TP FN FP TN       
per Patient Basis           
MRI 4 4 5 13 50 72.2 44.4 76.5 1.8 0.7 
     (15.7 -84.3) (46.5 - 90.3) (13.7 - 78.8)  (50.1 -93.2) (0.9 -3.8) (0.3-1.9) 
[11C]choline  PET  6 3 4 13 66.7 76.4 60 81.2 2.8 0.4 
     (29.9 - 92.5)  (50.1 -93.2)  (26.2 - 87.8)  (54.4 - 96) (1.7 - 4.8) (0.1 - 1.5) 
[11C]choline PET/CT  7 2 3 14 77.7 82.4 70 87.5 4.4 0.3 
     (40.0- 97.2) (56.6- 96.2) (34.8- 93.3) (61.7- 98.4) (2.9-6.7) (0.05-1.3) 
per Nodal basis           
MRI  5 22 5 374 18.5 98.7 50 94.4 14 0.8 
     (6.3-38.1) (96.9 - 99.6) (17.3 - 82.7) (91.7 - 96.5) (6.4 - 31.0) (0.3 - 2.0) 
[11C]choline  PET  11 16 6 373 40.7 98.4 64.7 95.9 25.7 0.6 
     (22.4-61.2) (96.6 - 99.4) (38.3 - 85.8) (93.4 - 97.6) (16.3 - 40.6) (0.3 - 1.4) 
[11C]choline PET/CT  14 13 6 373 51.9 98.4 70 96.6 32.8 0.5 
     (31.9-71.3) (96.6 - 99.4) (45.7 - 88.1) (94.3 - 98.2) (22.8 - 47.1) (0.2 - 1.2) 
TP-true positive; FN-false negative; FP-false positive; TN-true negative; CI-confidence intervals; PPV-positive predictive value; NPV-negative 
predictive value; LR-likelihood ratio; + positive; - negative. 
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Figure 28: ROC curve analysis.  
The area under the curve was 0.625, 0.820 and 0.830 respectively for MRI, [
11
C]choline PET 
and [
11
C]choline PET/CT on a per patient basis and 0.677, 0.745 and 0.766 respectively on per 
nodal analysis. The overall diagnostic performance improved in the following order MRI < 
[
11
C]choline PET < [
11
C]choline PET/CT. 
 
Table 11: Detection rate of the 3 imaging modalities by the size of the node 
 
Size No of MRI [
11
C]choline [
11
C]choline 
of infiltrated 
nodes (mm) 
Lymph nodes 
(LN) 
+ (%) PET + (%) PET/CT+ (%) 
0.1 – 1.9 1 0 (0) 0 (0) 0 (0) 
2 – 4.9 4 0 (0) 0 (0) 1 (25) 
5 – 9.9 12 0 (0) 4 (33) 4 (33) 
≥ 10 10 5 (50) 7 (70) 9 (90) 
  + - Positive 
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3.1.3.4: Sites of nodal involvement 
 
 The majority of the nodes were detected within the standard surgical template. 
However, four of 26 patients (15.4%) had focal increased uptake above the region of 
eLPL (Common Iliac (CI) region and lower para-aortic region – median SUV60,ave and 
SUV60,max of 1.12 and 3.91; median SUV15,ave and SUV15,max of 2.61 and 6.51 
respectively) as detected on imaging and therefore were not sampled. 8 out of 26 
(31%) patients had nodes detected below the surgical template, out of which 3 patients 
had discrete unilateral uptake in the inguinal LNs (median SUV60,ave, SUV60,max and 
Kimod-pat of 1.21,  2.50 and 0.0002; median SUV15,ave and SUV15,max of 1.54 and 2.63 
respectively); significantly lower as compared with true positive pelvic nodes (p-values 
of 0.002, 0.0002, 0.004, 0.0002 and 0.04, respectively, for SUV15 ave, SUV15 max, 
SUV60,ave, SUV60,max and Kimod-pat in the two-sided t-test) which was interpreted as 
probably reactive uptake and therefore were considered non-metastatic (Figure 29). 
One patient had a 5mm tumour focus in a genitofemoral node, which was outside the 
FOV. 
 
Figure 29: Coronal MIP showing focal uptake in bilateral inguinal nodes (hashed arrows). 
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3.1.3.5: Nodal Analysis on MRI 
 
 In 4 of 9 patients, MRI was positive for 5 malignant (true-positive (TP)) nodes 
with a median maximum diameter of 11 mm (range: 9 –21 mm; mean: 13.8 mm).  
 In 22 malignant nodes using size criteria, MRI was false negative (FN). 18/ 22 
(82%) nodes were sub-centimetre and were reported as normal. Four nodes > 10 mm 
were missed. This was due to a cluster of 3 nodes reported as one (Figure 24), lateral 
extension of tumour obscuring the obturator node and 2 nodes measuring 12 and 15 
mm on histology, which measured 4 and 5 mm on MRI , highlighting the pitfall of gross 
nodal measurements which may include surrounding perinodal fat and soft tissue.    
 In 4 patients, MRI was false-positive (FP) (a total of 5 nodes). This was due to a 
probable sampling error in 2 patients (Figure 23), reactive external iliac (EI) nodes in 1 
patient and a positive round reactive obturator node which was negative on PET/CT.   
3.1.3.6: Nodal Analysis on [11C]choline PET 
 
 In 6 of the 9 patients, [11C]choline PET alone was TP for 11/ 27 malignant LNs. 
In the 16 FN malignant nodes, 13 were due to micro-metastases, 2 were mistaken for 
focal ureteric activity which was resolved with PET/CT and one node was in the 
saturation band (i.e. where there was an overlap when the 2 bed positions were fused). 
This saturation band, obscuring some parts of the imaged area is not a general feature 
of PET/CT but probably related to specific equipment settings or reconstruction. 
 In 4/ 17 patients [11C]choline PET was FP (total of 6 nodes). There are varying 
reasons for this: one FP node was due to focal uptake in a calcified vessel mistaken for 
a node which was resolved with PET/CT; 2 nodes were reactive EI nodes; one node 
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was situated in the saturation band and for the remaining nodes in 2 patients, there was 
a probable sampling error given that 15 and 28 nodes were removed in total from those 
patients respectively. The median SUV15,ave: SUV60,ave and SUV15,max: SUV60,max of the 
false positive LNs were 2.54: 2.70 and 5.07: 6.51, respectively. SUVs of the TP LNs 
tended to be higher (median SUV15,ave: SUV60,ave – 2.99: 2.64 and SUV15,max: SUV60,max – 
7.04: 7.77 respectively) than SUVs of the FP LNs although statistical significance was 
never reached (p-values of 0.48, 0.28, 0.56 and 0.22 for SUV15,ave, SUV15,max, SUV60,ave 
and SUV60,max in the two-sided t-test). 
3.1.3.7: Nodal Analysis on [11C]choline PET/CT 
 
 In 7/ 9 patients, [11C]choline PET/CT was TP for 14 malignant LNs (Figure 23). 
The median maximum diameter of the malignant LNs detected was 9 mm (range: 4 – 
20 mm; mean: 9.4 mm).  
 In 13 malignant nodes, [11C]choline PET/CT was FN as explained in the 
preceding paragraph. In 3 patients, [11C]choline PET/CT was FP in 6 nodes. In one 
patient, a further FP node close to the saturation band was called on PET/CT but not 
PET only. The other 5 nodes in two patients were FP on both PET only and combined 
PET/CT as explained above.  
3.1.3.8: CHKα, Ki67expression and association with [11C]choline 
uptake 
 
3.1.3.8.1: CHKα Immunofluorescence (IF) 
 
Using IF, there was a good demonstration of cytoplasmic CHK expression 
(Figure 30). However, it was not possible to differentiate the glandular differentiation 
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and architecture in the sections. Hence staining by IF was stopped in favour of 
conventional IHC.      
 
Figure 30: CHKα Immunofluorescence.  
Cytoplasmic CHK expression is seen as red and the nuclei stain blue. The images to the left 
show cytoplasmic expression and the merged images to the right show nuclear staining (DAPI; 
appear pink) and cytoplasmic expression. Bronchus used as positive control (a, b), cytoplasmic 
and nuclear staining (white arrow) in the malignant prostate core (c, d). 
 
3.1.3.8.2: CHKα IHC 
 
There was CHKα staining in all the malignant prostate cores that varied in 
intensity from 1-3 (predominantly cytoplasmic and some nuclear staining) compared to 
the positive control. The different intensities of CHKα staining along with adjacent H&E 
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stained sections are shown in Figure 31. Various patterns of staining were observed in 
various sections (Figure 32). There was a varying intensity of staining seen in Gleason 
3, 4 and 5 glands. In one section an increased nuclear staining for CHKα with 
increasing Gleason scores was also observed, especially between Gleason 3 and 5 
visually differentiating the two grades. In one section, some benign glandular areas 
adjacent to the malignant glands were also stained. There was no relationship between 
cytoplasmic intensity and nuclear staining of CHKα. In one section an area of prostatic 
intra-epithelial neoplasia (PIN) showed nuclear staining.  When the pelvic node 
sections were stained, benign nodes showed no CHKα staining (Figure 33) whereas 
malignant nodes showed cytoplasmic and nuclear staining in the metastatic deposit. In 
3 patients, the cores from one of the lobes of the prostate gland were benign and the 
cores from the other lobe were malignant. The benign cores of these patients also 
demonstrated an increased CHKα expression (Figure 34). Ki67 staining revealed 
(Figure 35) that most primary and nodal prostate tumours had a low proliferation index 
(median 3%, range 1 to 17%). 
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Figure 31: CHK staining and the matched H&E sections in malignant prostate cores.  
The panels show different staining intensities at low (200X) and high (400X) magnifications. 
Panel (a) shows mild (grade 1) staining, panel (b) shows moderate (grade 2) staining, panel (c) 
shows strong cytoplasmic and nuclear staining (grade 3). 
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Figure 32: Patterns of CHK staining in malignant cores.  
(a) Cytoplasmic staining in Gleason 3 glands, (b) nuclear staining in Gleason 4 glands, and (c) 
in Gleason 5 glands, (d) increasing intensity of staining with increasing Gleason score (3 and 5), 
(e, f) nuclear staining in areas of PIN, (g) cytoplasmic and nuclear staining in malignant glands 
but not in benign gland and (h) cytoplasmic and nuclear staining in both malignant and benign 
glands. B – Benign, M – malignant, PIN – prostatic intra-epithelial neoplasia, GL – Gleason. 
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Figure 33: CHK expression in nodal tissue.  
(a) No staining seen in benign nodes, (b, c) brown cytoplasmic staining in a metastatic deposit, 
(d) mild cytoplasmic staining, (e, f) strong cytoplasmic and nuclear staining in the metastatic 
deposit. 
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Figure 34: CHK staining and the matched H&E sections in the benign cores of a 
malignant prostate gland.  
Mild staining is seen in the benign glands at low (200X) and high (400X) magnifications (a, b). 
The benign architecture is made out in the corresponding H&E sections; note the frilly pattern of 
the gland in (b). 
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Figure 35: Ki67 staining of prostate tumour cores and nodal tissue.  
The panel (a) shows a positive control, benign node and a node with metastatic deposit. Panel 
(b) shows prostate cores with lowest Ki-67 index and panel (c) showing cores with highest 
index. 
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3.1.3.8.3: Correlation with [11C]choline PET/CT parameters 
 
The [11C]choline uptake variables (SUV60,ave or SUV60,max) of the patients who 
had samples available for IHC, along with CHKα intensity scoring and Ki-67 indices are 
given in Table 12. There was a positive correlation between SUV60,ave, and SUV60,max 
(Figure 36) with cytoplasmic CHKα intensity in prostate tumours (r=0.7, p<0.0001, and 
r=0.6, p=0.0001 respectively). This positive correlation was seen even at early time 
points (SUV15,ave, SUV15,max: r= 0.5, p=0.0009 and r=0.5, p=0.003 respectively). There 
was a moderate correlation of SUV60,max with the initial PSA levels (r=0.6, p=0.0003), 
but not with SUV60,ave. However, there was no association between [
11C]choline uptake 
and Ki67 scores (Figure 36). The association between IHC scores for CHKα and Ki67 
with Gleason’s scores or PSA were also assessed (Table 13). Only Gleason scores 
and Ki67 indices showed a positive correlation (r=0.5, p=0.004).  
 
Figure 36: Correlation of [
11
C]choline uptake with IHC scores for CHKα and Ki67.  
The best Spearman’s correlation was with, (a) SUV60,ave with CHKα followed by, (b) SUV60, max 
and CHKα. There was no correlation between [
11
C]choline uptake and Ki67 (c and d). 
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Table 12: [11C]choline PET/CT parameters and the IHC scores for CHKα and Ki67 indices 
in malignant pelvic nodes and primary prostate tumours.  
Pt No* Tissue SUV SUV SUV SUV CHKα Ki67 Gleason PSA 
  15,ave 15,max 60,ave 60,max score score score  
1 node 7.24 11.57 7.26 12.88 3 1 7 8.5 
2 tumour 5.88 11.79 5.96 15.08 3 2 6 21 
4 tumour 5.03 15.56 5.24 17.46 3 1 7 84 
5 tumour 4.84 9.52 4.94 10.64 3 3 9 27.5 
6 tumour 4.27 8.81 3.52 9.99 1 7 9 79.4 
7 tumour 3.54 6.95 3.74 8.74 1 2 6 16.4 
8 tumour 5.57 8.55 5.39 9.83 2 17 9 29.6 
10 tumour 4.79 8.81 4.86 12.03 1 7 8 13.5 
 node 4.05 8.61 4.45 14.16 2 17   
11 tumour 4.99 7.44 4.3 7.38 3 2 7 8.1 
12 tumour 8.80 13.24 9.28 16.62 3 2 7 51 
14 tumour 3.98 6.24 3.7 7.7 1 17 9 15 
15 tumour 5.83 11.37 6.22 14.19 3 13 9 209 
 node 2.71 4.68 8.77 15.87 3 4   
17 tumour 8.75 13.65 7.01 13.6 3 2 7 169 
 node 2.37 5.11 2.46 5.99 1 4   
20 tumour 4.11 9.41 3.75 9.08 1 9 7 21 
 node 3.27 7.24 1.44 6.37 1 4   
22 tumour 3.97 6.80 4.03 9.18 2 2 7 22.7 
23 tumour 6.81 12.21 6.5 15.72 3 2 8 59.5 
24 tumour 4.67 8.04 4.84 10.49 3 3 9 45 
24 node 1.45 4.56 1.27 5.03 2 3   
25 tumour 4.65 9.52 3.55 9.39 1 1 9 24.5 
26 tumour 2.44 3.89 2.19 4.73 1 2 7 8.2 
27 tumour 2.72 5.38 2.73 7.98 1 2 7 44.8 
 node 2.09 6.84 1.82 8.72 3 3   
28 tumour 3.71 8.09 3.08 7.87 1 2 7 25 
2 tumour 3.79 6.85 3.95 6.92 2 3 7 5.4 
3 tumour 4.51 8.10 4.46 8.12 2 4 7 20 
4 tumour 4.98 9.34 5.64 12.49 1 1 6 9.2 
5 tumour 2.62 5.79 2.33 5.78 1 2 6 11 
6 tumour 5.11 10.23 4.70 8.13 3 1 7 13 
7 tumour 5.25 11.48 4.71 9.03 1 3 6 17.1 
8 tumour 6.61 12.74 6.24 12.23 3 7 7 16.5 
9 tumour 3.79 7.16 3.30 6.62 1 1 6 10.1 
10 tumour 4.38 10.81 3.95 9.35 3 2 7 30 
* Correspond to Pt Nos. in chapter 3 and 4. 
Tumour – indicates malignant cores from prostate biopsy 
Node – indicates metastatic pelvic nodes from eLPL 
 
 
 
 147 
 
Table 13: Correlation of [11C]choline PET/CT SUVs with IHC and biomarkers in prostate 
tumours.  
 SUV15,ave SUV15,max SUV60,ave SUV60,max 
 r p r p r p r p 
CHKα score 0.5 0.0009 0.5 0.003 0.7 <0.0001 0.6 0.0001 
Ki 67 score -0.1 0.42 -0.2 0.27 -0.03 0.86 -0.03 0.98 
GS 0.2 0.41 0.04 0.82 0.13 0.5 0.3 0.18 
PSA levels 0.3 0.07 0.5 0.01 0.3 0.07 0.6 0.0003 
GS= Gleason score, r= Spearman’s correlation coefficient, p= significance value. 
 
3.1.4: Discussion 
 
 This study supports the feasibility of using [11C]choline PET/CT in determining 
pelvic LN status in patients with high-risk prostate cancer. It is specific and shows early 
promise in yielding a greater diagnostic accuracy than either MRI or PET only 
scanning. This is especially evident in detecting sub-centimetre disease, although the 
sensitivity is not sufficient to exclude lymphadenectomy, as metastases <6 mm in 
particular may be missed. However, it has the potential to highlight nodal uptake 
outside the surgical template for LN dissection, especially in the CI and para-aortic area 
as demonstrated in this study, which can have significant consequences in terms of 
patient management. 
 The somewhat disappointing performance of [18F]FDG PET in the setting of 
prostate cancer has prompted interest in newer PET tracers such as [18F] and 
[11C]choline for the detection of primary tumour within the prostate and the staging of 
pelvic nodal disease. For the detection of the primary tumour, some authors have 
reported 100% sensitivity (Kwee, Coel et al. 2005; Yamaguchi, Lee et al. 2005; Reske, 
Blumstein et al. 2006) while others report lower detection rates ranging from 19 – 58% 
depending on whether results were reported on a per patient or per lesion basis 
(Farsad, Schiavina et al. 2005; Martorana, Schiavina et al. 2006; Scher, Seitz et al. 
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2007; Giovacchini, Picchio et al. 2008). For staging of pelvic nodal disease, the 
reported sensitivity and specificity ranged from 50 – 80% and 90 to 96%, respectively in  
the two studies that employed PET alone, based on a per patient analysis (Kotzerke, 
Prang et al. 2000; de Jong, Pruim et al. 2003). The published studies assessing LN 
stage using PET/CT showed varied and conflicting results with the sensitivity and 
specificity ranging from 10-100% and 82-100% (Hacker, Jeschke et al. 2006; Husarik, 
Miralbell et al. 2008; Schiavina, Scattoni et al. 2008; Beheshti, Imamovic et al. 2010; 
Poulsen, Bouchelouche et al. 2010; Budiharto, Joniau et al. 2011; Poulsen, 
Bouchelouche et al. 2012). The variation in sensitivity may be in part due to patient 
selection. Table 14 summarises the published studies. 
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Table 14: Review of literature for nodal staging 
Author 
Tracer 
(Administered Activity MBq) 
No. of patients 
Prevalence 
of LN metastases 
Sn 
(%) 
Sp 
(%) 
Sensitivity & Specificity – Per-patient analysis 
De Jong et al 
(de Jong, Pruim et al. 2003) 
[
11
C]choline PET (400) 67 22.4% (15/67) 80 96 
Kotzerke et al 
(Kotzerke, Prang et al. 2000) 
[
11
C]choline PET 
(mean 1000: range of 370-1250) 
12 16.6% (2/12) 50 90 
Schiavina et al 
(Schiavina, Scattoni et al. 2008) 
[
11
C]choline PET/CT (370) 57 26% (15/57) 60 98 
Husarik et al 
(Husarik, Miralbell et al. 2008) 
[
18
F]choline PET/CT (200) 25 12% (3/25) 33 100 
Hacker et al 
(Hacker, Jeschke et al. 2006) 
[
18
F]FCH PET/CT (4.07 MBq/ kg)* 20 50% (10/20) 10 80 
Behesti et al 
(Beheshti, Imamovic et al. 2010) 
[
18
F]FCH PET/CT (4.07 MBq/ kg)* 
130 
(111 LND) 
31% (40/130) 45 96 
Budiharto et al  
(Budiharto, Joniau et al. 2011) 
[
11
C]choline PET/CT (700-1000) 36 47% (17/36) 18 95 
Poulsen et al  
(Poulsen, Bouchelouche et al. 2010) 
[
18
F]FCH PET/CT 25 12% (3/25) 100 95 
Poulsen et al  
(Poulsen, Bouchelouche et al. 2012) 
[
18
F]FCH PET/CT 210 20% (41/210) 73 88 
This study [
11
C]choline PET/CT (700) 26 34.6% (9/26) 77.7 82.4 
Sensitivity & Specificity – Per-nodal analysis 
Author Tracer (Administered Activity MBq) No. of nodes 
Prevalence 
of LN metastases 
Sn 
(%) 
Sp 
(%) 
Schiavina et al  
(Schiavina, Scattoni et al. 2008) 
[
11
C]choline PET/CT (370) 892 4.6% (41/892) 41.4 99.8 
Husarik et al  
(Husarik, Miralbell et al. 2008) 
[
18
F]choline PET/CT (200) 115 4.3% (5/115) 20 100 
Budiharto et al  
(Budiharto, Joniau et al. 2011) 
[
11
C]choline PET/CT (700-1000) 733 5.2% (38/733) 9.4 99.7 
Poulsen et al  [
18
F]FCH PET/CT 1093 7% (73/1093) 56 94 
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(Poulsen, Bouchelouche et al. 2012) 
This study [
11
C]choline PET/CT (700) 406 6.7% (27/406) 52 98.4 
* Average weight of individual-70 kg - Administered activity of 285 MBq, Sn-sensitivity, Sp-specificity 
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In this study the value of MRI, [11C]choline PET and [11C]choline PET/CT 
imaging in the preoperative staging of high-risk prostate cancer patients has been 
assessed. An overall sensitivity and specificity of [11C]choline PET/CT on a per 
patient basis, of 77.7% and 82.4% respectively in the detection of nodal metastases 
was seen. These results were superior to both MRI (50% and 72.2%), and 
[11C]choline PET (66.6% and 76.4%), though were not significantly different 
probably due to relatively low patient numbers. For MRI, the sensitivity & specificity 
achieved in our study are in keeping with previously reported data (Hricak, Dooms 
et al. 1987; Harisinghani, Barentsz et al. 2003). Dynamic contrast MRI may help 
with tumour localisation within the prostate but there are no specific reports on the 
additional benefit in nodal staging. More importantly on a per nodal basis (27/406), 
the sensitivity was significantly higher for [11C]choline PET/CT (51.9%) compared 
with MRI (18.5%) (p=0.007) with a greater confidence for identifying sub-centimetre 
involved LNs, which occurred in 30% of the cases. However, in this study apart from 
one 4mm node, no other low volume metastases of less than 5mm in diameter were 
detectable, probably reflecting the limited spatial resolution of the current generation 
of scanners.  
 In one of the first published series, De Jong et al, obtained promising results 
with [11C]choline PET in the preoperative nodal staging of 67 patients, with a 
sensitivity of 80% in a per patient-based analysis. Metastatic LNs ranging from 0.5 – 
3 cm in size with a mean SUV of 4.7 (2.9 – 9.1) were demonstrated. FP activity in 2 
patients was attributed to inflammatory change and focal bowel activity. However, in 
their study, about 50% of the node positive patients had a PSA of >50ng/mL (range: 
3-500), compared to our mean PSA value of 44.25 ng/mL (range: 8.1-209), which 
may have contributed to a selection bias and may under-represent the cohort of 
high risk  localised prostate cancer patients  for which radiotherapy to the pelvis 
would be indicated (de Jong, Pruim et al. 2003). Conversely Hacker et al (Hacker, 
 152 
 
Jeschke et al. 2006) reported a very low sensitivity of 10% in a study of 20 patients 
assessed with F-18 fluorocholine. The mean diameter of metastatic lymph nodes in 
their study was 3.8mm which is well below the resolution of PET.  
 In studies utilising [11C]choline PET/CT, Schiavina et al, (Schiavina, Scattoni 
et al. 2008) evaluated 57 intermediate or high-risk prostate cancer patients prior to 
surgical treatment. They reported a sensitivity of 60% and a specificity of 98% for 
the detection of nodal metastases. Husarik et al, (Husarik, Miralbell et al. 2008) 
evaluated 111 patients with prostate cancer in a [18F]choline PET/CT study, 43 of 
whom had staging for assessment of primary disease. The PET/CT findings were 
correlated to the histopathological findings of 115 sampled LNs in 25 patients, with 
sensitivity & specificity on a per patient basis of 33% and 100% respectively.  
 Beheshti et al (Beheshti, Imamovic et al. 2010) evaluated 130 patients with 
intermediate or high-risk prostate cancer with [18F]fluorocholine (FCH) PET/CT prior 
to extended pelvic node dissection with sensitivity and specificity in the detection of 
malignant nodes of 45% and 96%, respectively. Furthermore they reported a 
change in management in 15% of cases. The authors also noted discrete FCH 
uptake in inguinal lymph nodes which was interpreted as probable reactive uptake 
and therefore excluded from data analysis. This was similarly observed in our study 
cohort (8 out of 26 patients), although the visible inguinal nodes had significantly 
lower SUVs than both the metastatic LNs and the malignant prostate. As nodal 
dissection does not routinely remove inguinal nodes as part of standard practice, it 
may be difficult to ascertain if these were involved. The underlying assumption is 
that inguinal nodes were all within physiological limits of <10 mm in dimension 
based on the fact that prostate tumours normally do not spread to inguinal nodes 
(Clements 2010). 
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 Budiharto et al. assessed 36 patients with [11C]choline PET/CT and diffusion 
weighted MRI (DW-MRI) prior to radical prostatectomy (RP) and pelvic 
lymphadenectomy (LND). Seventeen patients (47%) were pathologically node 
positive, with a total of 38 metastatic nodes identified. On a patient-based analysis, 
the sensitivity and specificity were 18.8% and 95% for PET/CT and 42.9% and 
81.8% for MRI, respectively. The poor performance of the [11C]choline PET/CT was 
attributed to the majority of the positive nodes (53.1%) containing micro metastases 
(Budiharto, Joniau et al. 2011). Poulsen et al. prospectively evaluated, 25 newly 
diagnosed high-risk PCa patients undergoing RP and LND with [18F]FCH PET/CT. 
Of these 25 patients, three patients had LN metastases on histology and four 
patients had PET positive nodes. On a patient basis, the sensitivity and specificity of 
[18F]FCH PET/CT were 100% and 95%, respectively (Poulsen, Bouchelouche et al. 
2010). In a more recent study, Poulsen et al. evaluated, 210 newly diagnosed 
intermediate and high-risk PCa patients undergoing LND with [18F]FCH PET/CT. 
Forty-one patients (20%) were pathologically node positive, with a total of 73 
metastatic nodes identified. On a patient-based analysis, the sensitivity and 
specificity were 73% and 88%, while on a nodal analysis they were 56% and 94%. 
In addition the PET detected bone metastases in 18 patients. They concluded that 
[18F]FCH PET/CT is not ideal for primary LN staging in patients with prostate cancer 
due to low sensitivity (Poulsen, Bouchelouche et al. 2012). However, the main 
limitation of this study was the lack of extended lymphadenectomy. More recently, in 
a meta-analysis of 10 selected studies, with 441 patients in total, the pooled 
sensitivity and specificity reported were 49.2% and 95% respectively. The authors 
concluded that the low sensitivity was due to limited patient numbers and 
inhomogeneous group of patients, and further studies in larger homogeneous 
patient population are warranted (Evangelista, Guttilla et al. 2013).  
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 Four other studies have reported on a per nodal analysis (Table 14). Husarik 
et al in their study including 25 patients staged with [18F]fluorocholine reported a low 
sensitivity of 20% (1out of 5 involved nodes) and a specificity of 100%. All the FN 
nodes had tumour foci of < 5 mm. The mean SUVmax of the detected LNs was 5.04 
(range 4.9–5.2). Notably only obturator nodes were removed rather than a more 
extensive lymphadenectomy and the authors did not comment on FCH positive 
nodes outside the obturator region. Similarly, Budiharto et al reported a sensitivity 
and specificity to be 9.4% and 99.7% (Budiharto, Joniau et al. 2011). Schiavina et 
al, in the study mentioned earlier, reported a sensitivity of 41.4% and a specificity of 
99.8% on a per-nodal analysis. The mean diameter (in mm) of the metastatic 
deposit of true positive nodes was significantly higher than that of false negative 
nodes (9.2 vs. 4.2; p = 0.001).  
The per nodal results of sensitivity & specificity with [11C]choline in this study 
were similar at 51.9% & 98.4%. A limitation of this study was the technical 
difficulties encountered with the interpretation of findings on the PET scans in the 
region of the saturation band (where there was an overlap when the 2 bed positions 
were fused) which accounted for some of the FP results on the PET alone. In the 
two patients in whom MRI and PET/CT were FP for a 26mm and 10mm node, there 
is the potential, despite careful use of surgical templates, that these nodes were not 
sampled. The median SUV60, max of FP LNs was 6.51, compared to 7.77 for the TP 
nodes.  
 This study is one of the first to evaluate the time dependent uptake of 
[11C]choline in prostate tumours up to 60 minutes. Dynamic TACs for [11C]choline in 
primary prostate tumours and the nodal metastases demonstrated a good sustained 
retention of activity after plateauing at ~15 min until 60 min with SUVave. However, 
with SUV max, there is a hint of increasing activity at 60 min which may be due to the 
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contribution of [11C]betaine. The results from the modelling of the [11C]choline breast 
data using arterial IF suggest that irreversible kinetics account for [11C]choline 
uptake in breast tumours. A discernable linear phase up to 60 minutes was seen in 
the modified Patlak model fits in most tumours signifying an irreversible net uptake 
component. Spectral analysis of tumour data was also suggestive of irreversible 
uptake both from the IRF and the presence of kinetic components at log10β 
approximating λ. The use of a validated population-based total plasma IF from the 
breast data, predicted that irreversible kinetics also account for [11C]choline uptake 
in prostate cancer, thus further validating the limited venous sampling approach 
(Contractor, Kenny et al. 2012). 
 It was shown for the first time in prostate tumour samples that tumour 
radiolabelled choline uptake (SUV60,ave, SUV60,max, and Kimod-pat) is closely related to 
CHKα expression in prostate cancer. Both semi-quantitative parameters of choline 
uptake in tumours correlated well with CHKα scores (best with SUV60,ave r=0.7, 
p<0.0001, Spearman’s test). It was observed that areas of PIN in the malignant 
cores also showed staining which may represent the range of CHKα expression in 
pre-malignant and malignant tissues. In certain tissue sections, nuclear staining was 
observed, particularly in areas of PIN and in certain high Gleason grade tumours 
and although this phenomenon is not fully understood, a possible reason is that, 
phosphorylated CHKα may translocate to the nucleus. This hypothesis needs 
further evaluation. 
 This study also showed that proliferation in prostate tumours was low, as 
reflected by the low Ki67 index in most tumours (median 3%; range: 1-17%), 
contrary to the high CHKα expression. This may account for the lack of correlation 
between [11C]choline SUV and Ki67 scores in tumours.  A possible explanation for 
this is that CHKα expression is not directly linked to proliferation and may be an 
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independent marker of the prostate tumour phenotype. This is contrary to the 
evidence in other cell/ tumour types linking CHKα or choline metabolites and 
proliferation (Katz-Brull, Seger et al. 2002; Ramirez de Molina, Banez-Coronel et al. 
2004; Al-Saeedi, Welch et al. 2005). The lack of correlation between [11C]choline 
uptake and proliferation marker has been previously demonstrated (Sutinen, Nurmi 
et al. 2004; Breeuwsma, Pruim et al. 2005; Reske, Blumstein et al. 2006). Of note, 
one study using mean tumour to benign prostate background ratio has reported an 
association between choline uptake and Ki67 scores in prostate tumours (Piert, 
Park et al. 2009). Piert et al showed that tumour to benign prostate background ratio 
was significantly high in tumours with a Ki67 score of > 5% (p<0.01). They also 
reported a good correlation between Ki67 score and Gleason score, similar to that 
seen in this cohort of patients (r=0.5, p=0.004). 
 The main drawback to [11C]choline is the relatively short half life (20.9 
minutes) and thus the compound needs to be used close to where it is 
manufactured. Newer more stable and specific choline compounds are in 
development ((Leyton, Smith et al. 2009): Chapter 5). 
 In summary, this detailed study establishes the feasibility of [11C]choline 
PET/CT as a noninvasive means of staging pelvic LNs in prostate cancer, being 
highly specific (98.4%) and more sensitive than PET alone or MRI. The high 
specificity is potentially helpful clinically in terms of selecting out those patients with 
high risk prostate cancer who may not need pelvic radiotherapy. Although it cannot 
currently replace MRI as a staging tool, its ability to detect sub-centimetre nodes 
and a differential SUV value between involved and physiological LNs, allows for a 
functional imaging methodology for assessing the radiation response to involved 
nodes. The relationship between CHKα expression and [11C]choline uptake, 
together with the avid intra-tumoural uptake of choline demonstrated in this study, 
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suggests that [11C]choline PET/CT could potentially be used as a noninvasive 
surrogate for CHK expression. 
 
3.2: Patterns of CHKα and Ki67 expression in 
additional prostate tissues.  
 
3.2.1: Rationale 
 
Based on the interesting observations seen in the cores of prostate tissue 
stained in the previous section, further cores of prostate tissue from 75 patients 
diagnosed with prostate cancer (malignant) and 25 patients with no prostate cancer 
(normal) were subsequently analysed. The aim was to reproduce and validate the 
patterns of CHKα expression seen in the patient cohorts discussed in the previous 
section, in a larger number of normal and malignant prostate cores. Ethical approval 
was obtained from the hospital tissue bank.  
3.2.2: Materials and Methods   
 
 The CHKα, Ki67 IHC and H&E staining to check primary antibody specificity 
were performed as discussed in the previous section. Paraffin embedded 
prostatectomy specimen blocks of 5 patients were also analysed for CHKα protein 
and gene expression in normal and malignant prostate tissue using western blotting 
and polymerase chain reaction (PCR), respectively.  
3.2.2.1: Western Blot analysis of CHKα protein 
 
 Protein and mRNA of formalin fixed paraffin embedded (FFPE) prostate 
tissues were extracted using Qproteome FFPE Tissue Kit (Qiagen, Cat. Nr: 37623) 
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and RNeasy FFPE Kit (Cat. Nr: 73504). After protein extraction the tissue lysates 
were analysed using Western Blot analysis. Twenty to thirty micrograms of tissue 
lysates were heated to 70°C for 10 minutes with LDS sample buffer and reducing 
agent (Invitrogen). Proteins were separated on Biorad 4-15% Mini-Protean TX-gels 
at 200V for 15 minutes. Following electrophoresis, proteins were transferred to a 
PVDF membrane using a semi-dry transfer system, Transblot Turbo Transfer 
system (Biorad) and then blocked with blocking buffer (1% milk in Tris-Buffered 
Saline and Tween 20 TBST) for 1h. The membranes were then probed with the 
CHKα primary antibody (Sigma-Aldrich, Cat. Nr: HPA024153) and β-actin loading 
control (Abcam, Cat. Nr: ab6276). Overnight antibody incubation in blocking buffer, 
was followed by 3x 10 min washes in fresh blocking buffer. The PVDF membrane 
was then incubated with peroxidase labelled relevant secondary antibodies (mouse 
and rabbit antibodies; Santa Cruz, Cat. Nr: sc-2004 and sc-2005). The Western blot 
reactions were detected by chemiluminescence-based photoblot system (ECL –. 
GE Healthcare, Chalfont St Giles, Bucks, UK). 
3.2.2.1: Quantitative Reverse transcriptase polymerase chain 
reaction (qRT-PCR)  
 
 The extracted RNA was reverse transcribed to cDNA using QuantiTect 
reverse transcription kit (Qiagen, Cat. Nr: 205311). Gene expression was quantified 
on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using TaqMan® 
Fast Advanced Master Mix (Applied Biosystems, Cat. Nr: 4444963) and TaqMan® 
gene expression assays (Applied Biosystems) detecting CHKα (Assay ID: 
Hs00957875_m1), CHKβ (Assay ID: Hs01925200_s1) and GAPDH (Assay ID: 
Hs02758991_g1). Relative expression was calculated by comparative (CT) method 
(Schmittgen and Livak 2008).  
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3.2.3: Results 
 
3.2.3.1: CHKα expression in normal prostate gland 
 
There was no CHKα expression demonstrable in a majority of the normal 
prostate cores (Figure 38). However, there was mild CHKα expression in 28% 
(7/25) of the normal prostate cores. This suggests that increased CHKα expression 
may not be specific to malignant prostate tissue.  
 
Figure 37: CHKα and Ki67 IHC on cores from a normal prostate gland and 
corresponding H&E stained sections.  
The sections show lack of CHKα and Ki67 expression in a majority of the cores (a) and mild 
CHKα expression (28% of the cores) but no Ki67 expression in any of the cores (b). 
 
3.2.3.2: CHKα and Ki67 IHC in malignant prostate cores 
 
 There was CHKα expression in all the malignant prostate cores (n=75) that 
varied in intensity from 1-3 (predominantly cytoplasmic and some nuclear staining) 
similar to that seen in the cores from patients discussed in the previous section. 
Areas of PIN consistently showed nuclear staining. However, visually there 
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appeared to be no increased CHKα expression with increasing Gleason scores. As 
seen before Ki67 staining revealed that most of the primary prostate tumours had a 
low proliferation index (median 2%, range 1 to 7%). In 28 patients the cores from 
one of the lobes of the prostate gland were benign and the cores from the other lobe 
were malignant. The benign cores in 7 of these patients showed that there was 
increased CHKα expression as seen before, which is similar to the pattern seen in 
the cores from the normal prostate gland. 
 There was a good correlation between the intensity of the CHKα staining 
and PSA but not with the degree of differentiation (Gleason score) in the malignant 
cores (Table 15). There was no association between Ki67 labelling index and 
Gleason scores or PSA. 
Table 15: Correlation of CHK and Ki67 scores with PSA and Gleason score in 
malignant prostate cores.  
 
 PSA GS 
 r p r p 
CHKα score 0.3 0.04 0.3 0.05 
Ki 67 score -0.1 0.52 -0.1 0.70 
GS= Gleason score, r= Spearman’s correlation coefficient, p= significance value. 
 
3.2.3.3: CHKα protein and gene expression in normal and 
malignant prostate tissue 
 
 Immunoblotting of the tissues from 2 patients showed good resolution of the 
CHKα protein in the malignant prostate. Amplification of CHKα mRNA by 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) showed 
CHKα gene expression in both normal and malignant prostate tissues (Figure 38).    
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Figure 38: Expression of CHKα protein and genes in the normal (N) and malignant (M) 
prostate tissue.  
(a) Western blot analysis of CHKα protein showed good resolution of bands in the malignant 
prostate tissue. β-actin was probed as protein loading control. (b) Quantitative expression of 
CHKα genes (mRNA) showed no significant differential expression in the normal and 
malignant prostate tissues.  qRT-PCR - Quantitative reverse transcriptase polymerase chain 
reaction.    
 
3.2.4: Discussion 
 
 The results obtained with the CHKα IHC are very interesting. There was 
increased expression of CHK (mild staining intensity) in up to 28% of the normal 
prostate cores and the benign cores in a malignant prostate. CHKα staining in areas 
of PIN, different intensities of positive staining and the low Ki67 labelling index in the 
malignant prostate cores were consistently seen. The CHKα primary antibody used 
in this study was able to identify cytoplasmic and nuclear CHK expression. The 
minor degree of CHKα expression (28%) in the normal prostate cores is supported 
by the CHKα gene expression in the normal prostate tissue seen on qRT-PCR. This 
could form the basis for the differential [11C]choline uptake seen in the normal and 
tumour prostate (as shown in chapter 4). The predominant nuclear staining seen in 
areas of PIN, could be due to the morphological and cytological features of PIN 
such as nuclear enlargement, prominent nucleoli and hyperchromasia (Merrimen, 
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Evans et al. 2013). Furthermore, the localisation of choline in areas of PIN has also 
been shown with MRS and dynamic contrast-MRI (Sciarra, Panebianco et al. 2010). 
The two isoforms of CHK: CHKα and CHKβ are significantly different in their 
role in tumourigenesis (Gallego-Ortega, Ramirez de Molina et al. 2009). Therefore, 
in order to confirm the specificity of the polyclonal antibody against CHKα used in 
this study, in vitro studies in cell lines (including siRNA knockdown and western 
blotting with both CHKα and CHKβ antibodies separately) were performed by 
another member of the Aboagye group. CHKα and CHKβ proteins have very 
different molecular weights and therefore were well resolved by western blot. 
As seen earlier, the prostate cores had low proliferation indices (median 
Ki67 of 2%; range: 1-7%). However, the Ki67 indices did not correlate with the 
Gleason score (r=-0.1, p=0.70, Spearman’s test). This lack of correlation could be 
due to the inhomogeneous group of patients selected randomly. 
In summary, a spectrum of cytoplasmic CHK expression was seen in the 
pre-malignant and malignant lesions. This could be exploited to develop new drug 
targets.  
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CHAPTER 4: Exploring the potential of [
11
C]choline 
PET/CT as a novel imaging biomarker for predicting 
early treatment response in prostate cancer. 
 
Rationale 
 
 [11C]Choline PET/CT has been shown to be an effective noninvasive method 
for detecting nodal disease (Contractor, Challapalli et al. 2011), metastatic disease 
(Krause, Souvatzoglou et al. 2011), and relapsed disease (Picchio and Castellucci 
2012) in prostate cancer (PCa). However, there is limited data on [11C]choline 
PET/CT in assessing response to a combination of androgen-deprivation and 
radiotherapy. 
 Radiotherapy (RT), along with androgen deprivation is a curative option for 
patients with localised or locally-advanced PCa (Peeters, Heemsbergen et al. 2006; 
Heidenreich, Bellmunt et al. 2011). Response to treatment is routinely assessed by 
prostate-specific antigen (PSA) levels. Standard magnetic resonance imaging (MRI) 
has limited value in assessing residual viable disease post-radiotherapy due to loss 
of zonal anatomy and diffuse low signal (Westphalen, McKenna et al. 2008). This 
limitation could potentially be overcome with dynamic contrast enhancement (DCE-
MRI), diffusion weighted imaging (DWI-MRI), magnetic resonance spectroscopy 
(MRS) and PET, which can provide biological information about tissue perfusion, 
cellularity and metabolism.  
 Functional MRI techniques using DWI and choline metabolism have been 
evaluated for monitoring therapy response with varying results (Barrett, Gill et al. 
2012; Valentini, Gui et al. 2012). The variable sensitivity of [11C]choline PET/CT in 
identifying intra-prostatic lesions (Souvatzoglou, Weirich et al. 2011; Van den Bergh, 
Koole et al. 2012) and its high cost mandates a prospective feasibility study.  
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Therefore, this study was designed with the aim  
 To evaluate the potential of [11C]choline PET/CT as an early response 
biomarker to neo-adjuvant androgen-deprivation (NAD) and radical 
radiotherapy combined with concurrent androgen-deprivation (RT-CAD).  
This study was used to test the hypothesis that use of functional imaging with PET 
would predict early response to treatment and the potential for alternative 
management strategies. 
Materials and Methods 
Patients 
 
 Consecutive patients with newly diagnosed, histologically confirmed 
localised (node-negative based on MRI size criteria) PCa fit for radical radiotherapy 
were enrolled. Thus the main inclusion and exclusion criteria for this study were: 
Inclusion Criteria: 
1) Histologically confirmed adenocarcinoma of the prostate.  
2) Patients with localised prostate cancer with disease visible on the staging 
MRI scan. 
3) Patients suitable for radical radiotherapy (conformally planned and treated 
with a dose of 74Gy/37fractions/7.5 weeks). 
4) WHO performance status ≤ 2  
5) Age 18 years and above. 
6) Written informed consent. 
Exclusion Criteria: 
1) Node positive patients on staging investigations. 
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2) Any serious co-existing medical illness which will contradict radical 
radiotherapy. 
3) Patients on any concurrent investigational agent.  
4) Life expectancy <5 years.  
5) Psychological, familial, sociological or geographical condition potentially 
hampering compliance with the study protocol and follow-up schedule. 
6) Previous androgen deprivation. 
7) Gold seed fiducial markers within the prostate. 
Each patient underwent sequential [11C]choline PET/CT scans at the 
following time points: prior to initiation of therapy (baseline), after at least 6-8 weeks 
of NAD (post-NAD) and finally at 4 months post radical RT-CAD (post-RT-CAD 
scan). Ethical approval for the study was granted by the North-London Ethics 
Committee. All patients gave written informed consent to participate in the study, 
according to the Declaration of Helsinki guidelines. The administration of 
radioactivity for the PET scans was approved by the Administration of Radioactive 
Substances Advisory Committee, United Kingdom.  
Treatment: NAD and RT-CAD  
 
 In all patients, androgen deprivation was achieved using depot injections of 
luteinizing-hormone releasing hormone (LHRH) agonists in conjunction with initial 
anti-androgens. Patients received NAD for at least 6-8 weeks prior to the post-NAD 
scan and concurrently (CAD) with radical radiotherapy. Radiotherapy was planned 
and delivered as per standard departmental protocol. The aim was to deliver a 
minimum dose of 74 Gy to the prostate prescribed according to the International 
Commission on Radiation Units guidelines, respecting rectal dose constraints. 
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Imaging protocol 
 
[11C]choline was synthesised according to the method  described by Pascali 
et al (Claudio Pascali 2000). Subjects fasted for 6 hours prior to procedure. All 
patients were scanned initially on a GE-Discovery-RX® PET/CT scanner. Due to unit 
closure, two patients could not have their post-NAD scans. The post RT-CAD scans 
in all ten patients were performed on a GE-Discovery-VCT PET/CT scanner. The 
images for both scanners were calibrated in Bq/mL which is the important 
parameter in calculating SUV. Phantom studies were performed to ensure protocol 
reproducibility on each machine, using near identical reconstruction parameters 
(Table 16). The patients were positioned such that the field of view (FOV) included 
the prostate with the lower border at the bottom of the ischial tuberosities. This was 
followed by a diagnostic quality CT scan (settings: 300 mA, 120kVp, 0.8 
sec/rotation, 40mm beam collimation (total beam width), pitch 1.375 and slice 
thickness 3.75mm) which was used for attenuation correction and co-registration 
with the PET images. [11C]choline was administered through a bolus intravenous 
injection over 10-30 seconds. The median (range) radioactivity administered per 
scan was 691 (479-745) MBq (specific activity of 5.7 GBq/µmol: radiochemical 
purity >97%). Dynamic PET scanning (3-dimensional acquisition) was commenced 
over a single bed position, covering the pelvis (axial FOV 15.7 cm; transaxial, 70 
cm), for 65 minutes. Raw PET data were corrected for scatter and attenuation and 
reconstructed using iterative ordered subset expectation maximisation (OSEM) 
algorithm (Table 16).  
All patients, except one in whom MRI was contraindicated, underwent 
standard MRI of the pelvis with phase array pelvic coil, from aortic bifurcation to 
pubic symphysis consisting of T1-weighted axial images; axial, sagittal and coronal 
T2 weighted sequences and small field of view (FOV) axial T2 weighted sequences 
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through the prostate. Diffusion weighted imaging was also available in 7 patients. 
The imaging was performed on a 1.5 Tesla scanner (Philips) in 2 patients and a 1.5 
Tesla scanner (Siemens: Magnetom) in 7 patients. 
Table 16: Reconstruction parameters used in the 2 scanners involved in this study. 
 
Reconstruction 
Parameters 
GE Discovery  RX PET/CT 
scanner 
GE Discovery  VCT PET/CT 
scanner 
Image reconstruction OSEM, 8 iterations 21 
subsets* 
OSEM, 8 iterations 20 
subsets* 
Reconstruction zoom 
diameter 
33.5 cm 33.5 cm 
Reconstructed voxel size 2.6 mm, 2.6 mm and 3.3 mm 
in X, Y and Z co-ordinates, 
respectively 
2.6 mm, 2.6 mm and 3.3 mm 
in X, Y and Z co-ordinates, 
respectively 
Scanner Resolution 
(distance from FOV centre) 
FWHM (mm) FWHM (mm) 
Axial (1cm) 5.3 5.8 
Axial (10cm) 6.0 6.3 
Transaxial (1cm) 4.8 4.9 
Transaxial (10cm) 5.6 5.6 
OSEM-Ordered subsets expectation maximisation, FOV-field of view, FWHM-Full width half 
maximum 
* Data were binned into time frames as follows: 1 * 30 (background), 6* 10, 4* 20, 4* 30, 5* 
120, 4* 180 and 4* 600 seconds. 
Even though the two scanners do not have identical sensitivity, noise-equivalent counting 
(NEC) characteristics and spatial resolution, due to the similarity of the detectors, these 
differences would be relatively small and would not have a significant impact on SUV 
calculation. 
 
Image analysis 
  
The [11C]choline PET/CT summed data (10–65 minutes) were reviewed 
slice-by-slice alongside the staging MRI studies by two experienced observers (AC, 
TB) in consensus, to manually outline the volumes of interest (VOIs; ROIs over 
several slices) for quantitative analysis. In addition the T2 weighted axial MRI was 
fused to the PET using MRI PET fusion software (Figure 39) to assist with ROI 
positioning, particularly for ‘normal’ prostate (Hermes diagnostics, Sweden). The 
following were outlined: most active tumour focus, normal (non-cancerous) prostate 
gland, obturator internus muscle (in high dose region of radiotherapy field), gluteus 
 168 
 
maximus muscle (in low dose region of radiotherapy field), bone marrow 
(acetabulum; in radiotherapy field) and visible pelvic nodes (with uptake above 
background). The prostate volume in cm3 was determined using a planimetric 
approach on the CT component of the PET/CT images. Data analysed with the 
whole prostate outlined and the results are given in Appendix 3. 
 
Figure 39: Axial [
11
C]choline PET (Baseline) fused with T2 weighted axial MRI.  
(a) Fused image at level of prostate showing active tumour focus (white arrow) in the right 
peripheral zone (PZ) and normal prostate (white dotted arrow) in the left PZ. (b) Fused 
image at level of seminal vesicles. The images correspond to patient no.1 as listed in Table 
17. 
 
The criteria for outlining the VOIs in each patient were as follows: The region 
with the most intense choline uptake corresponding to an area of disease on MRI 
(low T2 signal intensity with associated restricted diffusion) was outlined as tumour 
(Yamaguchi, Lee et al. 2005). The criteria for outlining ‘normal’ prostate was a 
region in the peripheral zone with no focal choline activity, absence of MRI criteria 
for disease and sextant free of disease on TRUS biopsy. In the one patient in whom 
MRI was contraindicated, tumour was outlined based on focal choline uptake in a 
sextant positive for disease on TRUS and normal prostate was not outlined (bilateral 
cores were positive on TRUS). 
For the follow up measurements, the VOIs for tumour and normal prostate 
were positioned in the same sextant of the prostate for each patient by visually 
 169 
 
referring to the baseline PET/ CT and MRI images, according to the distance from 
the level of the femoral head and pubic symphysis on the MR and CT images 
(Yamaguchi, Lee et al. 2005). All diameters of the manual ROIs were greater than 3 
times the full-width-half-maximum (FWHM) of the camera (Boellaard 2009). 
Analyses of the dynamic PET data were performed using Analyze® software 
(Analyze Version 7; Biomedical Imaging Resource, Rochester, USA). The  
[11C]choline radioactivity concentration within the VOIs was determined and 
normalised to injected radioactivity and body weight to obtain the average and 
maximum SUV at 60 minutes (SUV60,ave and SUV60,max). In order to account for 
inflammation post-radiotherapy, TMR60,max (ratio of tumour to gluteus maximus 
muscle SUV60,max) was also estimated. SUVmax of tumour was also estimated at 15 
and 30 min (SUV15,max and SUV30,max). Baseline parameters were estimated in all ten 
patients. The percentage change in [11C]choline uptake variables with treatment 
was calculated in eight patients who completed all scans as follows: changes with 
NAD as ((SUVbaseline – SUVpost-NAD)/ SUVbaseline)*100 and changes with combined 
NAD and RT-CAD as ((SUVbaseline – SUVpost-RT-CAD)/ SUVbaseline)*100. 
Modelling of PET data 
 
The venous blood proportions of [11C]choline and its metabolite, [11C]betaine 
were determined as previously described (Contractor, Kenny et al. 2009). A 
validated population-based total plasma input-function approach (Contractor, Kenny 
et al. 2012), and the modified-Patlak plot (Mankoff, Shields et al. 1996), were used 
(as described in detail in Chapter 3) to derive Ki (Kimod-pat) -  a measure of net 
irreversible retention at steady-state within a VOI. The method implicitly assumes 
that the majority of labelled betaine in tumours is derived from systemic circulation 
(Roivainen, Forsback et al. 2000; Witney, Alam et al. 2012). 
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Statistical considerations 
 
Preliminary studies have shown that patients with changes in [11C]choline 
uptake >40% in individual patients can be classified as radiotracer responsive; i.e., 
statistically greater than noise (Kenny, Contractor et al. 2010). Variability in the 
measured change in choline within individuals has been estimated at ~0.15.  
Expected response to therapy is 60% of patients receiving radiotherapy. Power 
calculation (paired t-test) suggests that a number, n=7, of patients will give to the 
design a minimum power of .90 to detect a group difference in choline at a .05 error 
rate.  The addition of n=2 patients to compensate for dropout and 2-3 patients to 
compensate for technical problems with imaging brings the total number of patients 
to n=12. 
 The median (range) was used as the primary descriptive statistics measure. 
Repeated-measures Analysis of Variance (ANOVA) and Tukey’s multiple 
comparisons test was used to assess the significance of the change in [11C]choline 
uptake between treatments (for the eight patients who completed all three scans). 
The association between baseline SUV60,ave or SUV60,max and initial PSA (n=10 
patients), as well as similar associations between changes in uptake variables and 
changes in PSA levels, were assessed by Pearson’s correlation test. The 
significance of differential uptake in tumour and the normal prostate was assessed 
by unpaired t test. A p value of ≤ 0.05 was considered significant. Statistical 
analyses were performed using Graph-Pad™ Prism software (version 4.0, San 
Diego California USA). 
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Results 
 
Patient Characteristics 
 
In total, 10 patients were recruited for the study, all of whom had [11C]choline 
scans at baseline, post-NAD, and post-RT-CAD, except two patients who could not 
complete their post-NAD scans. Patients were scanned (post-NAD) after a median 
NAD duration of 77 days (range: 46 – 107 days). Post-RT-CAD scans were 
performed after a median of 113 days (range: 99 – 128 days) following completion 
of RT-CAD. The patient characteristics are shown in Table 17. 
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Table 17: Patient characteristics  
 
Pt 
No 
Stage 
(MRI) 
Tumour 
on TRUS 
Biopsy 
GS (positive 
cores/total 
cores)  
R, L 
Overall 
GS 
iPSA 
(ng/mL) 
RT dose 
(Gy/#) 
WPRT 
Pelvic 
nodes
* 
Inguinal 
nodes
* 
Nadir 
PSA 
(ng/mL) 
Recent 
PSA 
(ng/mL)
 § 
1 T3bN0M0 Bilateral 4+3(3/5), 4+4(5/5) 8
 28.5 74/37 Y - - 0.06 0.79 
2 T2cN0M0 Bilateral 3+4(4/5), 3+3(1/5) 7 5.4 74/37 N - - 0.15 0.15 
3 T3aN0M0 Bilateral 3+3(5/5), 3+4(5/5) 7 20 74/37 Y R, L EI R, L ing <0.01 <0.01 
4 T1cN0M0 Bilateral 3+3(1/5), 3+3(4/4) 6 9.2 74/37 N - R, L ing 0.02 0.40 
5 T2aN0M0 Unilateral 0(2/2), 3+3(6/9) 6 11 74/37 N R, L EI R ing 0.11 0.27 
6 T3aN0M0 Bilateral 3+4(4/6), 3+4(3/6) 7 13 46/23 + BRT N - R, L ing 0.11 0.11 
7 T2bN0M0 Unilateral
†
  0(6/6), 3+3(1/3) 6 17.1 74/37 Y R, L EI R, L ing 0.16 0.16 
8 no MRI
‡ 
Bilateral 4+3(6/6), 4+3(6/6) 7 16.5 72/32 Y L, II - 0.1 0.1 
9 T3aN0M0 Unilateral 3+3(2/7),0(7/7) 6 10.1 74/37 N - - 0.01 0.01 
10 T3aN0M0 Bilateral 4+3(1/3), 4+3(3/3) 7 30 74/37 N R, L EI R, L ing <0.05 <0.05 
 Median   6.5 14.75       
TRUS – Trans-rectal ultrasound guided biopsy, GS – Gleason score, iPSA – initial Prostate specific antigen, RT – Radiotherapy, WPRT- whole pelvic 
radiotherapy, BRT-Brachytherapy, Y- yes, N – no, R – right, L – left, EI – external iliac, II – internal iliac, * nodes picked up on PET/CT, 
†
 Unilateral disease on 
biopsy, but bilateral on MRI, 
‡
 MRI contra-indicated due to presence of pacemaker, 
§
 PSA at 26 months since completion of radiotherapy. 
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[11C]Choline uptake in tumour, normal prostate, detected 
nodes and normal tissue 
 
The primary prostate tumours were visible in all the patients (Figure 40a). 
The baseline median (range) SUV60,ave and SUV60,max in the tumours was 4.58 (2.33-
7.08) and 8.58 (5.78-14.96), respectively. The median SUV60,ave and SUV60,max (2.76 
and 5.87) of the normal prostate gland were significantly lower than those of the 
tumours (unpaired-t test; p= 0.004 and 0.007, respectively). There was physiological 
activity in the rectum, small bowel and bone marrow. In addition, there was tracer 
uptake above background activity in iliac nodes in five patients and in inguinal 
nodes in six patients (Table 17). In four of the patients, these were bilateral distal 
external iliac nodes and in one patient, a left internal iliac node (Figure 41). All of 
these nodes were less than a centimetre in size, and hence reported as node 
negative on the staging investigations based on size criteria. The median (range) 
SUV60,ave and SUV60,max in the detected iliac nodes was 2.33 (1.31-3.18) and 4.65 
(3.06-9.34), respectively.  The median SUV60,ave and SUV60,max (1.57 and 3.49) of 
the inguinal nodes were significantly lower than those of the tumour (p<0.0001: 
unpaired t-test) and was considered as probably reactive uptake and, therefore, 
non-metastatic. Similar findings were seen in the patient cohort discussed in 
Chapter 3. 
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Figure 40: Axial [11C]choline PET and fused PET/CT at level of the prostate and 
seminal vesicles (SV).  
(a) Baseline scan with focal activity in the right peripheral zone (black & white arrows) and 
right SV (black & white dotted arrows). (b) Post-NAD scan (8-10 weeks after initiating neo-
adjuvant androgen deprivation) with a marked reduction in [
11
C]choline uptake in the 
peripheral zone and SV. (c) Post-RT-CAD scan (four months after completion of 
radiotherapy combined with concurrent androgen deprivation) with a further reduction in 
prostate activity, increased obturator internus muscular activity (asterisk) and reduced bone 
marrow activity (red arrows). The images correspond to patient no.1 as listed in Table 17. 
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Figure 41: Axial [
11
C]choline PET and fused PET/CT at the level of prostate and left 
internal iliac node. 
(a) Baseline scan shows bilateral focal intense activity in the peripheral zone (arrows) and a 
5mm left internal iliac node (dotted arrows). (b) Post-NAD (8-10 weeks after initiating neo-
adjuvant androgen deprivation) scan shows a marked reduction, but focal low uptake in 
bilateral prostate (arrows) and focal low uptake in left internal iliac node (dotted arrows). 
Post-RT-CAD (4 months after completion of radiotherapy combined with concurrent 
androgen deprivation) scan shows very low uptake in the prostate but no uptake in the node 
(c). The images correspond to patient no.8 as listed in Table 17. 
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The median time-activity curves (TACs) of the tumour, normal prostate and 
the iliac nodes are shown in Figure 42. In the primary prostate tumours, TACs 
expressed as SUV60,ave plateaued at ~ 15 min and demonstrated retention of activity 
until 60 min. There was an initial rise in the tumour radioactivity, when TACs were 
expressed as SUV60,max, probably due to heterogeneous tumour delivery. In contrast 
to the primary tumour, there was lower radioactivity (over time) in the normal 
prostate and the detected iliac nodes. 
There was a good linear fit of the modified Patlak plots suggesting net 
retention of [11C]choline. The median (range) Kimod-pat variables in the tumours, 
normal prostate and detected iliac nodes were 0.055 mL/min/cm3 (0.019-0.113), 
0.039 mL/min/cm3 (0.015-0.069) and 0.032 mL/min/cm3 (0.010-0.052), respectively. 
A significant association was seen between baseline tumour [11C]choline uptake 
and initial PSA when the imaging variable was SUV60,max (Pearson’s r=0.7, p=0.04) 
but not SUV60,ave (r=0.6, p=0.11) or Kimod-pat (r=0.2, p=0.16). 
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Figure 42: Time activity curves (TACs) in tumour, normal prostate and detected iliac 
nodes.  
Median TACs expressed as SUV60,ave and SUV60,max at baseline, following treatment with 
neo-adjuvant androgen deprivation (Post-NAD), and radiotherapy combined with concurrent 
androgen deprivation (Post-RT-CAD) in the prostate tumour (a, b),  normal prostate (c, d) 
and  in the iliac nodes (e, f).  
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Effect of NAD and RT-CAD on tissue [11C]choline uptake 
 
The effect of therapy on [11C]choline uptake in primary prostate tumours and 
normal tissues was compared. NAD and RT-CAD decreased tumour radiotracer 
uptake variables in all eight patients who completed both post-NAD and post-RT-
CAD scans (Figure 43; Table 18). Repeated measures ANOVA demonstrated 
significant reductions for the following imaging variables: SUV60,ave, SUV60,max, 
TMR60,max and Kimod-pat (p<0.001). There was a large reduction in radiotracer uptake 
in the interval between baseline and post-NAD scan. Within this period, NAD 
decreased tumour imaging variables by 26-60% for the following imaging variables: 
SUV60,ave, SUV60,max, TMRave, TMRmax, and Kimod-pat. The impact of NAD on iliac 
nodes (Figure 41, Table 18) and inguinal nodes (Table 19) was less remarkable. 
There was a reduction in [11C]choline uptake seen within primary prostate tumours 
after RT-CAD treatment, though the magnitude of reduction was much less (12-
27%; p>0.05) compared to that seen with NAD, except for TMRmax where a 
significant reduction (40%; p<0.05) was seen (Table 20). [11C]Choline uptake was 
lower with the combined NAD and RT-CAD, by 52-62 % for the following imaging 
variables compared to baseline values: SUV60,ave, SUV60,max, TMR60,max, and Kimod-pat 
(Table 18). The magnitude of reduction in uptake was similar even at early time 
points (SUV15,max and SUV30,max; p<0.001, Repeated measures ANOVA; Table 21).  
The reduction in tumour [11C]choline uptake variables was also seen when the 
patients who did not have a post-NAD scan were included in the analysis (Table 
22). Again, the effects of treatment were less remarkable for iliac lymph nodes. 
Notably, the reduction in imaging variable, Kimod-pat was more strongly associated 
with reduction in SUV60,ave (r=0.7, p=0.04) and SUV60,max (r=0.6, p=0.05) when all 
data (NAD and RT-CAD) were combined.  
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The therapy also caused a reduction in the [11C]choline uptake in the normal 
prostate gland (SUV60,ave: 43%; range: 13.8 – 72.2% and SUV60,max: 39%; range: -
13.7–70%: Figure 42). However, this was significantly lower than that observed in 
the primary tumours when the imaging variable was SUV60,ave, SUV60,max and Kimod-pat 
(unpaired t test; p=0.006, 0.02 and 0.04, respectively) with NAD and (unpaired t 
test; p=0.01, 0.02 and 0.03 respectively) with combined NAD and RT-CAD. 
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Figure 43: Semi-quantitative and quantitative measures of choline uptake in prostate 
tumour, normal prostate and PSA levels.  
Trends in SUV60,ave and SUV60,max of tumour (a, b), normal prostate (c, d), Ki of tumour (e) 
and normal prostate (f), maximum tumour-muscle ratio TMRmax, (g) and PSA (h) at baseline,  
following neo-adjuvant androgen deprivation (Post-NAD) and radiotherapy combined with 
concurrent androgen deprivation (Post-RT-CAD) in eight patients who completed all three 
scans. *, **, *** denotes significant changes p< 0.05, p<0.01 and p<0.001 respectively. 
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Table 18: Median [
11
C]choline uptake variables in tumour, normal prostate and iliac 
nodes.  
Variables at baseline and reduction with neo-adjuvant androgen-deprivation (NAD) and 
radiotherapy combined with concurrent androgen-deprivation (RT-CAD) in 8 patients. 
 
  SUV 60,ave SUV 60, max 
Kimod-pat 
(mL/min/cm
3
) 
TMR 60,max 
Tumour Baseline 4.71 8.58 0.052 3.58 
  (2.33-7.08) (5.78-14.96) (0.019-0.113) (2.50-5.96) 
 Post-NAD 1.97 5.27 0.030 2.66 
  (1.58-2.82) (3.66-6.61) (0.012-0.049) (1.75-3.25) 
 Post  1.79 4.13 0.022 1.59 
 RT-CAD (0.92-2.45) (1.83-5.38) (0.011-0.059) (0.5-2.45) 
 
% Reduction 
NAD 
58*** 39*** 42** 26*** 
 
% Reduction 
NAD+RT-CAD 
62*** 52*** 59* 57*** 
Normal  Baseline 2.76 5.87 0.033  
Prostate  (1.88-4.41) (3.23-9.01) (0.015-0.066)  
 Post-NAD 1.94 3.92 0.029  
  (1.56-2.47) (2.48-6.75) (0.012-0.044)  
 Post  1.57 3.60 0.021  
 RT-CAD (0.99-2.36) (1.82-5.03) (0.009-0.047)  
 
% Reduction 
NAD 
30** 33* 12  
 
% Reduction 
NAD+RT-CAD 
43*** 39** 36  
Iliac  Baseline 2.59 4.96 0.032  
nodes  (1.31-3.18) (3.06-9.34) (0.010-0.052)  
 Post-NAD 1.89 4.43 0.032  
  (1.43-2.74) (3.45-7.68) (0.010-0.052)  
 Post  1.93 3.80 0.022  
 RT-CAD (0.42-3.10) (0.87-7.73) (0.005-0.041)  
 
% Reduction 
NAD 
27 11 0 
 
 
% Reduction 
NAD+RT-CAD 
25 23* 31*  
TMR-Tumour-to-muscle ratio, *, **, *** denotes significant changes (p< 0.05, p<0.01, p<0.001, 
respectively; Repeated measures ANOVA, Tukey’s multiple comparison), Values in brackets 
represent the range.
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Table 19: Median [
11
C]choline uptake variables in inguinal nodes at baseline and 
reduction with neo-adjuvant androgen-deprivation (NAD) in 8 patients. 
 
  SUV 60, ave SUV 60, max 
Inguinal Baseline 1.61 4.24 
nodes  (1.15-2.69) (2.38-8.57) 
 Post-NAD 1.43 3.57 
  (0.78-2.22) (1.85-7.29) 
 % Reduction NAD 11 16 
 % Reduction with NAD not statistically significant  
Values in brackets represent the range. 
 
Table 20: Median [
11
C]choline uptake variables in tumour, normal prostate and iliac 
nodes.  
Reduction with radiotherapy combined with concurrent androgen-deprivation (RT-CAD) in 8 
patients. 
 
  SUV 60,ave SUV 60,max 
Kimod-pat 
(mL/min/cm
3
) 
TMR 60,max 
Tumour Post-NAD 1.97 5.27 0.030 2.66 
  (1.58-2.82) (3.66-6.61) (0.012-0.049) (1.75-3.25) 
 Post  1.79 4.13 0.022 1.59 
 RT-CAD (0.92-2.45) (1.83-5.38) (0.011-0.059) (0.5-2.45) 
 
% Reduction 
RT-CAD 
12 22 27 40* 
Normal  Post-NAD 1.94 3.92 0.029  
Prostate  (1.56-2.47) (2.48-6.75) 
(0.012-
0.044) 
 
 Post  1.57 3.60 0.021  
 RT-CAD (0.99-2.36) (1.82-5.03) 
(0.009-
0.047) 
 
 
% Reduction 
RT-CAD 
19 8 28  
Iliac  Post-NAD 1.89 4.43 0.032  
nodes  (1.43-2.74) (3.45-7.68) (0.010-0.052)  
 Post  1.93 3.80 0.022  
 RT-CAD (0.42-3.10) (0.87-7.73) (0.005-0.041)  
 
% Reduction 
RT-CAD 
-2 14 30*  
TMR-Tumour-to-muscle ratio, * denotes significant changes (p< 0.05; Repeated measures 
ANOVA, Tukey’s multiple comparison), Values in brackets represent the range. 
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Table 21: SUVmax of tumour at early and late imaging time points 
Median [
11
C]choline uptake variables in tumour at baseline and reduction with neo-adjuvant 
androgen-deprivation (NAD) and radiotherapy combined with concurrent androgen-
deprivation (RT-CAD) in 8 patients. 
 
  SUV15,max SUV30,max SUV60,max 
Tumour Baseline 9.78 9.15 8.58 
  (5.79-12.74) (4.35-11.77) (5.78-14.96) 
 Post-NAD 5.22 4.84 5.27 
  (3.28-801) (2.80-5.49) (3.66-6.61) 
 Post  5.05 3.32 4.13 
 RT-CAD (3.20-6.66) (2.20-4.38) (1.83-5.38) 
 
% Reduction 
NAD 
47*** 47*** 39*** 
 
% Reduction 
NAD+RT-CAD 
48*** 64*** 52*** 
*** denotes significant changes (p<0.001; Repeated measures ANOVA, Tukey’s multiple 
comparison), Values in brackets represent the range. 
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Table 22: Median [
11
C]choline uptake variables in tumour, normal prostate, iliac nodes, normal tissue and PSA at baseline and changes with 
combined neo-adjuvant androgen-deprivation (NAD) and radiotherapy combined with concurrent androgen-deprivation and RT-CAD in 10 patients. 
  SUV 60, ave SUV 60, max 
Kimod-pat 
(mL/min/cm
3
) 
  SUV 60, ave SUV 60, max 
Kimod-pat 
(mL/min/cm
3
) 
   
Tumour 
Base 
line 
4.58 8.58 0.055 OI 
Base 
line 
1.12 3.30 0.016 PSA 
Base 
line 
14.75 
  (2.33-7.08) (5.78-14.96) (0.019-0.113)   (0.64-2.06) (1.65-4.36) (0.006-0.030) (ng/mL)  (5.4-30) 
 Post Tx 1.79 4.04 0.027  Post Tx 1.96 4.63 0.031  Post Tx 0.12 
  (0.92-2.45) (1.83-5.38) (0.011-0.059)   (1.15-2.33) (1.82-7.20) (0.015-0.044)   (0.03-0.4) 
 
% 
Reduction  
61*** 53*** 51***  
% 
Reduction 
-76** -40** -89***  
% 
Reduction 
99*** 
Iliac 
nodes 
Base 
line 
2.33 4.65 0.032 GM 
Base 
line 
0.76 2.43 0.013 
Prostate 
Volume 
Base 
line 
33.73 
  (1.31-3.18) (3.06-9.34) (0.010-0.052)   (0.50-1.10) (1.79-3.75) (0.004-0.018) (cm
3
)  (17.29-73.87) 
 Post Tx 1.52 3.22 0.022  Post Tx 0.97 2.78 0.014  Post Tx 27.3 
  (0.42-3.10) (0.87-7.73) (0.005-0.041)   (0.69-1.14) (2.11-3.66) (0.007-0.027)   (14.58-56.03) 
 
% 
Reduction 
35* 31* 30*  
% 
Reduction 
-27** -14** -8*  
% 
Reduction 
19* 
TMR 60,max 
Base 
line 
 3.53  BM 
Base 
line 
1.22 4.25 0.021    
   (2.50-5.96)    (0.98-2.16) (2.47-6.71) (0.007-0.034)    
 Post Tx  1.48   Post Tx 0.39 1.65 0.006    
   (0.50-2.45)    (0.26-0.90) (0.76-3.19) (0.002-0.021)    
 
% 
Reduction 
 58***   
% 
Reduction 
68*** 61*** 71***    
Normal 
Base 
line 
2.76 5.87 0.039         
Prostate  (1.88-4.41) (3.23-9.01) (0.015-0.069)         
 Post Tx 1.57 3.6 0.024         
  (0.99-2.36) (1.82-5.35) (0.009-0.047)         
 
% 
Reduction 
43** 39** 39*         
-ve sign indicates an increase. Tx- treatment (NAD+ RT-CAD), TMR-Tumour-to-muscle ratio, OI-obturator internus, GM-gluteus maximus, BM-bone marrow, 
PSA-Prostate specific antigen. Values in brackets represent the range. *, **, *** denotes significant changes (p< 0.05, p<0.01, p<0.001, respectively; Paired t-
test).
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In contrast to changes in uptake seen in primary prostate tumours and to a 
lesser extent in iliac lymph nodes, NAD did not affect [11C]choline imaging variables 
within muscle (obturator internus and gluteus maximus muscles) or bone marrow 
(Figure 44, Table 23). RT-CAD in comparison significantly increased tracer uptake 
in muscle within the high-dose region of the radiotherapy field (obturator internus) 
by 47-123% depending on imaging variable. Visually, there was an increase in 
uptake in the obturator internus muscle (Figure 40c). Expectedly there was a less 
remarkable increase in uptake after RT-CAD, in muscle within the low-dose region 
of the radiotherapy field (gluteus maximus) by 2-26%. While NAD alone had no 
effect on bone marrow tracer uptake, RT-CAD significantly decreased tracer uptake 
in the bone marrow by 60-70%.  
Effect of NAD and RT-CAD on PSA levels 
 
The combination of NAD and RT-CAD decreased PSA levels in all eight 
patients who completed both post-NAD and post-RT-CAD scans (Table 23). 
Repeated measures ANOVA demonstrated significant reductions in PSA levels after 
combined therapy (99%; p <0.0001) with a large reduction (94%) after NAD (Figure 
43).  There was no measurable change in prostate volume within the study period.  
There was a good association between reductions in tumour tracer uptake 
and corresponding reductions in PSA levels when the imaging variable was 
SUV60,ave (r=0.7, p=0.04), but not SUV60,max (r=0.6, p=0.09) after NAD. However, this 
association with SUV60,ave was lost after RT-CAD (r=0.5, p=0.19). 
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Figure 44: Changes in the median SUV60,ave- and SUV60,max- derived TACs of normal 
tissues.  
TACs at baseline, after neo-adjuvant androgen deprivation (Post-NAD), and radiotherapy 
combined with concurrent androgen deprivation (Post-RT-CAD). The left panels represent 
SUV60,ave and the right panels represent plots of SUV60,max. The plots were obtained from 
manual regions of interest placed on the obturator internus muscle (a, b); gluteus maximus 
muscle (c, d) and bone marrow (e, f). 
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Table 23: Median [
11
C]choline uptake variables in normal tissue and PSA at baseline 
and changes with neo-adjuvant androgen-deprivation (NAD) and changes with 
radiotherapy combined with concurrent androgen-deprivation (RT-CAD) in 8 patients. 
 
  SUV 60, ave SUV 60, max 
Kimod-pat 
(mL/min/cm
3
) 
   
OI Baseline 1.12 3.30 0.013 PSA Baseline 14.75 
  (0.64-2.06) (1.65-4.36) (0.006-0.030) (ng/mL)  (5.4-28.5) 
 Post-NAD 1.02 3.77 0.017  Post-NAD 0.96 
  (0.89-1.19) (1.87-4.89) (0.008-0.024)   (0.41-6.16) 
 Post  2.03 4.86 0.029  Post  0.16 
 RT-CAD (1.15-2.33) (1.82-7.20) (0.015-0.040)  RT-CAD (0.03-0.4) 
 
% Reduction 
NAD 
9 -14 -33  
% Reduction 
NAD 
94*** 
 
% Reduction 
NAD+RT-CAD 
-81*** -47** -123**  
% Reduction 
NAD+RT-CAD 
99*** 
GM Baseline 0.74 2.45 0.010 
Prostate 
Volume Baseline 31.08 
  (0.50-1.10) (1.79-3.75) (0.004-0.018) (cm
3
)  (17.29-73.87) 
 Post-NAD 0.73 2.13 0.009  Post-NAD 30.66 
  (0.61-0.86) (1.30-3.29) (0.005-0.020)   (15.28-64.87) 
 Post  0.93 2.49 0.012  Post  27.3 
 RT-CAD (0.69-1.14) (2.11-3.66) (0.007-0.027)  RT-CAD (14.58-56.03) 
 
% Reduction 
NAD 
1 14 3  
% Reduction 
NAD 
1 
 
% Reduction 
NAD+RT-CAD 
-26* -2 -20  
% Reduction 
NAD+RT-CAD 
12 
BM Baseline 1.29 5.06 0.020    
  (0.98-2.16) (2.47-6.71) (0.007-0.034)    
 Post-NAD 1.01 3.74 0.016    
  (0.67-2.08) (2.11-6.33) (0.005-0.035)    
 Post  0.51 1.78 0.006    
 RT-CAD (0.26-0.90) (0.76-3.19) (0.002-0.021)    
 
% Reduction 
NAD 
22 26 22    
 
% Reduction 
NAD+RT-CAD 
60*** 65*** 70***    
-ve sign indicates an increase. OI-obturator internus, GM-gluteus maximus, BM-bone 
marrow, PSA-Prostate specific antigen, *, **, *** denotes significant changes (p< 0.05, 
p<0.01, p<0.001, respectively; Repeated measures ANOVA, Tukey’s multiple comparison). 
Values in brackets represent the range. 
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Discussion 
 
This proof of concept study shows that choline uptake in prostate tumours, 
determined by [11C]choline PET/CT, is sensitive to NAD and RT-CAD and could be 
used as an objective quantitative tool for response assessment. NAD decreased 
tumour imaging variables by 26-60% for SUV60,ave, SUV60,max, TMRave, TMRmax, and 
Kimod-pat. RT-CAD also decreased [
11C]choline uptake within primary prostate 
tumours (though of lesser magnitude: 12-27%; p>0.05), compared to that seen with 
NAD, except for TMRmax where a significant reduction (40%; p<0.05) was seen. The 
kinetics of tumour [11C]choline uptake was rapid, reaching a plateau within 15 min, 
suggesting that earlier time points, when levels of radiolabelled metabolites are low, 
could be explored to enhance patient comfort and improve PET count statistics. 
To date, only anecdotal reports (DeGrado, Coleman et al. 2001; De Waele, 
Van Binnebeek et al. 2010) and two small clinical studies (Giovacchini, Picchio et al. 
2008; Fuccio, Schiavina et al. 2011) have assessed the role of [11C]choline PET as 
a method to monitor the therapeutic effects of androgen deprivation therapy (ADT). 
Fuccio et al (Fuccio, Schiavina et al. 2011) retrospectively evaluated the effect of 6 
months of androgen deprivation (Zoladex in 12 and Bicalutamide in 2 patients) in 14 
prostate cancer patients with recurrence after radical prostatectomy. They 
concluded that androgen deprivation significantly decreases [11C]choline uptake in 
androgen sensitive patients. In another study Giovacchini et al (Giovacchini, Picchio 
et al. 2008), showed an average reduction of 45% in the [11C]choline uptake 
(SUVmax) from 11.8 to 6.4 with a 78% decrease in PSA with a median of 4 months of 
bicalutamide therapy in 6 patients with primary prostate cancer. This is a similar 
magnitude of reduction in SUVave and  SUVmax in the prostate tumours to our study, 
with a 94% reduction in PSA with NAD. The possible mechanisms of decrease in 
[11C]choline uptake consequent to androgen deprivation include: a) thinning and 
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atrophy of glandular cells, b) down-regulation of the expression of genes involved in 
lipid metabolism, and c) possible decrease in choline kinase and choline transporter 
activity and d) cell cycle arrest and apoptosis (Giovacchini 2011).  
Notably, the initial PSA showed good association with baseline SUV60,max 
(r=0.7, p=0.04) but not with SUV60,ave (r=0.6, p=0.11), a finding that may be 
attributed to potentially heterogeneous low-grade disease in four patients (Table 
17). Although NAD induced significant reductions in PSA (94%), the magnitude of 
change in [11C]choline uptake was lower than for PSA. Despite this, a good 
association was found between the changes in PSA and SUV60,ave (r=0.7, p=0.04), 
consistent with the effect of NAD on the prostate and systemic PSA expression. In 
support of this assertion, the net retention of radiotracer at steady-state (Kimod-pat; 
broadly indicative of the conversion of [11C]choline to [11C]phosphocholine) also 
decreased after treatment. Low-grade lesions probably precluded SUV60,max being a 
sensitive endpoint variable for evaluating efficacy of NAD (PSA correlation: r=0.6, 
p=0.09).  
Interestingly, a wide range of reduction in SUV60,ave (38 – 83.7%) and 
SUV60,max (22.2 – 85.3%) was seen with combined NAD and RT-CAD despite 
patients universally achieving PSA suppression (99% reduction: narrow range of 
93.5 – 99.7%). This suggests that in spite of a global reduction in PSA following 
NAD and RT-CAD there is a differential reduction in [11C]choline uptake which could 
perhaps provide prognostic information in a larger study with long term outcome 
data. Furthermore the wide range of reduction (2-71% reduction) in the TMR post-
RT-CAD highlights the fact that PSA may be a suboptimal surrogate for predicting 
overall biological response. While PSA is a useful marker of treatment response, it 
takes years for trials using PSA to mature. PSA also has other notable limitations: 
fluctuations in PSA (Hanlon, Pinover et al. 2001), long time to reach nadir 
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(Buyyounouski 2010), and lack of correlation with treatment outcomes (Collette, 
Burzykowski et al. 2006); also indicating that early PSA changes could have poor 
specificity. A promising alternative method, [11C]choline PET/CT offers the potential 
for spatial visualisation of choline-metabolism at multiple disease sites (local and 
distant) in a single scan (Jadvar 2012). 
 There is paucity of data on use of [11C]choline PET to monitor response to 
radiotherapy and the optimal time-point for this assessment is unknown. 
Casamassima and colleagues inferred that high dose radiotherapy is effective in 
eradication of limited nodal recurrences as detected by choline PET/CT 2 months 
post-RT (Casamassima, Masi et al. 2011). More recently, in a study of 11 patients 
with intermediate-risk PCa, Amani and co-workers evaluated sequential [11C]choline 
PET/CT scans before and up to 12 months after completion of RT (74Gy/ 37 
fractions). None of the patients received hormonal therapy. They concluded that RT 
significantly decreased intra-prostatic [11C]choline uptake (as measured by SUVmax 
and TMR) (Amanie, Jans et al. 2013). Selection of the four month RT-CAD interval 
was based on a 18F-fluorodeoxyglucose PET study, which reported false positive 
findings when imaging was conducted at 1 month (Greven, Williams et al. 1994). 
However, the optimum time point requires further study. 
Radiotherapy (RT-CAD) resulted in minor overall reductions in tumour 
[11C]choline uptake. It was postulated that this could signify sterilisation of the 
prostate. While direct investigation of this biology will entail histopathological 
assessment, the higher SUV60,max (above background) seen in the prostate could be 
due, in part to post-radiotherapy inflammation (all patients achieved excellent 
biochemical control (Table 17)). This probably resulted in the loss of association 
between PSA and SUV60,max after RT-CAD compared to NAD alone. Interestingly 
RT-CAD increased OI muscle activity. This and the decrease in bone-marrow 
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uptake could be attributed to radiotherapy, as there was no significant change in 
uptake in these normal tissues after NAD alone. 
Radiotherapy causes inflammation through release of pro-inflammatory 
cytokines (Rodemann and Blaese 2007). Potential mechanisms linking increased 
[11C]choline uptake with inflammation include up-regulation of CHKα in 
macrophages, and hyper perfusion associated with regional inflammation 
(Roivainen, Parkkola et al. 2003). TMR60,max was implemented in an attempt to 
overcome the systematic bias on SUV variables induced by radiotherapy. The 
magnitude of reduction in TMR60,max after RT-CAD (40%; p<0.05) was higher than 
that of SUV supporting the notion that tumour/tissues in the radiotherapy field-of-
view may have an increase in uptake due to radiotherapy related inflammation.  
The non-malignant normal prostate gland also showed [11C]choline uptake, 
albeit significantly lower than that in tumour foci. This heterogeneity of [11C]choline 
uptake was also reported in one other study (Piert, Park et al. 2009). A reduction in 
uptake (lower magnitude than in tumours) with NAD and RT-CAD was also seen in 
the normal gland suggesting a global metabolic change with therapy.  
A high radiotracer uptake over and above background levels in the iliac 
nodes of 5 patients was observed, which were less than a centimetre in size and, 
hence, reported as node negative on the staging MRI. It has been previously shown 
that [11C]choline PET/CT has higher sensitivity and specificity for detecting nodal 
disease, including sub-centimetre disease (Contractor, Challapalli et al. 2011). This 
could indicate the presence of microscopic metastatic disease in these nodes. Apart 
from the internal iliac node in patient 8, there was no change in the Kimod-pat of the 
distal external iliac nodes with therapy. This suggests that the uptake in the distal 
external iliac nodes (next echelon of nodes from inguinal), represents non-
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metastatic inflammatory uptake as in the inguinal nodes (Contractor, Challapalli et 
al. 2011). 
While this study focussed on detailed assessment of sequential imaging 
variables, a key limitation was the small sample size masking true associations. 
However, this study is a useful precursor to a larger study associated with long term 
outcome data, using imaging variables defined here. In addition, further studies 
should include patients with extra prostatic foci. The use of two different scanners 
was an additional limitation. Delineation of the tumour foci, normal prostate and 
subcentimeter lymphnodes could give rise to uncertainties in measuring choline 
uptake due to partial-volume effect. This has not been corrected, as the partial-
volume correction algorithms assume homogeneous tracer uptake (Aston, 
Cunningham et al. 2002). Ideally I would have liked to co-localise the foci of 
[11C]choline uptake with template-based pathology, however, this was not feasible 
as TRUS-guided biopsies are routinely used for diagnosis (2010). In an attempt to 
overcome this limitation, fusion of the MRI to the PET was performed to facilitate 
tumour localisation.  
In conclusion, the consistent decrease in the [11C]choline uptake variables 
with treatment, particularly SUV,ave and TMR,max, supports the choice of analysis. 
SUV and TMRmax (at early and/or late time-points) warrant further evaluation as 
objective measures of response to NAD and RT-CAD, alongside functional MRI 
parameters and PSA as early response biomarker endpoints in PCa during radical 
treatment. Long-term follow-up in a larger cohort of patients, including those with 
pelvic nodal disease will be required to conclusively determine whether [11C]choline 
PET/CT would predict true long-term biochemical control or relapse and to permit 
exploitation of this technology as a vehicle for response evaluation in radiotherapy 
dose-escalation trials, as well as novel hormonal therapies. 
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CHAPTER 5: Deuterium substituted [
18
F]fluoromethyl-
[1,2-
2
H4]choline PET/CT: Biodistribution, radiation 
dosimetry and imaging in Non-Small Cell Lung 
Carcinoma. 
 
5.1: [
18
F]D4-FCH: Biodistribution and radiation 
dosimetry in healthy volunteers 
 
5.1.1: Rationale 
 
The short physical half-life of [11C] in [11C]choline (20.4 min) is, 
disadvantageous for routine clinical use. As a result [18F]-labelled choline analogs 
were developed to overcome this limitation (Figure 45). The longer half-life of 18F 
(109.8 min) is potentially advantageous in permitting late imaging of tumours when 
sufficient clearance of parent tracer in systemic circulation had occurred. Since 
[18F]fluoromethylcholine ([18F]FCH) was first developed by DeGrado et al in 2001 
(DeGrado, Coleman et al. 2001), it has been extensively used in patients with no 
reported adverse effects. 
 
Figure 45: Major choline-based tracers in current use and in development. 
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[11C]Choline (and fluoro-analogue) is, however, readily oxidised to 
[11C]betaine by choline oxidase mainly in kidney and liver tissues, with metabolites 
detectable in plasma soon after injection of the radiotracer (Roivainen, Forsback et 
al. 2000; Bansal, Shuyan et al. 2008; Smith, Zhao et al. 2011). This makes 
discrimination of the relative contributions of parent radiotracer from catabolites 
difficult when a late imaging protocol is used. A more metabolically stable FCH 
analogue, [18F]fluoromethyl-[1,2-2H4]choline ([
18F]D4-FCH), based on the deuterium 
isotope effect (Gadda 2003) has been developed (Figure 45). The simple 
substitution of Deuterium [2D] for Hydrogen [1H] and the presence of [18F] improves 
the stability of the compound and reduces degradation of the parent tracer (Leyton, 
Smith et al. 2009; Smith, Zhao et al. 2011; Witney, Alam et al. 2012). This 
modification is hypothesised to increase the net availability of the parent tracer for 
phosphorylation and trapping within cells leading to a better signal-to-background 
contrast, thus improving tumour detection sensitivity of PET. 
[18F]D4-FCH has been validated for imaging tumours pre-clinically and was 
found to be a very promising, metabolically stable radiotracer for imaging choline 
metabolism in tumours (Leyton, Smith et al. 2009; Witney, Alam et al. 2012).  
In order to translate the pre-clinical findings into humans, this study in 
healthy volunteers was designed with the following aim: 
 To evaluate the biodistribution, dosimetry and safety of [18F]D4-FCH in 
healthy volunteers. 
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5.1.2: Materials and Methods 
 
5.1.2.1: Radiopharmaceutical Preparation 
 
[18F]D4-FCH was synthesised from the precursor as previously described 
(Smith, Zhao et al. 2011). The radiochemical purity of [18F]D4-FCH was 100% with a 
mean (±SD; range) specific activity of 48.4 GBq/μmol (±22.8; 27.3-99.4 GBq/μmol) 
and a pH of 5.5 (±0.39; 4.84-5.88). The average level of the precursor D4-N, N-
dimethylaminoethanol (D4-DMAE) used was 2.4 μg/ mL (±1.52; 0.8 – 4 μg/ mL).  
5.1.2.2: Subjects 
 
Eight healthy volunteers (4 men, 4 women), with a mean (±SD; range) age 
of 62.6 years (±6.12; range: 55-71 years), and mean weight of 65.4 kg (±16.6; 
range: 46.2-96.7 kgs) were enrolled. The main inclusion and exclusion criteria for 
this study were:  
Inclusion Criteria:  
Subjects were included in the study if they meet all of the following criteria: 
1) Male or female aged 50 years or above. 
2) If female, the subject is either post-menopausal (at least 1 year), or 
surgically sterilised (has had a documented bilateral oophorectomy and/or 
documented hysterectomy for at least 2 years).  All female subjects of child 
bearing potential must have a negative urine beta human chorionic 
gonadotropin (-hCG) pregnancy test (urine dipstick) done at initial 
screening (up to 21 days before administration) and on the day of tracer 
administration.  The result of the pregnancy test must be known before 
administration of [18F]D4-FCH Injection. 
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3) The subject was able and willing to comply with study procedures, and 
provide a signed and dated informed consent. 
4) The subject had a normal medical history with no significant co morbidities, 
physical examination findings, and vital signs during the screening period 
(from 21 days before administration). 
5) The subject’s ECG and clinical laboratory tests were within normal limits 
and/or considered clinically insignificant. 
6) Drug and Alcohol screening tests were negative.  
 
Exclusion Criteria:  
Subjects were excluded from participating in this study if they met any of the 
following criteria: 
1) The subject was lactating. 
2) The subject had been previously included in this study. 
3) The subject had received, or is scheduled to receive, another investigative 
medicinal product/radioactive tracer 1 month before administration of 
[18F]D4-FCH Injection. 
4) The subject had received any chemotherapy, immunotherapy, biologic 
therapy or investigational therapy within 14 days or five half-lives of a drug 
(whichever is longer) prior to the first dose of [18F]D4-FCH Injection.  
5) The subject had received ionising radiation exposure from their occupation 
or from participation in clinical trials within the 3 months prior to their 
enrolment. 
Subjects were asked to fast for 4-6 hours prior to tracer injection. Ethical approval 
for the study was granted by the West-London Research Ethics Committee. All 
volunteers gave written informed consent to participate in the study, according to 
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the Declaration of Helsinki guidelines. The administration of radioactivity for the 
PET/CT scans was approved by the Administration of Radioactive Substances 
Advisory Committee, United Kingdom. Medicines and Healthcare products 
Regulatory Agency (MHRA) has approved this study as a non-investigational 
medicinal product (IMP) study. 
5.1.2.3: Safety 
 
Safety data collected up to 72 h after injection included adverse events 
(AEs), graded according to common toxicity criteria (CTC v. 4.03); vital signs (blood 
pressure, respiratory rate, heart rate, and body temperature); physical examination 
(cardiovascular, lung, abdomen, and neurologic examinations); electrocardiogram; 
and laboratory parameters (serum biochemistry, haematology, coagulation, and 
urinalysis). Blood samples were collected through an in-dwelling cannula, and to 
avoid occlusion, heparinised saline was used to maintain line patency. 
5.1.2.4: Image Acquisition and In Vivo Activity Measurement 
 
Images were acquired on a Siemens Biograph 6 True Point PET/CT scanner 
(with TrueV; extended field of view) with 21.6cm axial and 60.5cm transaxial fields 
of view. Table 24 describes the image acquisition protocol. The mean (±SD; range) 
injected [18F]D4-FCH activity and D4-FCH cold dose in the subjects were 161 MBq 
(±2.17; 156-163 MBq) and 4.5 μg (±1.07; 2–5 μg), respectively.  
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Table 24: Image acquisition protocol 
 
Scan Field of view (FOV) 
Number of  
bed positions 
Minutes per  
bed position 
Attenuation CT1* Vertex to Mid-thigh 6-7  
[
18
F]D4-FCH Injection   
Emission scan 1† Vertex to Mid-thigh‡ 6-7 1 
Emission scan 2 Vertex to Mid-thigh 6-7 2 
Emission scan 3 Vertex to Mid-thigh 6-7 5 
Emission scan 4 Vertex to Mid-thigh 6-7 5 
Voiding   
Attenuation CT2* Vertex to Mid-thigh 6-7  
Emission scan 5 Vertex to Mid-thigh 6-7 7 
Emission scan 6 Vertex to Mid-thigh 6-7 7 
* CT settings; 130 kV, 15 effective mAs, pitch 1.5, slice thickness 5 mm, rotation time 0.6 
sec, and effective dose 2.5 mSv. 
†Emission data were reconstructed using the ordered-subsets expectation maximisation 
(OSEM) algorithm (3 iterations and 21 subsets). 
‡Imaging performed caudo-cranially. 
 
Volumes of interest (VOIs) were delineated manually on the attenuation CT 
scan, using a circle of a fixed diameter, depending on the size of the organ. In order 
to avoid tissue inhomogeneity, particularly near organ boundaries, the VOIs were 
defined within the boundaries of the normal tissue organs, as visualised on the CT 
images. The VOIs were mapped to the corresponding emission scans by means of 
shape-based interpolation to extract the [18F] activities using the Analyze analysis 
software (version 11; Biomedical Imaging Resource, Mayo Clinic). For urinary 
bladder where the volume changes over time, the organ was outlined manually on 
the emission scans. All the volumes were outlined by a single investigator to avoid 
any inter-observer variation. VOIs included brain, thyroid, thymus, breast, lungs, 
heart wall, aortic lumen, liver, gall bladder, spleen, stomach wall, pancreas, 
adrenals, kidneys, small intestine wall and contents, large intestine wall and 
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contents, urinary bladder contents, uterus, testes/ovaries, gluteus maximus muscle, 
and red marrow (iliac crest). 
5.1.2.5: Measurement of blood & urine radioactivity 
 
Venous blood samples were taken at nominal times of 5, 10, 15, 30, 60, 90, 
150, and 240 min after injection. Single aliquots, each of whole blood and plasma 
were obtained from each sample, and 18F activity concentration was measured in a 
well counter previously cross-calibrated to the PET scanner. Urine was collected as 
voided up to 240 min after injection, and the volume and time of each micturition 
recorded. Dual aliquots of urine were sampled from each void, and the mean [18F] 
activity was measured. The resulting [18F] activity concentration was multiplied by 
the volume of voided urine to provide the [18F] activity excreted. 
5.1.2.6: Metabolite analysis 
 
Discrete venous blood samples drawn at the above mentioned time points 
were centrifuged at ~8000 g for 3 min at 4º C to obtain plasma. Plasma metabolite 
analysis was performed and samples were clarified by protein precipitation (Smith, 
Zhao et al. 2011). All samples were instantly processed for analysis by high-
performance liquid chromatography (HPLC; Agilent 1200 series system). A guard 
column (Waters-Bondapak-C18: 10μm, 125A) and an analytical column 
(Phenomenex-luna-SCX: 240*4.6mm, 10μm) were used.  Briefly, ice-cold 
acetonitrile (3.75-12ml) was added to plasma samples (0.5-2.0ml). The resulting 
suspension was centrifuged (15,490 g, 4o C, 3 min). The supernatant was then 
decanted and evaporated to dryness on an evaporator under vacuum (at 40o C), 
then re-suspended in HPLC mobile phase (1.1ml) and filtered through a syringe 
filter (0.2 μm) to remove particulates. The mobile phase comprised of 0.25 M 
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Sodium dihydrogen phosphate (pH 4.8) and acetonitrile (9:1 v/v) delivered at a flow 
rate of 2 ml/min and a total run time of 10 min. A total of 30 fractions were collected 
over the course of the analysis and radioactivity was measured using a Perkin 
Elmer (Cambridge, UK) Wizard 1470 automated gamma counter.  
5.1.2.7: Biodistribution and Dosimetry 
 
For each subject and for each source region, the non-decay-corrected 18F 
activity concentration over the 6 time points (time-activity curve: TAC) was 
generated. The cumulative activity concentrations (area-under-curve: AUC) were 
calculated for all organ VOIs by applying a trapezoidal integration to the non-decay-
corrected TACs over the duration of the scan. The total number of disintegrations in 
each organ normalised to injected activity (subsequently referred to as the 
Residence Time (RT; ): kBq.hour/kBq) were calculated as follows (Eq. 10): 
activityInjectedAUC V organ /)(     Equation 10 
 
where AUC is the time integral of the non-decay corrected TAC and Vorgan is the 
tabulated organ volume as used in OLINDA/EXM version 1.1 (Stabin, Sparks et al. 
2005). For most organs, the AUC included a contribution beyond the scan duration 
assuming no further activity redistribution. As the volume of the urinary bladder 
changed over time, the image derived organ volume at each scan time point was 
used to estimate RT, rather than the tabulated organ volume. Lung activity was 
corrected for tissue density using a density value of 0.33 g/ml (Rhodes, Wollmer et 
al. 1981). The tissue density in the other organs was assumed to be 1.0 g/ml. With 
the exception of the urinary bladder, extrapolation of the integration past the last 
image data point (4 hours) only assumed physical decay of the [18F] label without 
biologic clearance, i.e. an additional contribution to the AUC of TACl/λ where TACl is 
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the last TAC value measured and λ the decay constant for 18F. For bladder, the 
measured voided activities were included to form an extended 8 time point TAC 
(Figure 46).  The bladder TAC was modelled according to (Eq. 11) 
 e tit
i
Aie
te BtA   )1(    Equation 11 
 
where A, B are fitted parameters, t the tracer administration time, Ai the urine 
activity voided at time ti (Graham, Peterson et al. 1997; Thomas, Stabin et al. 1999). 
Residual bladder activity was not included in the model since it was not known if 
complete voiding had occurred for these subjects, although any residual activities 
must have been small compared to the voided activities. The sum of the squared 
differences between the function and the extended TAC was minimised for each 
subject using the solver function in Excel 2010 (Microsoft, Inc., Redmond, WA). 
Across all 8 subjects the fitted AUCs matched the measured AUCs calculated 
above with a fractional mean difference of 3% and standard deviation of 7%. The 
fitted functions were extrapolated to estimate the bladder RT for each subject for the 
following voiding scenarios: complete bladder voids every hour, every 2 hours, and 
every 4 hours post tracer administration. Finally the RT of the remainder term 
(assumed to be homogeneously distributed in the body) was obtained by 
subtracting the sum of all defined organ RTs from the inverse of the decay constant 
for [18F]. 
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Figure 46: Representative bladder fits for a subject.  
(a) The measured image and urine sample-derived time activity curves (TACs) for one 
subject and the fitted function, Eq. 11 (both shown uncorrected for radioactive decay). The 
fitted functions extrapolated to the following voiding scenarios: complete bladder voids (b) 
every hour, (c) every 2 hours, and (d) every 4 hours post tracer administration. 
 
The internal radiation dosimetry was estimated from the RTs for the organs 
in each subject, which was provided as input to the OLINDA/EXM version 1.1 
(Stabin, Sparks et al. 2005). The organ absorbed doses, and effective dose (ED) for 
each individual subject were subsequently averaged. Since ICRP 103 (2007) tissue-
weighting factors (WT) are not implemented in OLINDA/EXM 1.1, the male and 
female EDs are based on WT from ICRP-60 (1991). 
 An additional correction to the dose estimates arises because OLINDA/EXM 
1.1 assumes that the stomach activity is all in the contents rather than the organ 
wall. The former was considered unlikely in this case. This only affects the beta 
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(positron) contribution to the dose and is corrected by noting that the energy 
deposited in the wall from the contents is assumed within OLINDA/EXM to be half 
that calculated for the contents. 
5.1.2.8: Statistical Considerations 
 
There was no formal sample size calculation performed for this study. Based 
on the biodistribution studies published in the literature, a total of 8 evaluable 
healthy volunteers (with a minimum of 3 females) were recruited.  Descriptive 
statistics were used for biodistribution data and absorbed doses to the target 
organs.  
5.1.3: Results  
 
5.1.3.1: Safety 
 
[18F]D4-FCH was found to be safe and well tolerated in all subjects. No 
tracer related serious AEs or AEs were observed in relation to [18F]D4-FCH 
injection. No significant changes in vital signs, clinical laboratory blood tests or 
electrocardiograms were observed. 
5.1.3.2: Biodistribution 
 
Following the administration of [18F]D4-FCH, radioactivity was initially 
detected in the vascular compartment and then rapidly distributed to the liver, 
kidneys, pancreas and spleen.  About 7% of the injected activity (decay-corrected to 
injection time) was eliminated within the first 4 hours through the kidneys (6% after 
2h). Radioactivity was already detectable in the urinary bladder at about 7 min after 
tracer administration. The initial radioactivity uptake in the liver gradually increased 
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with time after tracer injection. Increased uptake was also noted in the pituitary, 
salivary glands and bone marrow. Typical images illustrating tracer uptake at 
various time points from a representative female and male subject are shown in 
Figure 47. There were no differences in biodistribution profiles between men and 
women. TACs were generated for various organs (Figure 48). The mean RTs for 
male and female subjects are summarised in Table 25. The RT contribution from 
the extrapolated part of AUC beyond the last time point for imaging accounted for 
38% of the total RT, contributing to 61% of the total ED. 
 
Figure 47: A series of whole body maximum intensity projection (MIP) images. 
MIP images of representative female (a) and male (b) subjects showing biodistribution of 
[
18
F] activity following tracer injection up to 194 min post injection of [
18
F]D4-FCH. The 
incidental increased uptake of the radiotracer noted in the prostate of the male subject was 
secondary to benign prostatic hyperplasia. The apparent delayed uptake in the liver of the 
male subject was not present in other male subjects. 
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Figure 48: Mean decay corrected time-activity curves (TACs).  
TACs normalised to injected activity (kBq) and body weight (grams), for [
18
F]D4-FCH. TACs 
were generated for several organs at various time points up to 4 hours after tracer 
administration in (a) the elimination organs (liver, kidney and urinary bladder), (b) pancreas, 
spleen and bone marrow, (c) cranium, and (d) thorax. Error bars represent one standard 
deviation from the mean and are shown one-sided for clarity. 
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Table 25: Mean Residence Times ( ) of [18F]D4-FCH for different organs in Male (n=4) 
and Female (n=4) Volunteers. 
   (kBq.h/ kBq) - Males   (kBq.h/ kBq) - Females 
Organ Mean SD Mean SD 
Adrenal 0.003 0.001 0.003 0.001 
Brain 0.009 0.001 0.012 0.003 
Breast   0.005 0.001 
Gall Bladder 0.005 0.001 0.006 0.006 
Heart contents 0.009 0.003 0.009 0.001 
Heart wall 0.017 0.004 0.017 0.001 
Kidney 0.126 0.043 0.170 0.046 
Liver 0.534 0.138 0.681 0.097 
LLI 0.008 0.003 0.007 0.003 
Lung* 0.061 0.009 0.042 0.006 
Muscle 1.036 0.381 0.873 0.191 
Ovaries†   0.00004 0.00008 
Pancreas 0.027 0.002 0.025 0.006 
Red marrow 0.102 0.018 0.125 0.013 
Small Intestine 0.071 0.015 0.108 0.033 
Spleen 0.022 0.002 0.026 0.002 
Stomach wall 0.027 0.008 0.022 0.012 
Testis 0.001 0.000   
Thymus 0.00047 0.00015 0.00164 0.00038 
Thyroid 0.001 0.000 0.001 0.000 
ULI 0.010 0.001 0.013 0.001 
Urinary Bladder‡ 0.059 0.027 0.075 0.025 
Uterus   0.004 0.003 
Remainder 0.511 0.450 0.414 0.076 
LLI-lower large intestine, ULI-upper large intestine, SD-standard deviation  
* Lung activity was corrected for tissue density value of 0.33 g/ml and other organs with a 
density value of 1 g/ml. 
† In three subjects ovaries were not visible due to post-menopausal atrophy. 
‡ Urinary Bladder residence time is for a 2-hour voiding scenario. 
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5.1.3.3: Dosimetry 
 
Table 26 summarises the mean organ absorbed dose estimates for [18F]D4-
FCH injection. The mean effective dose averaged over both males and females 
(±SD) was estimated to be 0.025±0.004 mSv/MBq (male 0.022±0.002; female 
0.027±0.002). The 5 organs receiving the highest absorbed dose (mGy/MBq), 
averaged over both males and females (±SD), were the kidneys (0.106±0.03), liver 
(0.094±0.03), pancreas (0.066±0.01), urinary bladder wall (0.047±0.02), and 
adrenals (0.046±0.01). The values quoted are based on the 2-hour bladder voiding 
scenario. This is likely to be conservative in routine imaging scenarios where 
subjects would be encouraged to consume moderate quantities of fluids and empty 
their bladders regularly as is done for [18F]FDG studies. If the 4-hour voiding 
scenario were used, this would increase the bladder wall absorbed dose by 59% 
(increase of 0.027 mGy/MBq: averaged for male and female). 
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Table 26: Mean organ absorbed dose estimates expressed in mGy/MBq for [
18
F]D4-
FCH (n=8) with bladder voiding scenarios. 
 
 
Mean Absorbed 
Dose estimates 
Mean Absorbed 
Dose estimates 
 (mGy/MBq) (mGy/MBq) 
Bladder Voiding 
2-hr voiding 
scenario 
4-hr voiding 
scenario 
Organ Mean SD Mean SD 
Adrenals 0.046 0.011 0.046 0.011 
Brain 0.004 0.001 0.004 0.001 
Breasts 0.007 0.001 0.007 0.001 
Gall Bladder wall 0.034 0.009 0.033 0.009 
LLI wall 0.015 0.002 0.015 0.002 
Small Intestine 0.031 0.009 0.031 0.009 
Stomach wall 0.040 0.010 0.040 0.010 
ULI wall 0.019 0.003 0.019 0.003 
Heart wall 0.023 0.004 0.023 0.004 
Kidneys 0.106 0.034 0.106 0.033 
Liver 0.093 0.028 0.093 0.029 
Lungs 0.019 0.002 0.019 0.002 
Muscle 0.014 0.003 0.014 0.003 
Ovaries 0.013 0.002 0.013 0.002 
Pancreas 0.066 0.009 0.066 0.008 
Red marrow 0.017 0.001 0.017 0.001 
Osteogenic cells 0.015 0.002 0.014 0.002 
Skin 0.005 0.001 0.005 0.001 
Spleen 0.038 0.007 0.038 0.007 
Testes 0.010 0.002 0.010 0.002 
Thymus 0.015 0.006 0.015 0.006 
Thyroid 0.017 0.003 0.017 0.003 
Urinary Bladder wall 0.046 0.018 0.074 0.030 
Uterus 0.017 0.006 0.018 0.006 
Total body 0.014 0.002 0.014 0.002 
Mean ED 
(mSv/MBq) 
0.025 0.004 0.027 0.004 
   LLI-lower large intestine, ULI-upper large intestine, ED-effective dose 
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5.1.3.4: Metabolism of [18F]D4-FCH 
 
The metabolism of [18F]D4-FCH in plasma at discrete time points after tracer 
injection was evaluated using HPLC. Typical HPLC chromatograms of [18F]D4-FCH 
and its metabolite in the plasma at various time points after tracer injection are 
shown in Figure 49a-h. [18F]D4-FCH eluted at approximately 6 min and [18F]D4-
betaine at 3min. [18F]D4-betaine was detected as early as 10 min after injection. The 
chromatogram of [18F]D4-FCH and its metabolite in urine (Figure 50) shows 
elimination of [18F]D4-betaine predominantly. The [18F]D4-FCH parent fraction 
(fraction of radioactivity in blood remaining as [18F]D4-FCH) and the whole blood to 
plasma ratio of radioactivity are shown in Figure 51a-b. At about 3.5 h post tracer 
injection, 31% of radioactivity remained as parent 18F-D4-FCH in circulation. The 
ratio of radioactivity in blood to that in plasma approximated unity, over the time 
course of the study. 
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Figure 49: Typical high-performance liquid chromatography (HPLC) chromatogram of 
[
18
F]D4-FCH and its metabolite [
18
F]D4-betaine in plasma.  
Analysis of the metabolism of [
18
F]D4-FCH at (a) 2.5 min, (b) 10 min, (c) 20 min, (d) 30 min, 
(e) 60 min, (f) 90 min, (g) 150 and (h) 240 min post tracer injection, shows detection of 
[
18
F]D4-betaine as early as 10 min, the proportion of which increases with time. Note that the 
Y-axis scale is different due to decrease in counts per minute (CPM). 
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Figure 50: Typical high-performance liquid chromatography (HPLC) chromatogram of 
[
18
F]D4-FCH and its metabolite [
18
F]D4-betaine in urine.  
Analysis of the metabolism of [
18
F]D4-FCH at (a) 90 min, (b) 240 min post tracer injection, 
shows predominant excretion of [
18
F]D4-betaine. 
 
Figure 51: Time course of in vivo oxidation of [
18
F]D4-FCH and the ratio of whole 
blood to plasma radioactivity.  
Thirty-one percent of radioactivity remains as parent [
18
F]D4-FCH in circulation at about 3.5 
h post tracer injection (a). The ratio of radioactivity in blood to that in plasma was close to 
unity (b). 
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5.1.4: Discussion 
 
This first in human study has shown that the deuterium substituted FCH 
analogue, [18F]D4-FCH, is safe and well tolerated. To date, [11C]choline and 
[18F]FCH have been extensively used for the clinical imaging of prostate, brain, 
breast and oesophageal carcinomas (Treglia, Giovannini et al. 2012; Umbehr, 
Muntener et al. 2013). Due to the metabolic instability of choline radiotracers and 
the desire to use late imaging protocols (~60 min, to permit elimination of non-
specific metabolites), a more stable choline radiotracer, [18F]D4-FCH was developed 
(Smith, Zhao et al. 2011). A series of pre-clinical studies showed that the new tracer 
has improved protection against oxidation by choline oxidase, the key choline 
catabolic enzyme, via a 1H/2D isotope effect, together with fluorine substitution 
(Leyton, Smith et al. 2009; Smith, Zhao et al. 2011; Witney, Alam et al. 2012). The 
objective of this study was to investigate the biodistribution and dosimetry in human 
subjects, and extend pharmacokinetic aspects of the pre-clinical findings into human 
application.  
The early tissue distribution of [18F]D4-FCH was not dissimilar from that of 
[18F]FCH reported by DeGrado and colleagues (DeGrado, Reiman et al. 2002), 
though their study evaluated the distribution and dosimetry over a period of up to 1 
h only. Injection of [18F]D4-FCH led to rapid washout of the 18F activity from the 
vascular compartment, and elimination was primarily via the renal and hepatic 
routes. Renal excretion (7% in 4 h) was relatively lower than for routinely used 
radiotracers such as [18F]FDG (21% in 2 h) (Jones, Alavi et al. 1982; 1998) and 
similar to that of the other choline analogs (Table 27). The mean ED of [18F]D4-FCH 
was determined as 0.025 mSv/MBq, which is comparable with the ED of [18F]FDG 
(0.019 mSv/MBq) (1998).  The dose limits specified in the Code of Federal 
Regulations (USA) per single administration of a radioactive drug for research 
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purposes, are 30 mSv to the whole-body, blood-forming organs, lens of the eye, and 
gonads, with a maximum annual dose of 50 mSv. The maximum allowable single 
and annual dose to all other organs are 50 and 150 mSv, respectively (2012). If a 
370 MBq administered radioactivity for [18F]D4-FCH (typical of many PET tracers) 
was assumed, the ED would be 9.3 mSv. For this administered radioactivity level, 
the equivalent dose received by the gonads would be estimated as 1.1 mSv. These 
are well within the dose limits specified above. 
 
Table 27: Comparison between [
18
F]D4-FCH, [
11
C]choline and [
18
F]FCH 
 
 
[
11
C]Choline * 
(Hara 2002) 
[
11
C]Choline†  
(Tolvanen, Yli-
Kerttula et al. 
2010) 
[
18
F]FCH*  
(DeGrado, 
Reiman et al. 
2002) 
[
18
F]D4-FCH†  
(this study) 
Absorbed dose (mGy/ MBq) 
Kidney 0.018 0.021 0.16 0.106 
Liver 0.017 0.02 0.061 0.094 
Pancreas 0.013 0.029  0.066 
Urinary Bladder  0.003 0.065 0.047 
Adrenals  0.004  0.046 
Stomach wall  0.006  0.04 
Spleen 0.008 0.009 0.055 0.038 
ED (mSv/ MBq) 
 0.0028 0.0044‡ 0.020‡ 0.025‡ 
Urinary Excretion (% of injected activity) 
  2% in 1.5 h 3.4% in 1 h 
4% in 1h, 6% in 2h,  
7% in 4h 
*Estimated using MIRDOSE 
†Estimated using OLINDA/EXM 
‡The higher radiation dose of [
18
F]FCH compared to that of [
11
C]choline is due to the longer 
half life of [
18
F] 
 
As indicated above, both transport and phosphorylation by CHKαare 
putative mechanisms for radiotracer localisation. Examination of [18F]D4-FCH 
localisation in brain tissue was very low, with the pituitary being the only organ of 
the brain showing a high uptake (Figure 48c). This is in keeping with previous 
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reports of radiolabelled choline (Hara, Kosaka et al. 1997; Mertens, Ham et al. 
2012). The brain has a limited capacity to synthesise choline de novo. Thus, the 
majority of choline enters the brain from the circulation through saturable transport 
at the blood-brain barrier (Allen and Smith 2001) or through the high affinity choline 
transporters (CHTs), which are highly expressed in the neural tissues (Michel, Yuan 
et al. 2006). The lack of significant radiotracer localisation in healthy brain in some 
ways leads us to speculate that the rate limiting step for [18F]D4-FCH tissue 
localisation in humans is phosphorylation by CHK rather than transport. The higher 
uptake in the pituitary gland noted in this study and in the report of Mertens and 
colleagues (Mertens, Ham et al. 2012), could be due to this gland being situated 
outside the blood-brain barrier. This is in contrast to that reported by Schillaci and 
colleagues, who documented physiological uptake in the pituitary in only 1 of the 80 
subjects evaluated (Schillaci, Calabria et al. 2010). Physiological accumulation of 
[18F]D4-FCH was also seen in the salivary glands and pancreas as reported 
previously (Hara, Kosaka et al. 1998; Mertens, Ham et al. 2012). However, the 
mechanism of uptake is unclear. It has been suggested that uptake in the pancreas 
could be due to the incorporation of radiolabelled choline into phosphatidylcholine 
and lysophosphatidylcholine, which are in abundance in the pancreatic exocrine 
secretions (Hara, Kosaka et al. 1998).  
There is paucity of plasma metabolism information on [18F]choline analogs in 
humans. In translating the findings from pre-clinical validation to patients, it was 
hypothesised that the slower metabolism of choline tracers in humans compared to 
rodents (Roivainen, Forsback et al. 2000; Bansal, Shuyan et al. 2008) will result in 
relatively slow metabolism of [18F]D4-FCH to [18F]D4-betaine compared to published 
studies for [11C]choline (Contractor, Kenny et al. 2009; Contractor, Challapalli et al. 
2011; Contractor, Kenny et al. 2011). In support of this hypothesis, there was 38% 
of parent [18F]D4-FCH in plasma at 60 min, decreasing to 31% at 4h. This 
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represents an improvement in metabolic stability for choline tracers in use clinically; 
for example a 2-fold higher metabolic stability is observed for [18F]D4-FCH relative 
to published data for [11C]choline by the Aboagye group (Figure 52a). The 
metabolic stability of [18F]D4-FCH observed, was not due to a high total cold 
compound(s) in the radiopharmaceutical which may negatively impact on clearance. 
In contrast, the dose solution had higher specific activity (48.4 GBq/μmol) and 
pseudo-specific activity (relative to the precursor, D4-DMAE) than previously 
reported for [11C]choline (Pascali 2000); the upper quality control release limit with 
respect to precursor being set at 10 µg (at least 10-20-fold lower). The lower levels 
of the precursor D4-DMAE along with the high specific activity is an added 
theoretical advantage, as DMAE is known to modulate the transport and 
phosphorylation of radiolabelled choline (Hara 2001). The lower concentration of 
DMAE is also known to enhance the visualisation of the tumours (Slaets, De Bruyne 
et al. 2010). The role of specific activity on [18F]D4-FCH tumour uptake requires 
further evaluation. 
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Figure 52: TACs of [
18
F]D4-FCH liver, kidney and bladder and comparison with 
[
11
C]choline in breast and prostate cancer patients  
(primary data excluding the metabolites and normal tissue uptake were published in 
(Contractor, Kenny et al. 2011) and (Contractor, Challapalli et al. 2011). (a) Comparison of 
parent radiotracer fraction over 1 h post tracer injection. Thirty-eight percent of parent 
[
18
F]D4-FCH remains in circulation compared with 17% of parent [
11
C]choline in the breast 
(mean injected activity: 320 MBq) patient cohort. The mean decay-corrected and normalised 
radioactivity levels for [
18
F]D4-FCH and [
11
C]choline in: (B) liver (C) kidney and (D) bladder. 
The key difference between the two [
11
C]choline studies relates to the approximately ten fold 
higher levels of unlabelled choline and dimethylaminoethanol precursor ([
11
C]choline 
synthesised as per Pascali et al (Pascali 2000)). The [
18
F]D4-FCH dose solution has 
extremely low levels of both precursor and unlabelled cold material, i.e., high specific 
radioactivity.
 
[
11
C]choline metabolite analysis was performed as described in (Contractor, 
Kenny et al. 2009). 
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In keeping with the pre-clinical studies (Leyton, Smith et al. 2009; Smith, 
Zhao et al. 2011; Witney, Alam et al. 2012), localisation of the [18F]D4-FCH was 
most pronounced in kidneys and liver. Radiotracer uptake in kidneys and liver is 
likely to represent phosphorylation by CHKα with minor oxidation of [18F]D4-FCH to 
[18F]D4-betaine (Leyton, Smith et al. 2009; Witney, Alam et al. 2012). Comparison of 
the early phase (0-60 min) biodistribution profiles of [18F]D4-FCH and [11C]choline 
showed lower liver radioactivity and higher kidney and bladder radioactivity’s for 
[18F]D4-FCH (Figure 52b-d). The differences in radiotracer distribution kinetics are 
likely due to the preponderance of phosphorylation over oxidation (Witney, Alam et 
al. 2012). The higher activity of [18F]D4-FCH in the bladder (enhanced urinary 
clearance; Figure 52d) and the predominance of [18F]D4-betaine in the excreted 
urine chromatograms (Figure 50) suggests incomplete tubular reabsorption of the 
parent tracer, similar to that seen with [18F]FCH (DeGrado, Coleman et al. 2001). 
This is in contrast to the efficient tubular reabsorption of the nature-identical 
[11C]betaine (Pummer, Dantzler et al. 2000). 
Given the low background uptake of [18F]D4-FCH in thorax and brain it is 
envisaged that this radiotracer will find utility in the following clinical scenarios: a) as 
a prognostic marker in lung cancer, supported by the observation that 
overexpression of CHKα predicts for patient survival in lung cancer (Ramirez de 
Molina, Sarmentero-Estrada et al. 2007) and b) detection of primary and recurrent 
brain tumours, supported by MRS imaging studies (Horska and Barker 2010).  The 
use of [18F]D4-FCH in prostate cancer including localised and advanced disease 
remains to be determined. In this regard, the urinary excretion of [18F]D4-FCH while 
lower than [18F]FDG, for example, may still obscure detection. Furthermore, it 
should be noted that patients were fasted in this study, thus, the impact of post-
prandial bowel uptake needs further clarification. 
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In summary, [18F]D4-FCH injection is safe and well tolerated with a 
favourable dosimetry profile in healthy volunteers. Organ dose estimates are similar 
to that seen with other routine [18F]-labelled tracers. The potential risks due to 
radiation are within accepted limits. The radiotracer was relatively stable in vivo. 
Further clinical studies are now warranted to evaluate the utility of [18F]D4-FCH in 
cancer patients.  
 
5.2: [
18
F]D4-FCH PET/CT in Non-Small Cell Lung 
Carcinoma: Proof of concept study. 
 
5.2.1: Rationale 
 
After establishing the safety, biodistribution and radiation dosimetry in 
human volunteers, [18F] D4-FCH, was used to image patients with newly diagnosed 
non-small cell lung cancer (NSCLC) to establish an initial proof of concept. The 
choice of lung cancer was predicated in part by important emerging data linking 
choline kinase activity to patient survival in lung cancer patients (Ramirez de Molina, 
Sarmentero-Estrada et al. 2007). The aim of this proof of concept study was 
 To examine the kinetics and magnitude of uptake of [18F]D4-FCH and its 
association with CHK expression in lung cancer patients.  
This will test the hypothesis that untreated malignant lung lesions will have 
enhanced radiolabelled choline accumulation due to their high expression and 
activity of CHKα.  
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5.2.2: Materials and Methods 
 
5.2.2.1: Patients 
 
Patients with newly diagnosed, biopsy confirmed NSCLC, suitable for radical 
surgery, radiotherapy or systemic therapy (i.e. localised or locally advanced or 
metastatic NSCLC), ECOG performance status ≤2 and with at least one (primary or 
metastatic) lesion ≥20 mm as assessed by the most recent CT were included.  
Thus the main inclusion and exclusion criteria were: 
Inclusion Criteria: 
1. Histologically confirmed, newly diagnosed NSCLC fit for radical surgery, 
radiotherapy or systemic therapy (localised or locally advanced or 
metastatic) 
2. At least one measurable lesion of ≥ 2cm (primary tumour or lymph node) 
3. WHO performance status ≤ 2  
4. Written informed consent 
5. Clinically acceptable full blood count, renal and liver function (as judged by 
the investigator) 
Exclusion Criteria: 
1) Concurrent treatment with other experimental drugs. Participation in another 
clinical trial with any investigational drug within 30 days prior to study entry. 
2) Pregnant or lactating women. 
3) Previous invasive malignancy within the last five years other than basal cell 
carcinoma.  
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Ethical approval for the study was granted by the West London REC 1 Committee. 
All patients gave fully informed consent to participate in the study, which was done 
according to the Declaration of Helsinki guidelines. The administration of 
radioactivity for the PET scans was approved by the Administration of Radioactive 
Substances Advisory Committee, United Kingdom. 
5.2.2.2: Imaging Protocol 
 
 The patients were scanned on a Siemens Biograph 6 TruePoint PET/CT 
scanner (specifications given in previous section), after being positioned such that 
the field of view (FOV) included the primary tumour (thorax). This was followed by a 
helical CT scan (settings: 30 mAs, 0.6 sec rotation. 1.5 pitch) over the region of the 
thorax which was used for attenuation correction and accurate anatomical 
localisation. [18F]D4-FCH was administered by a bolus intravenous injection (up to 
370 MBq) over 10 to 30 seconds. Dynamic PET scanning (3-dimensional 
acquisition) was commenced over a single bed position covering the thorax for 65 
minutes. This was followed by a static whole body sweep (vertex to mid thigh) 
attenuation CT and PET scan (around 25 min, depending on the height of the 
patient; 3 min per bed position).  
5.2.2.3: Image Analysis 
 
 Raw PET data were corrected for scatter and attenuation, and reconstructed 
with an iterative OSEM (ordered subset expectation maximum) algorithm 
comprising 8 iterations and 21 subsets. Decay corrected dynamic images were then 
viewed using Analyze® software (Analyze Version 11; Biomedical Imaging 
Resource, Rochester, MN, USA). From summed images, VOIs were drawn 
manually around the primary tumours in the lung, any visible metastatic lesions and 
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normal lung.  The [18F]D4-FCH radioactivity concentration within the VOIs was then 
determined and normalised for injected radioactivity and body weight to obtain SUV. 
The average and maximum SUV at 60 minutes (SUV60, ave, and SUV60, max) were 
then determined. The static whole body images of [18F]D4-FCH and [18F]FDG were 
analysed using Hermes diagnostic software (Sweden). The primary tumours and 
distant metastatic lesions were outlined using an automated isocontour adjusted to 
41% of the maximum pixel intensity in the region (Kobe, Scheffler et al. 2012). The 
nodal lesions were outlined manually. 
5.2.2.4: Statistical Considerations 
 
 As this is an exploratory study, there will be no power calculations involved 
for an estimate of the sample size. Based on previous studies with similar 
fluorinated radiotracers, it was estimated that 25 patients will be sufficient to provide 
initial estimates of the magnitude of tracer uptake. Hence it was intended to use a 
sample size of 25. Up to 30 patients may be enrolled to account for dropouts. 
 The mean (± SD) was used as the primary descriptive measure. The 
significance of differential uptake in tumour and normal lung was assessed by 
Mann-Whitney test. P ≤ 0.05 was considered significant. Statistical analyses were 
performed using Graph-Pad™ Prism (USA).  
5.2.3: Results 
 
5.2.3.1: Patients 
 
Five patients were recruited so far, out of whom 3 had [18F]FDG scans as 
part of their routine staging. The patient characteristics are given in Table 28. All 
patients tolerated the [18F]D4-FCH PET/CT scans without any complications. The 
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mean (±SD) injected activity of [18F]D4-FCH was 260.9 (±100.5) MBq with a 
radiochemical purity of >95%. 
5.2.3.2: Imaging characteristics of [18F]D4-FCH uptake  
 
 On visual analysis all the lung tumours were visible above the background 
(Figure 53a).  The liver metastases, in one patient were photopenic 
(adenocarcinoma) and in the other it showed a higher uptake (squamous cell 
carcinoma) relative to normal liver background (Figure 54). Physiological activity 
was seen in the salivary glands, liver, kidneys, pancreas and the bladder. 
 223 
 
Table 28: Patient Characteristics 
     [
18
F]D4-FCH Dynamic Scan [
18
F]D4-FCH Static Scan [
18
F]FDG Static Scan 
Pt. No Sex 
TNM  
Stage 
Histology Lesion SUV60,ave SUV60,max SUV60,ave SUV60,max SUV60,ave SUV60,max 
1 F T3bN2M1b 
Adeno 
carcinoma 
Pri Tumour 4.78 8.46 4.73 8.64   
    Satellite nodule 7.65 11.14 7.18 13.72   
    Normal Lung 0.19 0.67 0.19 0.67   
    Scapular Met 7.78 10.62 7.17 10.64   
    Scalp Met   6.73 10.56   
    Liver Met   6.36 8.36   
    Liver   12.31 17.84   
2 F T4N1M0 SqCC Pri Tumour 5.69 8.96 6.06 10.13   
    Hilar node 6.37 9.51 7.17 9.75   
    Normal Lung 0.17 0.58 0.17 0.58   
    Liver Met   8.83 12.7   
    Liver   5.52 8.15   
3 M T2aN0M0 SqCC Pri Tumour 2.95 5.72 2.95 6.14 7.46 11.95 
    Paratracheal node* 2.7 4.25 3.42 5.11 2.38 2.82 
    Hilar node* 2.18 3.28 3.01 4.32 2.04 2.19 
    Normal Lung 0.6 0.99 0.6 0.99   
4 F T1bN1M0 SqCC Pri Tumour 2.9 4.53 3.46 5.41 7.1 10.77 
    Hilar node† 2.35 2.92 2.41 3.13 4.48 6.12 
    Normal Lung 0.71 1.02 0.71 1.02   
5 M T4N1M0 SqCC Pri Tumour 5.06 7.79 5.47 9.15 8.02 14.1 
    Normal Lung 1.13 1.86 1.13 1.86   
M-Male, F-Female, SqCC- Squamous cell carcinoma, Pri - Primary, Met – Metastasis. * No nodal metastatic deposits on histology after surgery. † Nodal 
metastases present on histology after surgery.
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Figure 53: Axial slices of the CT, PET and fused PET/CT showing uptake of [
18
F]D4-
FCH and [
18
F]FDG in a right upper lobe primary lung tumour in the same patient.  
Visually, the uptake of [
18
F]D4-FCH (a) in the primary tumour (red arrow) appears lower than 
that of [
18
F]FDG uptake (b).  
 
Figure 54: Axial slices of the PET and fused PET/CT showing uptake of [
18
F]D4-FCH in 
the liver metastases of two patients.  
In one patient the metastasis (red arrow) is photopenic (a) and in the other it shows a higher 
uptake relative to normal liver background (b). The images are windowed to 50% of the 
maximum intensity. 
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5.2.3.3: Kinetics of [18F]D4-FCH uptake 
 
The mean SUV60,max (±SD) for the primary tumours was significantly higher 
than that of the normal lung; 7.89 (±2.02), and 0.99 (±0.55), respectively. The 
distant metastatic lesions had a higher uptake than the primary tumours, with a 
mean SUV60,max (±SD) of 11.2 (±2.09). Dynamic time activity curves (TAC’s) for 
[18F]D4-FCH in primary lung tumours (Figure 55) and the nodal metastases 
demonstrated a good retention of activity after plateauing at ~30 min until 60 min 
with SUVave and SUVmax.  
 
Figure 55: Kinetics of [
18
F]D4-FCH uptake in tumours and normal lung.  
The time activity curves show good retention and plateauing of uptake after 30 min of tracer 
injection (a, b). There is a significant difference between uptake of [
18
F]D4-FCH in the 
tumour and normal lung (c). The bar represents the mean SUV. 
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5.2.3.4: Comparison with [18F]FDG 
In the three patients who routinely had [18F]FDG PET/CT as part of their 
staging, the [18F]FDG uptake (SUV60,max) was higher than that of [
18F]D4-FCH 
uptake. Interestingly, the reactive paratracheal and hilar nodes (mediastinoscopy 
proven) in patient 3 showed a higher uptake with [18F]D4-FCH (Table 28). 
5.2.4: Discussion 
 
The early preliminary results of [18F]D4-FCH PET/CT have shown that 
imaging primary lung tumours is feasible. The kinetics of tumour [18F]D4-FCH 
uptake were rapid, reaching a plateau within 30 min, suggesting that earlier time 
points could be explored to enhance patient comfort and improve PET count 
statistics. The higher uptake seen in the distant metastatic lesions suggests that 
more aggressive disease may have higher CHK expression. This hypothesis 
however, needs further evaluation and correlation with CHK expression. The 
different appearance of the liver metastases in patients with adenocarcinoma and 
squamous cell carcinoma also requires further evaluation. 
The discordance in the uptake of [18F]FDG compared to that of [18F]D4-FCH 
could be the reflection of the mechanism of tracer accumulation;  [18F]FDG uptake 
relating to rate of glycolysis and the [18F]D4-FCH uptake relating to rate of cell 
membrane synthesis (Khan, Oriuchi et al. 2003).  
PET imaging with [18F]FDG, has allowed more accurate detection of both 
nodal and distant metastatic disease (Pieterman, van Putten et al. 2000; 
Vansteenkiste and Dooms 2007). Staging [18F]FDG PET/CT has been shown to 
reduce futile thoracotomies compared to conventional work up (van Tinteren, 
Hoekstra et al. 2002) and to be cost effective (Verboom, van Tinteren et al. 2003). 
However the performance of [18F]FDG PET/CT in the evaluation of nodal disease is 
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limited by false positives in reactive nodes such that patients with equivocal N2 
nodal disease on PET/CT require mediastinal nodal sampling confirmation (2011). 
Therefore, there is a clinical need for more specific PET tracers. 
An early study by Hara et al, comparing  [11C]choline and [18F]FDG PET for 
the detection of mediastinal lymph node metastases in 29 patients prior to surgical 
thoracotomy and ipsilateral nodal dissection, reported excellent results with 100% 
sensitivity of choline PET (Hara, Inagaki et al. 2000). However this sensitivity may 
be overestimated by the low SUV criteria used for detection of disease.  Two similar 
small studies have shown discrepant results reporting [11C]choline to be less 
sensitive than FDG PET for nodal disease but superior for the detection of 
metastatic disease (Pieterman, Que et al. 2002; Khan, Oriuchi et al. 2003). Notably 
these studies were all on PET only cameras. However, more recently when the 
diagnostic performance of [11C]choline PET/CT was evaluated against the standard 
CECT, a higher accuracy of [11C]choline PET/CT for nodal staging was reported but 
not for primary lesion characterisation (Peng, Liu et al. 2012; Li, Peng et al. 2013). 
Given the uptake of [18F]D4-FCH in reactive nodes, the diagnostic performance of 
[18F]D4-FCH in nodal staging remains to be assessed.  
CHK has been linked to proliferation index and survival outcome in lung 
cancer (Ramirez de Molina, Sarmentero-Estrada et al. 2007). A moderate 
correlation between [11C]choline uptake and CHK expression has been shown in a 
study of  53 patients with NSCLC, thus establishing the biological basis of choline 
uptake in lung cancer (Li, Peng et al. 2013). Therefore, [18F]D4-FCH PET/CT could 
be used as a noninvasive surrogate for CHK expression and thus potentially used 
as a prognostic marker and for predicting patient outcome. It is also envisaged that 
[18F]D4-FCH PET/CT could play a further role in selection and/ or evaluation of lung 
cancer patients for targeted therapy. 
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CHAPTER 6: [
18
F]ICMT-11, a caspase-3 specific PET 
tracer for apoptosis: Biodistribution and radiation 
dosimetry 
 
Rationale 
 
Apoptosis is an essential process for eliminating unwanted cells during 
embryonic development, growth, differentiation, and maintenance of tissue 
homeostasis. Apoptosis is regulated by both intrinsic (via mitochondria) and 
extrinsic (activation of death receptors) signaling networks that control a family of 
enzymes known as caspases (cysteine aspartate specific proteases) (Nicholson 
and Thornberry 1997; Degterev, Boyce et al. 2003). The pathways activate “initiator” 
caspases 8 (extrinsic) or 9 (intrinsic), which in turn cleave the inactive pro-caspases 
3, 6, and 7 into the active “executioner” caspases-3, -6, and -7 (Okada and Mak 
2004). Deregulation of apoptosis signaling pathways is therefore associated with 
various pathologies including autoimmunity, neuro-degeneration, cardiac ischemia, 
and transplant rejection (Reed 2002), and the capacity to evade apoptosis has been 
defined as one of the hallmarks of cancer (Hanahan and Weinberg 2000).  
In cancer, apoptosis is induced by a large variety of stimuli including 
cytotoxic and mechanism-based therapeutics, and radiotherapy. Although those 
stimuli trigger different apoptotic signaling pathways, the molecular events in the 
execution phase of apoptosis are largely shared and involve caspases. Within the 
caspase family, the effector caspases (caspases-3, -6, and -7) orchestrate the 
demolition phase of apoptosis that results in the controlled dismantling of a range of 
key structures within the cell and its subsequent disposal (Taylor, Cullen et al. 
2008). Moreover, one of the most noticeable and specific features of apoptosis is 
the degradation of the DNA into numerous fragments, often down to multiples of 
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200 base pairs, driven by the activation of caspase-3 (Porter and Janicke 1999), the 
central effector caspase, which makes it an attractive biomarker of apoptosis. 
Effective anticancer therapy often requires induction of tumour cell death 
through apoptosis. Monitoring of this process could provide important predictive 
outcome information in the context of routine patient management and early clinical 
trials (Dubray, Breton et al. 1998; Chang, Ormerod et al. 2000). Apoptotic index has 
been shown to correlate with chemotherapy efficacy and has been shown to be of 
prognostic significance (Faried, Sohda et al. 2004; Jia, Dong et al. 2012). A 
noninvasive apoptosis imaging technology such as PET could permit the detection 
of biological changes in the tumour that evolve over hours of initiating treatment. 
This is in contrast to changes in tumour size that evolve over months, which forms 
the basis for Response Evaluation Criteria in Solid Tumours (RECIST 1.1) 
guidelines (Eisenhauer, Therasse et al. 2009).  
Based on various biochemical events that characterize apoptosis, a number 
of positron emitting radiotracers have been developed to noninvasively detect this 
process, both in preclinical studies and in humans (Nguyen, Challapalli et al. 2012). 
[18F](S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4 
difluorophenoxymethyl)-pyrrolidine-1-sulfonyl) isatin ([18F]ICMT-11) was designed 
as a small molecule radiotracer with potential advantages such as facile 
radiolabelling and improved biodistribution and clearance profiles. It has been 
characterised as a novel reagent designed to noninvasively image caspase-3 
activation and, hence, drug-induced apoptosis. [18F]ICMT-11 was validated as a 
caspase-3 specific PET imaging radiotracer for the assessment of tumour apoptosis 
preclinically in murine lymphoma xenografts treated with cyclophosphamide 
(Nguyen, Smith et al. 2009).  
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The promising mechanistic and biological profile of [18F]ICMT-11 supports its 
transition into clinical development (Nguyen, Challapalli et al. 2012).  
In order to translate the pre-clinical findings into humans, this study in 
healthy volunteers was designed with the following aim: 
 To evaluate the biodistribution, dosimetry and safety of [18F]ICMT-11 in 
healthy volunteers. 
Materials and Methods 
Radiopharmaceutical Preparation 
 
[18F]ICMT-11 was synthesised from the precursor as previously described 
(Fortt, Smith et al. 2012). The radiochemical purity of [18F]ICMT-11 was 100% with a 
mean (±SD; range) specific activity of 1951.5 GBq/μmol (±4084; 110-12032 
GBq/μmol: the high specific activity in one subject was due to a lower cold 
concentration of [18F]ICMT-11, below the limit of quantification) and a pH of 5.41 
(±0.16; 5.16-5.71).  
Subjects 
 
Eight healthy volunteers (4 men, 4 women), with a mean (±SD; range) age 
of 63.1 yrs (±2.58; range: 59-68 yrs), and weighing an average of 74 kg (±15.4; 
range: 52.1-98.7 kgs) were enrolled. The main inclusion and exclusion criteria for 
this study were the same as that used for the study discussed in chapter 5, section 
5.1. No specific subject fasting/ food protocol was implemented. Ethical approval for 
the study was granted by the West-London Research Ethics Committee. All 
volunteers gave written informed consent to participate in the study, according to 
the Declaration of Helsinki guidelines. The administration of radioactivity for the 
PET/CT scans was approved by the Administration of Radioactive Substances 
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Advisory Committee, United Kingdom. MHRA has approved this study as a non- 
IMP study. 
Safety, Image acquisition, analysis and dosimetry 
 
Collection of safety data, image acquisition protocol, image analysis, 
measurement of blood and urine radioactivity and the dosimetry calculations were 
performed as previously described in Chapter 5. The mean (±SD; range) injected 
[18F]ICMT-11 activity and ICMT-11 cold dose in the subjects were 159 MBq (±3; 
154-161 MBq) and 2.18 μg (±1.39; 0.1–4.44 μg) respectively. 
For each subject and for each source region, the non-decay-corrected 18F 
activity concentration over the 6 time points (time-activity curve: TAC) was 
generated. The total number of disintegrations in each organ normalised to injected 
activity (subsequently referred to as the Residence Time (RT; ): kBq.hour/kBq) 
were calculated as follows (Eq. 12): 
activityInjectedAUC V organ /)(     Equation 12 
 
where AUC is the time integral of the non-decay corrected TAC, Vorgan the tabulated 
organ volume as used in OLINDA/EXM version 1.1 (Stabin, Sparks et al. 2005). For 
most organs, the AUC included a contribution beyond the scan duration assuming 
no further activity redistribution. For bladder, the measured voided activities were 
also included to form an extended 8 time point TAC (Figure 56).  The bladder TAC 
was modelled according to (Eq. 13) 
A(1− e
− Bt
)e
− Ct
− ∑ i Ai e
− λ (t− ti)
   Equation 13 
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where A, B, C are the estimated parameters, t the time since administration of the 
tracer, Ai the urine radioactivity voided at time ti (Graham, Peterson et al. 1997; 
Thomas, Stabin et al. 1999). Residual bladder activity was not included in the model 
since it was not known if complete voiding had occurred for these subjects, although 
any residual activities must have been small compared to the voided activities. The 
sum of the squared differences between the function and the extended TAC was 
minimised for each subject using the solver function in Excel 2010 (Microsoft, Inc., 
Redmond, WA). Across all 8 subjects the AUCs derived from the fitted function 
matched the measured AUCs calculated above with a fractional mean difference of 
-3% and standard deviation of 6%. The decay constant C is usually assumed to be 
the same as λ on physical grounds but in this case a larger value was observed. 
This may be attributed to activity becoming trapped in other tissues of the body, 
most notably the gall bladder. As a result, for t greater than 5 hours, Eq 13. predicts 
a faster decline in bladder activity than is physically possible. This is however, 
beyond the observation time in the present study for which the bladder activity 
accumulation rate was always positive and was predicted to be very small after 4 
hours. The fitted functions were extrapolated to estimate the bladder RT for each 
subject for the following voiding scenarios: complete bladder voids every hour, 
every 2 hours, and every 4 hours post tracer administration. Finally the RT of the 
remainder term (assumed to be homogeneously distributed in the body) was 
obtained by subtracting the sum of all defined organ RTs from the inverse of the 
decay constant for 18F. The internal radiation dosimetry was calculated from the   
for the organs in each subject, whihc was provided as input to the OLINDA/EXM 
version 1.1 (Stabin, Sparks et al. 2005).  
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Figure 56: Representative bladder fits for a subject.  
 
(a) The measured image and urine sample derived time activity curves (TACs) for one 
subject and the fitted function Eq. 2 (both shown uncorrected for radioactive decay). The 
fitted functions extrapolated to the following voiding scenarios: complete bladder voids (b) 
every hour, (c) every 2 hours, and (d) every 4 hours post tracer administration.  
 
 
 
Statistical Considerations 
 
There was no formal sample size calculation performed for this study. Based on the 
biodistribution studies published in the literature, a total of 8 evaluable healthy 
volunteers (with a minimum of 3 females) were recruited.  Descriptive statistics were 
used for biodistribution data and absorbed doses to the target organs.  
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Results  
 
Safety 
 
[18F]ICMT-11 was found to be safe and well tolerated in all subjects. No 
tracer related serious AEs or AEs were observed in relation to [18F]ICMT-11 
injection. Three of the eight subjects had a total of 4 non-tracer related AEs (grade 
1), including headache, transient blurring of vision, transient fluctuations in blood 
pressure, and neutropenia (associated with a concurrent eye infection) which 
resolved spontaneously within 24-48 hours. No significant changes in vital signs, 
clinical laboratory blood tests or electrocardiograms were observed. The safety 
results were reviewed by an independent data monitoring committee. 
Biodistribution 
 
Following the administration of [18F]ICMT-11, radioactivity was initially 
detected in the vascular compartment and then rapidly distributed to the liver and 
kidneys, followed by rapid elimination through the kidneys and the hepatobiliary 
system. About 18% of the injected activity (decay corrected back to injection time) 
was eliminated within the first 4 hours through the kidneys (9% in the first hour, 14% 
after 2 hours). Radioactivity was already detectable in the urinary bladder at 8 min 
after tracer administration. The initial radioactivity uptake in the liver was gradually 
cleared approximately 3 h after injection. At about 30 minutes after the [18F]ICMT-11 
injection, there was a gradual increase in accumulation of radioactivity in the gall 
bladder and bowel. Typical images illustrating tracer uptake at various time points 
from two representative subjects are shown in Figure 57 a, b. TACs were 
generated for various organs (Figure 58). There were no differences in the 
biodistribution profiles between men and women. The mean RTs for male and 
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female subjects are summarised in Table 29. The residence time contribution from 
the extrapolated part of AUC beyond the last time point for imaging accounted for 
40% of the total residence time, contributing to 65% of the total ED and 57% of total 
EDE. 
 
 
 
Figure 57: A series of whole body maximum intensity projection (MIP) images of 
representative subjects  
MIPs show biodistribution of 
18
F activity following tracer injection up to 219 min post injection 
of [
18
F]ICMT-11. (a) Biodistribution of 
18
F activity in a subject who had a meal 2-3 hours prior 
to tracer injection; Note, the rapid clearance of radioactivity in the cranium and thorax 
approximately 20 min after tracer injection. There is accumulation of radioactivity in the gall 
bladder and bowel from about 30 min after tracer injection. (b) Biodistribution of 
18
F activity 
in a subject who had a meal just before tracer injection (due to delays in tracer production); 
The notable difference, compared to (a), is the reduced physiological activity in the liver at 
earlier time points and increased activity in the bowel at later time points. 
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Figure 58: Mean non-decay corrected time-activity curves (TACs) normalised to 
injected activity (kBq) and body weight (grams), for [
18
F]ICMT-11.  
TACs were generated for several organs at various time points up to 4 hours after tracer 
administration in (a) the elimination organs (renal and hepatobiliary system), (b) the bowel 
(small intestine, upper and lower large intestine), (c) cranium and thorax, and (d) organs 
with potential physiological apoptosis (gonads, spleen and bone marrow). Error bars 
represent one standard deviation from the mean and are shown one-sided for clarity. 
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Table 29: Mean Residence Times ( ) of [18F]ICMT-11 for different organs in Male (n=4) 
and Female (n=4) Volunteers. 
 
   (kBq.h/ kBq) - Males   (kBq.h/ kBq) - Females 
Organ Mean SD Mean SD 
Adrenal 0.001 0.0001 0.001 0.001 
Bladder*  0.127 0.020 0.120 0.033 
Brain 0.001 0.0004 0.001 0.0003 
Breast   0.004 0.002 
Gall Bladder 0.369 0.407 0.321 0.143 
Heart contents 0.006 0.001 0.005 0.0004 
Heart wall 0.006 0.002 0.004 0.001 
Kidney 0.021 0.004 0.019 0.011 
Liver 0.381 0.062 0.351 0.130 
LLI 0.004 0.001 0.005 0.004 
Lung† 0.018 0.007 0.012 0.007 
Muscle 0.255 0.025 0.170 0.043 
Ovaries‡   0.0003 0.00002 
Pancreas 0.007 0.006 0.005 0.005 
Red marrow 0.026 0.022 0.013 0.003 
Small Intestine 0.449 0.202 0.514 0.306 
Spleen 0.003 0.0004 0.002 0.001 
Stomach 0.005 0.002 0.003 0.001 
Testis 0.001 0.0001   
Thyroid 0.000 0.00004 0.0001 0.00003 
ULI 0.214 0.242 0.039 0.064 
Uterus   0.005 0.001 
Thymus 0.0001 0.00003 0.0003 0.0001 
Remainder 0.745 0.321 1.059 0.200 
LLI-lower large intestine, ULI-upper large intestine, SD-standard deviation  
*Bladder residence time is for a 2-hour voiding scenario. 
†Lung activity was corrected for tissue density value of 0.33 g/ml and other organs with a 
density value of 1 g/ml. 
‡In two subjects ovaries were not visible due to post-menopausal atrophy. 
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Dosimetry 
 
Table 30 summarises the mean organ absorbed dose estimates for 
[18F]ICMT-11 injection. The mean effective dose averaged over both males and 
females (±SD) was estimated to be 0.025±0.004 mSv/MBq (male 0.022±0.004; 
female 0.027±0.004). The 5 organs receiving the highest absorbed dose 
(mGy/MBq), averaged over both males and females (±SD) were the gall bladder 
wall (0.59±0.44), small intestine (0.12±0.05), upper large intestinal wall (0.08±0.07), 
urinary bladder wall (0.08±0.02), and liver (0.07±0.01). The values quoted are 
based on the 2-hour bladder voiding scenario. This is likely to be conservative in 
routine imaging scenarios where subjects would be encouraged to consume 
moderate quantities of fluids and empty their bladders regularly as done for 
[18F]FDG studies. If the 4-hour voiding scenario were used, this would increase the 
bladder wall absorbed dose by 64% (increase of 0.05 mGy/MBq: averaged for male 
and female). 
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Table 30: Mean organ absorbed dose estimates expressed in mGy/MBq for [
18
F]ICMT-
11 (n=8) with bladder voiding scenarios. 
 
 
Mean Absorbed  
Dose estimates 
Mean Absorbed  
Dose estimates 
 (mGy/MBq) (mGy/MBq) 
Bladder Voiding 
2-hr voiding 
scenario 
4-hr voiding  
scenario 
Organ Mean SD Mean SD 
Adrenals 0.022 0.005 0.022 0.005 
Brain 0.003 0.001 0.002 0.001 
Breasts 0.006 0.001 0.006 0.001 
Gall Bladder wall 0.594 0.446 0.593 0.446 
LLI wall 0.021 0.006 0.022 0.006 
Small Intestine 0.122 0.056 0.122 0.056 
Stomach wall 0.016 0.002 0.016 0.002 
ULI wall 0.084 0.071 0.084 0.071 
Heart wall 0.012 0.001 0.012 0.001 
Kidneys 0.027 0.005 0.027 0.005 
Liver 0.065 0.016 0.065 0.016 
Lungs 0.010 0.002 0.010 0.002 
Muscle 0.010 0.001 0.010 0.001 
Ovaries 0.025 0.007 0.026 0.007 
Pancreas 0.029 0.008 0.029 0.008 
Red marrow 0.012 0.001 0.012 0.001 
Osteogenic cells 0.012 0.003 0.012 0.003 
Skin 0.006 0.001 0.006 0.001 
Spleen 0.011 0.001 0.011 0.001 
Testes 0.007 0.000 0.008 0.000 
Thymus 0.007 0.001 0.007 0.001 
Thyroid 0.005 0.001 0.005 0.001 
Urinary Bladder wall 0.080 0.019 0.131 0.031 
Uterus 0.028 0.009 0.030 0.009 
Total body 0.013 0.002 0.013 0.002 
Mean ED 
(mSv/MBq) 
0.025 0.004 0.026 0.004 
   LLI-lower large intestine, ULI-upper large intestine, ED-effective dose 
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Effect of Food 
 
 Three of the 8 subjects had a meal just before the tracer injection due to 
delays in tracer production and scan scheduling on the day. Interestingly, in those 3 
subjects, the distribution of radioactivity in the abdomen was notably different when 
compared to the other subjects (Figure 57b). The intake of food has reduced 
physiological activity in the liver at earlier time points and increased activity in the 
bowel (changed the absorbed dose as follows: Stomach (5% decrease), SI (79% 
increase), ULI (197% increase) and LLI (25% increase) at later time points. This is 
consistent with normal postprandial physiology, with emptying of gall bladder 
content (bile juice) to aid digestion. This is also demonstrated in the TAC profiles of 
the elimination organs (Figure 59). However, there was no difference in the other 
organs and in the plasma 18F activity concentrations.  
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Figure 59: Mean time-activity curves (TACs; normalised to injected activity (kBq), 
body weight (grams) and uncorrected for radioactive decay) and plasma 
18
F 
radioactivity concentrations for [
18
F]ICMT-11 in subjects who had a meal and in 
subjects who did not have a meal prior to tracer injection.  
There was a difference in the TAC profiles of (a) Liver, (b) Gall Bladder, (c) Small intestine, 
(d) Upper large intestine and (e) Urinary bladder, but no difference in the (f) Kidneys, (g) 
Spleen or the (h) plasma 
18
F radioactivity concentrations. Error bars represent one standard 
deviation from the mean and are shown one-sided for clarity. 
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Discussion 
 
This first in human study has shown that the caspase-3 specific apoptosis 
imaging agent [18F]ICMT-11 is safe and well tolerated. Injection of [18F]ICMT-11 led 
to rapid washout of the 18F activity from the vascular compartment and elimination 
primarily via the renal and hepatobiliary routes. Renal excretion (18% in 4 hours) 
was comparably lower than for routinely used radiotracers such as [18F]FDG (30%) 
(Jones, Alavi et al. 1982; 1998) and [18F]Fluorodihydroxyphenylalanine 
([18F]FDOPA) (31%) (Brown, Oakes et al. 1998). In contrast, tracer localisation 
within the gall bladder was relatively high, with slow washout into the 
gastrointestinal tract.  
 The mean ED of [18F]ICMT-11 was 0.025 mSv/MBq, which is comparable 
with the ED of [18F]FDG (0.019 mSv/MBq) (1998).  The dose limits specified in the 
Code of Federal Regulations (USA) per single administration of a radioactive drug 
for research purposes, are 30 mSv to the whole-body, blood-forming organs, lens of 
the eye, and gonads, with a maximum annual dose of 50 mSv. The maximum 
allowable single and annual dose to all other organs are 50 and 150 mSv, 
respectively (2012). If a 370 MBq administered radioactivity for [18F]ICMT-11 (typical 
of many PET tracers) was assumed, the ED would be 9.3 mSv. For this 
administered radioactivity level, the equivalent dose received by the gonads would 
be estimated as 1.9 mSv. These are well within the dose limits specified above.  
Regarding radiotracer uptake in normal adult tissues with potentially high 
intrinsic apoptosis, increased [18F]ICMT-11 uptake was not seen in testes. 
Apoptosis plays a significant role in normal testicular physiology and up to 75% of 
the spermatogonia die by apoptosis before reaching maturity thus regulating sperm 
production, a phenomenon that is accentuated in patients with infertility (Martincic, 
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Virant Klun et al. 2001). The biodistribution study of [18F]ML-10, a small molecule 
apoptotic tracer, demonstrated a distinct pattern of uptake in the testes (Hoglund, 
Shirvan et al. 2011). However, the biodistribution studies of annexin-V based 
radiotracers, (99mTc-annexin-V, 99mTc-hydrazino nicotinate (HYNIC)-annexin-V and 
99mTc-4,5-bis thioacetoamide pentanoyl (BTAP)-annexin-V) did not show increased 
uptake in the testes, with the absorbed dose in the testes ranging from 0.005 – 
0.015 mGy/MBq (Kemerink, Boersma et al. 2001; Kemerink, Liem et al. 2001; 
Kemerink, Liu et al. 2003). This is comparable to the absorbed testes dose 
observed with [18F]ICMT-11 (0.007 mGy/MBq). The significantly increased uptake of 
[18F]ML-10 in testes could be attributed to the young age of the male volunteers 
enrolled in the study (mean; 23 years, range 21-44 yrs). The average age of the 
male volunteers in the 99mTc-annexin-V, and 99mTc-BTAP-annexin-V  biodistribution 
studies was 53 years, which is comparable to the age range in our study (63.1 yrs 
(±2.58; range: 59-68 yrs)). There is a strong relationship between testicular 
apoptotic index and age (Ng, Donat et al. 2004; Schmelz, Meiswinkel et al. 2005), 
with a reduction in semen volume by nearly 50% and reduced sperm production 
(Johnson 1986) with increasing age. This suggests a decrease in the physiological 
apoptosis with increasing age, which could explain the lack of significant uptake 
seen in the testes with [18F]ICMT-11.  
There was uptake of [18F]ICMT-11 in the bone marrow, with a mean 
absorbed dose of 0.012 mGy/MBq. This is comparable to that of 99mTc-HYNIC-
annexin-V (0.004 – 0.008 mGy/MBq) (Ohtsuki, Akashi et al. 1999; Kemerink, Liu et 
al. 2003), suggesting that the marrow uptake was physiologic, since apoptotic cell 
death is a physiologic component of normal hematopoiesis (Domen 2000). 
While no specific instructions were given to the subjects to fast prior to the 
scan, in three of the subjects who had a meal before the scan, there was notably 
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reduced physiological activity in the liver at earlier time points and increased activity 
in the bowel at later time points. The impact of food appeared to be restricted to the 
hepatobiliary and intestinal elimination organs as no differences in the TACs from 
other organs or the plasma 18F radioactivity were observed. This interesting 
observation suggests that abdominal imaging could be facilitated by incorporating a 
standard pre-scan meal and/or a pro-motility agent to help clear out the bowel 
activity and improve the signal to background ratio.  
 In summary, [18F]ICMT-11 injection is safe and well tolerated with a 
favourable  dosimetry profile in healthy volunteers. Organ dose estimates are similar 
to that seen with other routine [18F]labelled tracers. The potential risks due to 
radiation are within accepted limits. Further clinical studies are now warranted to 
evaluate the utility of [18F]ICMT-11 in measuring the effects of treatment on tumour 
apoptosis.  
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Summary and Future Directions 
 
This thesis has demonstrated the ability of the newer PET radiotracers, 
[18F]FLT and [11C]choline to image cell proliferation, characterise various tumour 
phenotypes and to be used as imaging biomarkers for early response evaluation. 
Furthermore, a more stable novel choline analogue [18F]D4-FCH, was successfully 
translated for clinical imaging. The elucidation of the biological basis of tracer 
uptake provides important information about the tumour biology. The improved 
diagnostic performance of these tracers would aid in decision making of the delivery 
of appropriate treatment. The early metabolic changes with therapy could potentially 
enable the treating oncologist to help stratify and tailor the patients’ treatment and/ 
or consider alternative treatment options, if required. This would prevent exposure 
of patients to unnecessary treatment related morbidity and thus, improve their 
quality of life. These novel noninvasive imaging biomarkers could be used in 
conjunction with the existing generic tumour biomarkers as an aid to the existing 
diagnostic and decision making process. 
The main outcomes of studies done as part of this thesis are as follows: 
Chapter 2 
The use of the novel kinetic filtering method (KSF) enabled visual distinction 
between tumours and normal pancreas, liver. All the primary pancreatic tumours 
were visualised and of the 11 liver metastases, 8 were visible after kinetic filtering. 
As seen previously (Contractor, Challapalli et al. 2012) the KSF has a detection rate 
of ~73% for liver metastases. Similarly, the larger liver metastases showed a central 
core of almost no FLT uptake surrounded by a rim of uptake at the periphery. This 
suggests that the rim of proliferation phenotype of the liver metastases is 
independent of the site of origin of the primary tumours. FLT uptake was quantified 
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by semi-quantitative measures and it was seen that SUV60,max significantly increased 
in the non-responders (p=0.04). The voxel analysis to explore the detailed changes 
of FLT uptake in tumours revealed that high intensity voxel occurrences decreased 
with chemotherapy. This supported the mechanism of action of chemotherapeutic 
agents which act on rapidly proliferating cells to cause their anti-tumour and anti-
proliferative effects. The persistence of the low intensity voxels (lack of change in 
activity with therapy), on the other hand, may explain why these tumours progress. 
To summarise, FLT PET/CT and FLT PET/CTKSF detected changes in proliferation, 
with early changes in SUV60,max being a negative predictor for response. Therefore, 
FLT PET/CT could be used as a response biomarker for gemcitabine based 
chemotherapy and to evaluate efficacy of novel therapeutic agents in advanced 
pancreatic cancer. 
Since the tumours, not within the predefined range of the defined tumour 
class in the filtering algorithm were completely filtered out, future studies should 
involve pooling together of the missing patients’ datasets to refine the limits set by 
the filter in tumours. This would improve the detection rate. In view of the 
encouraging results and the proliferation phenotype of the liver metastases being 
independent of the site of origin of the tumours, the KSF application could be 
extended to characterise other tumours. To this effect, a study is underway to image 
cell proliferation in HCC using FLT PET/CTKSF.  
 
Chapter 3  
Dynamic PET/CT imaging of prostate tumours with [11C]choline 
demonstrated a good retention of activity after plateauing (achieving a steady state) 
at ~15 min until 60 min with SUVave.  However, with SUVmax there was a suggestion 
of increasing activity at 60 min which could be due to the contribution of 
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[11C]betaine. Out of the 406 lymph nodes assessed, in 26 patients, 27 (6.7%) 
involved pelvic nodes at eLPL were detected in 9 patients. 17 out of these 27 nodes 
were sub-centimetre. The sensitivity and specificity on a per nodal basis were 18.5 
% and 98.7%, 40.7% and 98.4 %, and 51.9% and 98.4% for MRI, [11C]choline PET 
and [11C]choline PET/CT, respectively. Sensitivity was higher for [11C]choline 
PET/CT compared with  MRI (p=0.007). This study established the feasibility of 
using [11C]choline PET/CT as a noninvasive means of staging pelvic lymph nodes in 
high risk prostate cancer, being highly specific and more sensitive than PET alone 
or MRI including the detection of sub-centimetre disease.  The high specificity could 
potentially be helpful clinically in terms of selecting out patients who may not require 
pelvic radiotherapy. The use of [11C]choline PET/CT in patients with node positive 
disease could help in the integration with radiotherapy planning to allow the 
potential for dose escalation to nodal disease using Intensity Modulated 
Radiotherapy while avoiding unnecessary inclusion of normal healthy tissues.  
Quantitative analyses of the [11C]choline breast data using arterial IF showed 
that irreversible kinetics account for [11C]choline uptake in breast tumours. The use 
of a validated population-based total plasma IF from the breast data, predicted that 
irreversible kinetics also account for [11C]choline uptake in prostate cancer, thus 
further validating the limited venous sampling approach (Contractor, Kenny et al. 
2012).  
In order to establish the biological basis of [11C]choline uptake in prostate 
cancer, IHC of the 29 malignant prostate cores and 7 nodal sections was performed 
with CHKα and Ki-67 antibodies. A spectrum of cytoplasmic CHKα expression was 
seen in the pre-malignant and malignant lesions. This study showed for the first time 
that tumour radiolabelled choline uptake is closely related to CHKα expression in 
prostate cancer, suggesting that [11C]choline PET/CT could be used as a 
noninvasive surrogate for CHK expression. Both semi-quantitative parameters of 
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choline uptake in tumours correlated well with CHKα scores (best with SUV60,ave 
r=0.7, p<0.0001). Interestingly, the CHKα expression was found to be a proliferation 
independent phenotype in prostate cancer, unlike that seen in breast cancer 
(Contractor, Kenny et al. 2011).  
Based on the interesting observations seen in the malignant prostate cores 
of patients who had [11C]choline PET/CT, further cores of prostate tissue from 75 
patients diagnosed with prostate cancer (malignant) and 25 patients with no 
prostate cancer (normal) were subsequently analysed. There was increased 
expression of CHK (mild staining intensity) in up to 28% of the normal prostate 
cores and the benign cores in a malignant prostate. This was supported by the 
increased CHKα gene expression in the normal prostate cores, seen on qRT-PCR. 
This could form the basis for the differential [11C]choline uptake seen in the normal 
and tumour prostate (as shown in chapter 4). CHKα staining in areas of PIN, 
different intensities of positive staining and the low Ki67 labelling index in the 
malignant prostate cores were consistently seen. This pattern of CHKα expression 
and the availability of [11C]choline PET/CT as a noninvasive surrogate could be 
exploited to develop and test new drug targets against CHKα in prostate cancer. 
Chapter 4 
 
[11C]choline PET/CT was explored as imaging biomarker to assess the 
effects of neoadjuvant-androgen deprivation (NAD) alone and radical radiotherapy 
combined with concurrent-androgen deprivation (RT-CAD) to the prostate, in 10 
patients with histologically confirmed prostate cancer. It was seen that the 
combination of NAD and RT-CAD significantly decreased tumour [11C]choline 
uptake (SUV60,ave, SUV60,max, TMR60,max or Kimod-pat) and prostate-specific-antigen 
(PSA) levels (Analysis-of-Variance, p<0.001 for all variables). Although, the 
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magnitude of reduction in the variables was larger after NAD, there was a smaller 
additional reduction after RT-CAD. A wide range of reduction in tumour SUV60,ave 
(38 – 83.7%) and SUV60,max (22.2 – 85.3%) was seen  with combined NAD and RT-
CAD despite patients universally achieving PSA suppression (narrow range of 93.5 
– 99.7%).  
This feasibility study shows that [11C]choline PET/CT detects metabolic 
changes within tumours following NAD and RT-CAD to the prostate. A differential 
reduction in [11C]choline uptake in spite of a global reduction in PSA following NAD 
and RT-CAD could provide prognostic information. SUV and TMRmax (at early 
and/or late time-points) warrant further evaluation as objective measures of 
response to NAD and RT-CAD, alongside functional MRI parameters and PSA as 
early response biomarker endpoints in PCa during radical treatment. This would 
enable the use of [11C]choline PET/CT as a vehicle for response evaluation in 
radiotherapy dose-escalation trials, as well as novel hormonal therapies. 
Chapter 5 
 
The safety, biodistribution, and internal radiation dosimetry study of [18F]D4-
FCH in eight healthy human volunteers, showed it to be a safe and well tolerated 
tracer. There were no radiotracer-related serious adverse events reported. The 
mean effective dose averaged over both males and females was estimated to be 
0.025 (male 0.022; female 0.027) mSv/MBq. The 5 organs receiving the highest 
absorbed dose (mGy/MBq) were the kidneys (0.106), liver (0.094), pancreas 
(0.066), urinary bladder wall (0.047), and adrenals (0.046). Elimination was through 
the renal and hepatic systems. [18F]D4-FCH was found to be more stable with 38% 
of parent tracer in plasma at 60 min, decreasing to 31% at 4h. This represented an 
improvement in metabolic stability for choline tracers in use clinically; for example a 
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2-fold higher metabolic stability was observed for [18F]D4-FCH relative to published 
data for [11C]choline (17% at 60 min). 
To summarise, [18F]D4-FCH was safe, with a dosimetry profile comparable 
to other common [18F] PET tracers. These data support the further development of 
[18F]D4-FCH for clinical imaging of choline metabolism. Proof-of-concept study of 
[18F]D4-FCH in non-small cell lung cancer patients is underway. The early 
preliminary results of [18F]D4-FCH PET/CT in 5 patients with NSCLC have shown 
that imaging primary lung tumours is feasible. In future [18F]D4-FCH PET/CT could 
be used as a noninvasive surrogate for CHK expression and thus potentially used 
as a prognostic marker and for predicting patient outcome. It is also envisaged that 
[18F]D4-FCH PET/CT could play a further role in selection and/ or evaluation of lung 
cancer patients for targeted therapy. 
Chapter 6 
 
The safety, biodistribution, and internal radiation dosimetry study of 
[18F]ICMT-11 in eight healthy human volunteers, showed it to be a safe and well 
tolerated tracer. There were no radiotracer-related serious adverse events reported. 
The mean effective dose averaged over both males and females was estimated to 
be 0.025 (male 0.022; female 0.027) mSv/MBq. The 5 organs receiving the highest 
absorbed dose (mGy/MBq), averaged over both males and females, were the gall 
bladder wall (0.59), small intestine (0.12), upper large intestinal wall (0.08), urinary 
bladder wall (0.08), and liver (0.07). Elimination was both renal and via the 
hepatobiliary system. [18F]ICMT-11 is safe, with a dosimetry profile comparable to 
other common [18F] PET tracers. These data support the further development of 
[18F]ICMT-11 for clinical imaging of apoptosis, as there is a need for biomarkers, for 
imaging both cell proliferation and cell death. A study is underway to evaluate 
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chemotherapy induced activation of caspase 3/7 using [18F]ICMT-11 in breast 
cancer patients. 
In summary, this thesis has established the feasibility of using [18F]FLT and 
[11C]choline PET as imaging biomarkers. The application of the novel KSF has been 
extended and validated for application to pancreatic cancer. It was also shown that 
[11C]choline PET could be used as a noninvasive surrogate for CHK expression and 
for response evaluation in radiotherapy dose-escalation trials and novel hormonal 
therapies. It also translated [18F]D4-FCH for clinical imaging. Additional work 
included translation of a novel isatin sulphonamide ([18F]ICMT-11), to detect 
activated caspase 3, into humans for biodistribution and radiation dosimetry. 
Therefore, exciting times await future imaging strategies using the novel PET 
tracers translated for clinical use in this thesis.   
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Appendix 1  
 
The Eastern Co-operative Cancer Group (ECOG) performance scoring 
 
Grade Performance scale 
0 Able to carry out all normal activity without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out light work. 
2 Ambulatory and capable of all self-care but unable to carry out any 
work; up and about more than 50% of waking hours. 
3 Capable of only limited self-care; confined to bed or chair more than 
50% of waking hours 
4 Completely disabled; cannot carry on any self-care; totally confined 
to bed or chair. 
5 Death 
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Appendix 2 
 
METHODS 
Selection of target lesions 
 
 Target lesions in the pancreas and the liver were defined as lesions with the 
longest diameters (LD) as defined by RECIST 1.1 (Eisenhauer, Therasse et al. 
2009) on CT. The lesions on the FLT PET/CT corresponding to those on the CT, 
showing an increased uptake and visualised on both the unfiltered and the filtered 
images were considered as target lesions. In patients with multiple lesions, the sum 
of the parameters (SUV) of all the lesions was calculated and the change with 
treatment documented. The data were analysed as described in Chapter 2. 
RESULTS 
Effect of Treatment on FLT PET variables 
 
 The waterfall plots of the changes in tumour variables are shown in Figure 
(1a-c). The changes were similar to those seen with only the most metabolically 
active lesion taken for analysis. For SUV60,ave and SUV60,max nearly half of the 
tumours showed some degree of reduction in proliferation. Most of tumours also 
showed some degree of reduction in proliferation when the measure was HiVox. 
Interestingly, majority of the RECIST lesion P showed an increase in SUV60,max; 6 
out of the 7 progressors had a 12-132% increase in the SUV60,max. The one 
progressed patient, who had a decrease in the SUV60,max, was classed as a P by 
virtue of developing new liver metastases. The mean percentage reduction after 
treatment was 6%, -2%, and 21% for SUV60,ave, SUV60,max, and HiVox, respectively.  
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Figure 1: Waterfall plots of the sum of all the lesions. 
Waterfall plots for the measures of (a) SUV60,ave, (b) SUV60,max, (c) HiVox. The RECIST 
lesion non-responders are shaded in grey. Majority of the RECIST lesion progressors 
showed an increase in FLT uptake when the measure was SUV60,ave, SUV60,max; 6 out of the 
7 progressors had the biggest increase in SUV60, max.  
 
 
 Group analyses of the imaging data were also performed. The difference 
between baseline and post-treatment FLT uptake showed a statistically significant 
decrease of SUV60,max in the non-progressors. In the P there was a significant 
increase in the SUV60,max but a significant decrease in the HiVox (Figure 2 a-c).  
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Figure 2: Group analysis of the imaging data  
showing the difference between baseline and post-treatment FLT uptake in the most 
metabolically active lesions in non-progressors and progressors: box and whiskers plots for 
the measures of (a) SUV60,ave, (b) SUV60,max, and (c) HiVox.  
 
 
Prediction of Survival 
 
 Of the 20 patients only 6 patients were alive after mean follow up of 10 
months (range: 1.4 to 32.4 months). Based on the cut-off of 12% reduction in 
SUV60,max derived from the ROC curves, the median PFS of FLT non-progressors 
and progressors  was 7.6 and 3.9 months (p=0.5, CI=0.24-2.01; Log rank test), 
respectively and the median OS was 11.5 and 8.7 months (p=0.15, CI=0.15-1.33; 
Log rank test), respectively  in the non-progressors and progressors (Figure 3). 
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Figure 3: Kaplan-Meier Survival curves  
for progression free survival (PFS; a) and overall survival (OS; b). The response 
classification was based on a cut-off of 12% reduction in SUV60, max for FLT.  
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METHODS 
Image analysis 
The whole prostate was outlined assuming that the maximum activity is always in 
the tumour. This method of assessment avoided bias on repeat measurements. The 
data were analysed using the methodology described in Chapter 4. 
RESULTS 
[11C]Choline uptake in malignant prostate 
 The baseline median (range) SUV60,ave and SUV60,max in the whole prostate 
(tumour) was 2.81 (1.78-4.22) and 12.04 (5.78-14.96), respectively.  The median 
(range) Kimod-pat was 0.041 mL/min/cm
3 (0.015-0.064). 
Effect of NAD and RT-CAD on tissue [11C]choline uptake 
 NAD and RT-CAD decreased tumour radiotracer uptake variables in all eight 
patients who completed both post-NAD and post-RT-CAD scans (Figure 1; Table 
1). Repeated measures ANOVA demonstrated significant reductions for the 
following imaging variables: SUV60,ave, SUV60,max, TMR60,max and Kimod-pat (p<0.001, 
<0.001, <0.001 and <0.05, respectively). There was a large reduction in radiotracer 
uptake in the interval between baseline and post-NAD scan. Within this period, NAD 
decreased whole prostate (tumour) imaging variables by 37-54% for the following 
imaging variables: SUV60,ave, SUV60,max, TMRave, TMRmax, and Kimod-pat. The reduced 
[11C]choline uptake seen within whole prostate (tumour) with NAD was maintained 
after RT-CAD treatment. [11C]Choline uptake was lower by 48-52% for the following 
imaging variables compared to baseline values: SUV60,ave, SUV60,max, TMR60,max, and 
Kimod-pat (Figure 1; Table 1). The magnitude of reduction in uptake was similar even 
at early time points (SUV15,max and SUV30,max; Table 2).  The reduction in whole 
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prostate (tumour) [11C]choline uptake variables was also seen when the patients 
who did not have a post-NAD scan were included in the analysis (Table 3). 
 
Figure 1: Time activity curves (TACs) in whole prostate (tumour) at baseline, following 
treatment with neo-adjuvant androgen deprivation (Post-NAD), and radiotherapy combined 
with concurrent androgen deprivation (Post-RT-CAD). Median TACs expressed as (A) 
SUV60,ave or (B) SUV60,max in the whole prostate. 
 
Figure 2: Semi-quantitative and quantitative measures of choline uptake in whole prostate 
(tumour). Trends in (A) SUV60,ave, (B) SUV60,max, (C) maximum tumour-muscle ratio TMRmax, 
and, (D) Ki  at baseline,  following neo-adjuvant androgen deprivation (Post-NAD) and 
radiotherapy combined with concurrent androgen deprivation (Post-RT-CAD) in eight 
patients who completed all three scans. *, **, *** denotes significant changes p< 0.05, 
p<0.01 and p<0.001 respectively. 
Table 1: Median [
11
C]choline uptake variables in whole prostate (tumour) at baseline 
and reduction with neo-adjuvant androgen-deprivation (NAD) and radiotherapy 
combined with concurrent androgen-deprivation (RT-CAD) in 8 patients. 
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  SUV 60, ave SUV 60, max 
Kimod-pat 
(mL/min/cm
3
) 
TMR 60, max 
Tumour Baseline 3.26 12.04 0.046 4.80 
  (1.74-3.76) (5.78-14.96) (0.015-0.064) (2.71-5.96) 
 Post-NAD 1.83 7.08 0.021 3.02 
  (1.3-2.37) (4.07-9.13) (0.011-0.040) (2.48-3.90) 
 Post  1.71 5.98 0.024 2.30 
 RT-CAD (1.38-1.89) (4.97-8.16) (0.012-0.055) (1.68-3.0) 
 
% Reduction 
NAD 
44*** 41*** 54** 37** 
 
% Reduction 
NAD+RT-CAD 
48*** 50*** 48* 52*** 
TMR-Tumour-to-muscle ratio, *, **, *** denotes significant changes (p< 0.05, p<0.01, 
p<0.001 respectively; Repeated measures ANOVA, Tukey’s multiple comparison), Values in 
brackets represent the range. 
 
 
 
 
 
 
Table 2: SUVmax of whole prostate (tumour) at early and late imaging time points. 
Median [
11
C]choline uptake variables in whole prostate (tumour) at baseline and 
reduction with neo-adjuvant androgen-deprivation (NAD) and radiotherapy combined 
with concurrent androgen-deprivation (RT-CAD) in 8 patients. 
 
  SUV15,max SUV30,max SUV60,max 
Tumour Baseline 12.27 10.48 12.04 
  (5.79-15.18) (6.42-12.15) (5.78-14.96) 
 Post-NAD 7.55 5.30 7.08 
  (4.02-10.72) (3.22-6.77) (4.07-9.13) 
 Post  6.63 5.08 5.98 
 RT-CAD (5.20-8.61) (3.32-6.23) (4.97-8.16) 
 
% Reduction 
NAD 
39*** 49*** 41*** 
 
% Reduction 
NAD+RT-CAD 
46*** 52*** 50*** 
*** denotes significant changes (p<0.001; Repeated measures ANOVA, Tukey’s multiple 
comparison), Values in brackets represent the range. 
 
 
 
 
Table 3: Median [
11
C]choline uptake variables in whole prostate (tumour) at baseline 
and changes with combined neo-adjuvant androgen-deprivation (NAD) and 
radiotherapy combined with concurrent androgen-deprivation and RT-CAD in 10 
patients. 
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  SUV60,ave SUV60,max TMR60,max 
Kimod-pat 
(mL/min/cm
3
) 
Tumour Baseline 2.81 12.04 4.74 0.041 
  (1.78-4.22) (5.78-14.96) (2.71-5.96) (0.015-0.064) 
 Post Tx 1.67 5.73 2.25 0.024 
  (1.38-1.89) (4.25-8.16) (1.27-3.0) (0.012-0.055) 
 % Reduction 41*** 52*** 53*** 41** 
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